

CITATION REPORT

List of articles citing

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

DOI: 10.1016/s0140-6736(02)08512-4
Lancet, The, 2002, 359, 1541-9.

Source: <https://exaly.com/paper-pdf/34204628/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2315	Viability Analysis in Biological Evaluations: Concepts of Population Viability Analysis, Biological Population, and Ecological Scale. 1994 , 8, 364-372		53
2314	Antitumour necrosis factor therapy in Crohn's disease. 2002 , 2, 715-21		2
2313	Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. 2002 , 97, 2962-72		144
2312	SNPs: sorry, not predictive. 2002 , 12, 507-508		
2311	Treatment of Crohn's disease--the new era. 2002 , 34, 689-91		1
2310	Infliximab in treatment of Crohn's disease: the Milan experience. 2002 , 34, 411-8		34
2309	Inflammatory bowel disease. 2002 , 347, 417-29		2967
2308	Anti-TNF agents for the treatment of spondyloarthropathies. 2002 , 7, 235-46		11
2307	Maintenance infliximab for Crohn's disease. <i>Lancet, The</i> , 2002 , 360, 1602; author reply 1602-3	40	5
2306	Konservative Standardtherapie des Morbus Crohn. 2002 , 18, 325-330		
2305	Funding the new biologics--what can we learn from infliximab? The CCOHTA report: a gastroenterologist's viewpoint. 2002 , 16, 865-8		7
2304	Funding the New Biologics [CCOHTA Report on the Cost Effectiveness of Infliximab for Crohn's Disease: Pearls and Pitfalls. 2002 , 16, 877-879		1
2303	Advances in medical therapy for Crohn's disease. 2002 , 4, 506-12		1
2302	Gut inflammation and spondyloarthropathies. 2002 , 4, 525-32		55
2301	[Standard therapy of Crohn disease. Consensus-based recommendations]. 2002 , 43, 1376, 1379-85		2
2300	[Genetics and the environment. Has the picture become clearer?]. 2002 , 43, 1335-41		1
2299	[Chronic inflammatory bowel diseases competence network. Results and significance for general practice]. 2002 , 43, 1419-29		1

2298	[Therapeutic innovations in chronic inflammatory bowel diseases with "biological therapy"--anti-TNF and more]. 2002 , 43, 1386-99	1
2297	[Not Available]. 2002 , 44, 1151-74	
2296	Monoclonal antibodies in immune and inflammatory diseases. 2002 , 13, 615-20	37
2295	Inhibiteurs du TNF-alpha en 2002: effets indésirables, surveillance, nouvelles indications en dehors de la polyarthrite rhumatoïde et des spondylarthropathies. 2002 , 69, 982-991	2
2294	Inflammatory bowel disease: new insights into pathogenesis and treatment. 2002 , 252, 475-96	136
2293	Updates from the British Association of Dermatologists 82nd Annual Meeting, 9-12 July 2002, Edinburgh, U.K. 2002 , 147, 1080-95	3
2292	Molecular therapies in Crohn's disease: coming of age. 2002 , 17, 285-6	
2291	Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. 2003 , 348, 601-8	1686
2290	Strategies for targeting tumour necrosis factor in IBD. 2003 , 17, 105-17	65
2289	Crohn's disease: step up or top down therapy. 2003 , 17, 131-7	52
2288	Traitements biologiques des maladies inflammatoires intestinales. 2003 , 33, 233-240	
2287	Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes. 2003 , 6, 183-200	4
2286	Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. 2003 , 5, 501-5	37
2285	Optimizing immunomodulator therapy for inflammatory bowel disease. 2003 , 5, 506-11	27
2284	Future therapies for inflammatory bowel disease. 2003 , 5, 518-23	11
2283	[Suspected cases of severe side effects after infliximab (Remicade) in Germany]. 2003 , 98, 429-36	12
2282	Die Rolle von Zytokinen in der Pathogenese und Therapie chronisch-entzündlicher Darmerkrankungen. 2003 , 46, 217-224	
2281	Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. 2003 , 48, 2224-33	168

2280	Transitioning the paediatric IBD patient to adult care. 2003 , 17, 197-212	10
2279	Review article: maintenance treatment of Crohn's disease. 2003 , 17 Suppl 2, 31-7	25
2278	Review article: medical treatment of moderate to severe Crohn's disease. 2003 , 17 Suppl 2, 23-30	11
2277	Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. 2003 , 17, 75-84	92
2276	Treatment of active Crohn's disease with oncept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. 2003 , 17, 185-92	74
2275	Mycophenolate mofetil in refractory inflammatory bowel disease. 2003 , 17, 1365-9	20
2274	Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition. 2003 , 17, 1435-50	33
2273	Review article: mitogen-activated protein kinases in chronic intestinal inflammation - targeting ancient pathways to treat modern diseases. 2003 , 18, 17-32	23
2272	Response to infliximab is related to disease duration in paediatric Crohn's disease. 2003 , 18, 425-31	116
2271	Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. 2003 , 18, 175-81	74
2270	Infliximab in the treatment of medically refractory indeterminate colitis. 2003 , 18, 741-7	32
2269	Drug interaction between infliximab and azathioprine in patients with Crohn's disease. 2003 , 18, 917-25	59
2268	A lupus-like syndrome associated with infliximab therapy. 2003 , 9, 176-8	55
2267	Is there still a role for cyclosporine in the treatment of inflammatory bowel disease? Con argument. 2003 , 9, 198-201; discussion 202-4	4
2266	Inflammatory bowel disease in African Americans. 2003 , 9, 380-5	34
2265	GI clinical research 2002-2003: the year in review. 2003 , 1, 415-20	10
2264	[Biological therapies in inflammatory bowel disease]. 2003 , 26, 161-2	
2263	Infliximab treatment of rheumatoid arthritis and Crohn's disease. 2003 , 37, 1256-65	79

2262	Maintenance therapy for inflammatory bowel disease. 2003 , 98, S6-S17	49
2261	Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. 2003 , 125, 32-9	271
2260	Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab. 2003 , 125, 633-4; author reply 635-6	36
2259	Considerations in the management of steroid-dependent Crohn's disease. 2003 , 125, 906-10	11
2258	Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. 2003 , 134, 565-72; discussion 572-3	88
2257	Discussion. 2003 , 134, 572-573	13
2256	IBD: the drugs workBut do the patients?. 2003 , 98, 722-723	
2255	Natalizumab: a new hope for Crohn's disease. 2003 , 98, 1197-1199	1
2254	Acute leukemia after infliximab therapy. 2003 , 98, 2577	7
2253	Infliximab-induced lupus in Crohn's disease: a case report. 2003 , 35, 814-7	46
2252	Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. 2003 , 124, 917-24	468
2251	Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. 2003 , 124, 1140-5	66
2250	Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. 2003 , 47, 1-10	28
2249	Autoimmune aspects of cytokine and anticytokine therapies. 2003 , 115, 390-7	69
2248	Immunogenicity of infliximab in Crohn's disease. 2003 , 348, 2155-6; author reply 2155-6	9
2247	What's new in Gastroenterology. 2003 , 31, 1-4	
2246	[Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists]. 2003 , 62, 218-27	4
2245	The biology of TNF blockade. 2003 , 2, 346-57	81

2244	Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. 2004 , CD003574	57
2243	Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. 2003 , 98, 104-11	111
2242	The incidence and management of infusion reactions to infliximab: a large center experience. 2003 , 98, 1315-24	366
2241	Molecular Discoveries Alter Our View of Inflammatory Bowel Disease. 2003 , 119, 524-539	7
2240	Adamantiades-Behçet Disease. 2003 ,	13
2239	Systematic safety follow up in a cohort of 107 patients with spondyloarthritis treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?. 2003 , 62, 829-34	116
2238	Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. 2003 , 3, 141-68	25
2237	Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). 2003 , 62 Suppl 2, ii2-9	35
2236	Complement activation in plasma before and after infliximab treatment in Crohn disease. 2003 , 38, 1050-4	17
2235	Cytokine gene polymorphisms in chronic hepatitis B: a step up the immunology ladder. 2003 , 98, 6-8	24
2234	Infliximab treatment of Crohn's disease in children: it's time to not go retro(spective). 2003 , 98, 5-6	7
2233	The effects of infliximab maintenance therapy on health-related quality of life. 2003 , 98, 2232-8	94
2232	IBD: the drugs work...but do the patients?. 2003 , 98, 722-3	4
2231	Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. 2003 , 98, 1821-6	173
2230	Acute leukemia after infliximab therapy. 2003 , 98, 2577	19
2229	Management of Crohn's disease of the ileoanal pouch with infliximab. 2003 , 98, 2239-44	129
2228	TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. 2003 , 100, 8366-71	164
2227	Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. 2003 , 12, 1097-109	27

2226 Clinical quiz. Leiomyoma. **2003**, 37, 461, 521

2225 Management of Crohn's disease from efficacy, quality of life and health economic perspectives. **2003**, 3, 587-98

1

2224 [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease]. **2003**, 41, 11-7

26

2223 [Maintaining a remission]. **2003**, 41, 36-42

1

2222 Cytokine and anti-cytokine therapies for inflammatory bowel disease. **2003**, 9, 1107-13

95

2221 [Chronically active Crohn's disease]. **2003**, 41, 31-5

3

2220 Natalizumab: a new hope for Crohn's disease?. **2003**, 98, 1197-9

1

2219 Inducing remission in inflammatory bowel disease. **2003**, 41, 30-2

2218 Targeting tumor necrosis factor-alpha in inflammatory bowel disease: why, how, and when?. **2003**, 19, 350-7

8

2217 Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis. **2003**, 15, 267-73

27

2216 Infliximab for severe recurrent Crohn's disease presenting with massive gastrointestinal hemorrhage. **2003**, 36, 238-41

40

2215 Biologic therapies in the spondyloarthritis: new opportunities, new challenges. **2003**, 15, 394-407

34

2214 . **2003**, 28, 750-753

8

2213 . **2003**, 28, 753-754

2212 Therapies with potential toxicity of neuro-ophthalmic interest. **2003**, 14, 339-43

2

2211 Mucosal T cells: mediators or guardians of inflammatory bowel disease?. **2003**, 19, 343-9

22

2210 Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. **2003**, 37, 125-8

28

2209 Recent advances in immunomodulation in the treatment of inflammatory bowel disease. **2003**, 15, 215-8

10

2208	Photopheresis treatment in severe Crohn disease. 2003 , 37, 517-20	6
2207	Tumor Necrosis Factor- β Monoclonal Antibody, Infliximab, Used to Manage Severe Sciatica. 2003 , 28, 750-753	60
2206	Point of View. 2003 , 28, 753-754	
2205	Tumor necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis. 2003 , 76, 516-23	32
2204	Infectious complications of biologic treatments of rheumatoid arthritis. 2003 , 15, 179-84	55
2203	[Pharmacological profile of anti-human TNF alpha monoclonal antibody, infliximab (Remicade)]. 2003 , 121, 57-64	
2202	Chapter 15. Emerging opportunities for the treatment of inflammatory bowel disease. 2003 , 38, 141-152	
2201	New indications for treatment of chronic inflammation by TNF-alpha blockade. 2003 , 325, 75-92	74
2200	Emerging biotherapies for inflammatory bowel disease. 2003 , 8, 339-47	23
2199	Biological therapy in Crohn's disease. 2003 , 64, 708-12	2
2198	Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. 2003 , 62, 561-4	93
2197	Current issues in Crohn's disease. 2003 , 178, 532-3	2
2196	Medical management of Crohn's disease. 2003 , 64, 713-8	3
2195	Standard therapy of Crohn's disease. 2003 , 21, 146-56	4
2194	[Clinical experience with the use of infliximab in 44 patients with Crohn's disease]. 2003 , 40, 198-200	2
2193	Biological therapy in IBD. Anti-tumor necrosis factor-alpha and others. 2003 , 21, 180-91	11
2192	. 2004 ,	
2191	Crohn's Disease. 2004 , 509-520	

2190	Infliximab for the treatment of paediatric Crohn's disease: Obstacles to accessing a necessary therapy. 2004 , 9, 87-9	1
2189	The ultimate therapeutic goal: establishing and maintaining quality of life. 2004 , 18, 465-6	
2188	Espondiloartropatias: outras artropatias. 2004 , 44, 470-475	
2187	Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. 2004 , 18, 503-8	21
2186	Recent developments in the pharmacological treatment of Crohn's disease. 2004 , 13, 373-91	14
2185	Inflammatory bowel disease - therapy. 2004 , 129, 2246-2250	
2184	[Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH]. 2004 , 42, 1256-63	3
2183	[Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD]. 2004 , 42, 1033-45; discussion 1046-7	4
2182	[Inflammatory bowel disease: anti-TNF strategies and beyond]. 2004 , 129 Suppl 2, S76-8	
2181	Novel therapy for Crohn's disease targeting IL-6 signalling. 2004 , 8, 287-94	20
2180	Etanercept for Crohn's disease. 2004 , 350, 840; author reply 840	6
2179	Closing fistulas in Crohn's disease--should the accent be on maintenance or safety?. 2004 , 350, 934-6	36
2178	Infliximab maintenance therapy for fistulizing Crohn's disease. 2004 , 350, 876-85	1727
2177	Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy. 2004 , 63, 1754	48
2176	Increased gut permeability in Crohn's disease: is TNF the link?. 2004 , 53, 1724-5	103
2175	Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. 2004 , 53, 780-2	50
2174	Drugs acting on the immune system. 2004 , 27, 373-404	
2173	Recurrent bile duct stones after endoscopic sphincterotomy. 2004 , 53, 1725-7	9

2172	An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo. 2004 , 53, 339-45	48
2171	Safety of infliximab in patients suffering from inflammatory bowel disease. 2004 , 70, 1-2	1
2170	TNFalpha therapy in psoriatic arthritis and psoriasis. 2004 , 63, 755-8	76
2169	CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. 2004 , 53, 1485-93	121
2168	Molecular diagnosis of pancreatobiliary malignancies in brush cytologies of biliary strictures. 2004 , 53, 1727-9	11
2167	Endoscopic therapy of Barrett's: what more do we need to know?. 2004 , 53, 779-80	2
2166	Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. 2004 , 53, 1295-302	230
2165	Pivotal roles of interleukin-6 in transmural inflammation in murine T cell transfer colitis. 2004 , 76, 1111-7	29
2164	Large abdominal mass in Crohn's disease. 2004 , 53, 1493, 1503	0
2163	Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. 2004 , 70, 3-9	53
2162	Proinflammatory cytokines alter/reduce esophageal circular muscle contraction in experimental cat esophagitis. 2004 , 287, G1131-9	70
2161	Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. 2004 , 39, 265-9	51
2160	Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. 2004 , 63, 1664-9	92
2159	Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. 2004 , 53, 849-53	224
2158	Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. 2004 , 53, 70-7	142
2157	Antibody-mediated blockade of interferon- γ for the treatment of Crohn's disease and psoriasis. 2004 , 14, 1373-1378	
2156	Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. 2004 , 99, 1532-8	62
2155	An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. 2004 , 99, 1984-9	221

2154	Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. 2004 , 99, 91-6	216
2153	Early events in spontaneous bacterial peritonitis. 2004 , 53, 782-4	12
2152	Atopic manifestations are more common in patients with Crohn disease than in the general population. 2004 , 39, 731-6	19
2151	The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease. 2004 , 5, 479-86	21
2150	Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. 2004 , 63 Suppl 2, ii2-ii12	41
2149	Behçet's syndrome: from aetiology to treatment. 2003 , 528, 481-6	
2148	Unilateral localized hyperhidrosis associated with frontal lobe meningioma. 2004 , 63, 1753-4	2
2147	Biologics in inflammatory bowel disease: how much progress have we made?. 2004 , 53, 1366-73	47
2146	Infliximab. 2004 , 17, 409-26	32
2145	Infliximab in the management of the extra-intestinal manifestations of Crohn's disease. 2004 , 19, 1332-3	2
2144	Growth of hepatic angiomyolipoma indicating malignant potential. 2004 , 19, 1328-30	29
2143	Remission of ulcerative colitis after anaphylaxis. 2004 , 19, 1330-1	
2142	Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. 2004 , 19, 295-301	55
2141	The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. 2004 , 19, 749-54	180
2140	Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients. 2004 , 19, 1019-24	55
2139	Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. 2004 , 20, 303-10	126
2138	How effective are the usual treatments for Crohn's disease?. 2004 , 20, 151-9	29
2137	Review article: chronic active disease and maintaining remission in Crohn's disease. 2004 , 20 Suppl 4, 102-5	6

2136	Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. 2004 , 20, 607-14	62
2135	Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. 2004 , 20, 1337-46	104
2134	Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. 2004 , 135, 146-53	27
2133	Novel biological strategies in inflammatory bowel diseases. 2004 , 10 Suppl 1, S44-51	5
2132	Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. 2004 , 10, 91-6	82
2131	Pharmacogenetics and inflammatory bowel disease: progress and prospects. 2004 , 10, 148-58	12
2130	A pilot study of adalimumab in infliximab-allergic patients. 2004 , 10, 333-8	86
2129	Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. 2004 , 10, 346-51	37
2128	Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. 2004 , 10 Suppl 2, S2-10	26
2127	Fatal staphylococcal sepsis in Crohn's disease after infliximab. 2004 , 10, 655-6	16
2126	Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. 2004 , 10, 657-60	63
2125	C-reactive protein as a marker for inflammatory bowel disease. 2004 , 10, 661-5	319
2124	CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease. 2004 , 10, 723-30	16
2123	Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. 2004 , 10, 801-10	52
2122	[Anti-TNF agents in inflammatory bowel disease: indications and management]. 2004 , 28, D61-9	2
2121	[Corticodependent Crohn's disease]. 2004 , 28, D194-201	
2120	[Paroxysmal nocturnal hemoglobinuria revealed by hepatic vein thrombosis (Budd-Chiari syndrome) during Infliximab therapy]. 2004 , 28, 596-9	4
2119	[Immunosuppressants and MICI]. 2004 , 28, 685-95	

2118	Peut-on optimiser l'utilisation de l'azathioprine (Imurel®) et de la 6-mercaptopurine (Purinthol®) dans le traitement de la maladie de Crohn ?. 2004 , 28, 699-700	
2117	Efficacité du méthotrexate au cours de la maladie de Crohn Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators, B.G. Feagan, J. Rochon, R.N. Fedorak, E.J. Irvine, G. Wild, L. Sutherland, et al., in: N Engl J Med, 332 (1995), pp. 292-297. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators, B.G. Feagan, R.N. Fedorak, E.J. Irvine, G. Wild, L. Sutherland, 2004, 28, 700	
2116	Traitement d'entretien de la maladie de Crohn par infliximab. 2004 , 28, 700-701	
2115	Assessment of Crohn's disease activity in the small bowel with MR and conventional enteroclysis: preliminary results. 2004 , 14, 1017-24	156
2114	Fecal lactoferrin: a new parameter to monitor infliximab therapy. 2004 , 49, 1036-9	67
2113	Immunomodulatory therapy for inflammatory bowel disease. 2004 , 39, 1129-37	10
2112	[Biologicals: a new therapeutic approach for inflammatory diseases]. 2004 , 45 Suppl 1, S31-7	0
2111	Chronisch-entzündliche Darmerkrankungen. 2004 , 152, 133-144	2
2110	Advances in medical therapy for Crohn's disease. 2004 , 6, 496-505	6
2109	Newer Therapies for Inflammatory Bowel Disease. 2004 , 7, 161-167	4
2108	Choosing Therapy on the Basis of Disease Classifications in Inflammatory Bowel Disease. 2004 , 7, 169-179	
2107	The use of infliximab in South-east Asian children with severe Crohn's disease. 2004 , 46, 198-201	2
2106	Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. 2004 , 15, 557-63	51
2105	Pharmacogenetics of inflammatory bowel disease. 2004 , 18, 597-609	1
2104	Biological therapies in the spondyloarthritides--the current state. 2004 , 43, 1072-84	74
2103	[Indications for infliximab. How long should treatment last? Risk/benefit evaluation]. 2004 , 27, 172-6	
2102	Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. 2004 , 36, 342-7	129
2101	[Systemic candidiasis and infliximab therapy]. 2004 , 27, 365-7	6

2100	Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade. 2004 , 22, 437-47, ix	20
2099	[TNF-alpha inhibitors in inflammatory bowel disease]. 2004 , 123, 627-34	4
2098	Medical management of the pregnant patient with inflammatory bowel disease. 2004 , 33, 361-85, xi	13
2097	Guidelines for the management of inflammatory bowel disease in adults. 2004 , 53 Suppl 5, V1-16	774
2096	Treatment of luminal and fistulizing Crohn's disease with infliximab. 2004 , 33, 387-406, xi	14
2095	Treatment of fistulizing Crohn's disease. 2004 , 33, 421-54, xi-xii	32
2094	General principles of medical therapy of inflammatory bowel disease. 2004 , 33, 191-208, viii	32
2093	Medical management of severe ulcerative colitis. 2004 , 33, 235-50, viii	16
2092	High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. 2004 , 2, 309-13	152
2091	Management of refractory inflammatory bowel disease. 2004 , 33, 319-34, x	3
2090	Pharmacogenetics of inflammatory bowel disease\$star;*1. 2004 , 18, 597-609	1
2089	Novel biologics in inflammatory bowel disease. 2004 , 33, 251-69, ix	16
2088	Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab. 2004 , 33, 285-301, ix	9
2087	The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. 2004 , 126, 19-31	754
2086	Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. 2004 , 126, 402-13	810
2085	Episodic retreatment versus scheduled maintenance therapy of crohn's disease with infliximab: not so far apart. 2004 , 126, 598-601	34
2084	A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. 2004 , 126, 989-96; discussion 947	529
2083	Advances in the treatment of Crohn's disease. 2004 , 126, 1574-81	56

2082	Optimizing anti-TNF treatment in inflammatory bowel disease. 2004 , 126, 1593-610	401
2081	Successful treatment of cap polyposis with infliximab. 2004 , 126, 1868-71	52
2080	Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. 2004 , 126, 1550-60	163
2079	Keratin 8 Y54H and G62C mutations are not associated with inflammatory bowel disease. 2004 , 36, 388-91	16
2078	Infliximab and quality of life in steroid-dependent Crohn's disease. 2004 , 36, 557-8	
2077	Inflammatory Bowel Disease. 2004 , 649-673	1
2076	Current therapy of ulcerative colitis in children. 2004 , 5, 37-53	9
2075	Safety of tumour necrosis factor-alpha antagonists. 2004 , 27, 307-24	141
2074	Maintenance of remission in Crohn's disease: current and emerging therapeutic options. 2004 , 64, 1069-89	23
2073	Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. 2004 , 64, 1767-77	57
2072	Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. 2004 , 2, 542-53	502
2071	Expanding the armamentarium for the spondyloarthropathies. 2004 , 6 Suppl 2, S36-43	5
2070	Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. 2004 , 113, 47-55	113
2069	Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. 2004 , 322, 778-86	111
2068	The role and importance of endoscopic mucosal healing in Crohn's disease. 2004 , 6, 138-143	4
2067	Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. 2004 , 51, 534-42	464
2066	Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab. 2004 , 144, 541-4	77
2065	Serious infections associated with anticytokine therapies in the rheumatic diseases. 2004 , 19, 320-34	93

2064	[Bronchiolitis with airflow obstruction in adults]. 2004 , 25, 275-86	1
2063	Infliximab attenuates immunoreactivity of brain-derived neurotrophic factor in a rat model of herniated nucleus pulposus. 2004 , 29, 1857-61	46
2062	Inflammatory bowel disease. 2004 , 15, 67-90, ix	15
2061	Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. 2004 , 16, 627-30	46
2060	Inflammatory Bowel Disease: A Genomic Picture Predicts a Changing Response From the Laboratory Part I. 2004 , 35, 241-243	
2059	Management of ulcerative colitis and Crohn's disease. 2004 , 59, 304-14	27
2058	Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. 2004 , 38, 502-8	101
2057	Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction. 2004 , 16, 941-2	19
2056	Biomarkers in inflammatory bowel disease. 2004 , 20, 318-27	42
2055	Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. 2004 , 39, 46-52	72
2054	Medical therapy of Crohn disease. 2004 , 20, 351-9	1
2053	Infliximab: how to use it in pediatric Crohn's disease. 2004 , 39, 12-4	6
2052	[Focus on biological agents in rheumatoid arthritis: newer treatments and therapeutic strategies]. 2004 , 59, 451-61	4
2051	Infliximab use in Crohn's disease: impact on health care resources in the UK. 2005 , 17, 1047-52	57
2050	Infliximab-induced headache and infliximab-induced meningitis: two ends of the same spectrum?. 2005 , 98, 564-6	20
2049	Anti-tumor necrosis factor alpha antibody in the treatment of Behçet's disease. 2005 , 45, 179-89	13
2048	Unemployment and disability in patients with moderately to severely active Crohn's disease. 2005 , 39, 390-5	103
2047	Low-dose oral methotrexate for maintaining Crohn's disease remission: where we stand. 2005 , 39, 751-6	13

2046	Inflammatory bowel diseases: clinical update of practical guidelines. 2005 , 26, 649-55	17
2045	Anti-TNF Biological Agents in Rheumatoid Arthritis and Other Inflammatory Diseases. 2005 , 54, 191-202	9
2044	Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease. 2005 , 41, 357-9	26
2043	Signaling and Reverse Signaling in the Tumor Necrosis Factor/TNF Receptor System. 2005 , 171-209	1
2042	Methotrexate for Crohn's disease: experience in a district general hospital. 2005 , 17, 893-8	11
2041	The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. 2005 , 56, 169-78	43
2040	Autoimmunity and anti-TNF-alpha agents. 2005 , 1051, 559-69	135
2039	Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan. 2005 , 28, 221-30	24
2038	Are there predictors of Remicade treatment success or failure?. 2005 , 57, 237-45	26
2037	Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. 2005 , 67, 1812-20	113
2036	Progress in inflammatory bowel disease. 2005 , 6, 59-61	2
2035	Successful treatment with adalimumab in infliximab-resistant Crohn's disease. 2005 , 20, 1464-5	19
2034	A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. 2005 , 21, 373-84	31
2033	Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. 2005 , 21, 363-71	73
2032	Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. 2005 , 21, 733-8	219
2031	Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. 2005 , 21, 1063-71	46
2030	Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. 2005 , 22, 453-61	28
2029	Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. 2005 , 22, 613-26	154

2028	Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?. 2005 , 22, 1107-13	78
2027	Unusual presentation of tuberculosis after infliximab therapy. 2005 , 11, 82-4	4
2026	Human papilloma virus infection in a recurrent squamous cell carcinoma associated with severe Crohn's disease. 2005 , 11, 84-6	11
2025	A survey of methodological variation in the Crohn's disease activity index. 2005 , 11, 133-8	37
2024	Gastrointestinal parasites: potential therapy for refractory inflammatory bowel diseases. 2005 , 11, 178-84	24
2023	Methods to avoid infections in patients with inflammatory bowel disease. 2005 , 11, 685-95	50
2022	Infliximab efficacy in pediatric ulcerative colitis. 2005 , 11, 213-8	73
2021	Immunogenicity of biological agents in inflammatory bowel disease. 2005 , 11, 497-503	10
2020	Infliximab and semen quality in men with inflammatory bowel disease. 2005 , 11, 395-9	98
2019	Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent. 2005 , 11, 667-73	28
2018	Comparative phenotypic and CARD15 mutational analysis among African American, Hispanic, and White children with Crohn's disease. 2005 , 11, 631-8	61
2017	State of the art: IBD therapy and clinical trials in IBD. 2005 , 11 Suppl 1, S3-12	68
2016	Successful infliximab therapy for a duodenal stricture caused by Crohn's disease. 2005 , 11, 1123-5	26
2015	Severe pyogenic infections in patients taking infliximab: a regional cohort study. 2005 , 72, 330-4	19
2014	Predictors of response to infliximab in luminal Crohn's disease. 2005 , 29, 145-9	36
2013	The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. 2005 , 34, 819-36	171
2012	Differentiating the efficacy of the tumor necrosis factor inhibitors. 2005 , 34, 7-11	71
2011	Infections associated with tumor necrosis factor-alpha antagonists. 2005 , 25, 1181-92	94

2010	Infections sŕives ^ pyogŕies chez les patients traitŕs par infliximab. Œtude d'ŕne cohorte rŕgionale. 2005 , 72, 650-655	0
2009	Crohn's colitis presenting with node-negative colon cancer and liver metastasis after therapy with infliximab: report of two cases. 2005 , 48, 1651-5	10
2008	Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis. 2005 , 20, 9-17	19
2007	Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn's disease: a retrospective data analysis in Germany. 2005 , 20, 18-23	5
2006	Standards of medical treatment and nutrition in Crohn's disease. 2005 , 390, 503-9	1
2005	Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease. 2005 , 5, 141-60	13
2004	Local injection of Infliximab for the treatment of perianal Crohn's disease. 2005 , 48, 768-74	87
2003	Diagnose en behandeling van inflammatoire darmziekten bij kinderen anno 2005. 2005 , 73, 233-239	
2002	Anti-tnf-behandeling bij de ziekte van Crohn. 2005 , 73, 256-260	1
2001	Infliximab: Use in Inflammatory Bowel Disease. 2005 , 8, 187-196	26
2000	Medical Therapy of Crohn's Disease. 2005 , 8, 19-30	3
1999	Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis. 2005 , 7, 485-91	3
1998	Gut inflammation in the spondyloarthropathies. 2005 , 7, 188-94	27
1997	Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. 2005 , 50, 163-6	73
1996	Listeria meningitis complicating infliximab treatment for Crohn's disease. 2005 , 16, 289-92	27
1995	The Japanese art of Ju-jitsu. 2005 , 330, 720	
1994	Rheumatoid arthritis--Crohn's disease connection. 2005 , 20, 110-1, 115-22	2
1993	Extraintestinal manifestations in inflammatory bowel disease. 2005 , 11, 7227-36	299

1992	Advances in the Medical Treatment of Crohn's Disease. 2005 , 59-92	1
1991	Chronisch entzündliche Darmerkrankungen. 2005 , 248-287	
1990	A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. 2006 , 55, 1138-44	130
1989	Tumor necrosis factor inhibition and opportunistic infections. 2005 , 41 Suppl 3, S187-8	13
1988	Acute toxic gastric mucosal damage induced by Lugol's iodine spray during chromoendoscopy. 2005 , 54, 886-7	33
1987	Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. 2005 , 54, 237-41	501
1986	Mutations in anionic trypsinogen gene are not associated with tropical calcific pancreatitis. 2005 , 54, 728-9	21
1985	Liver failure after delivery. 2005 , 54, 672, 709	2
1984	Genetic evidence that juvenile nasopharyngeal angiofibroma is an integral FAP tumour. 2005 , 54, 1046-7	29
1983	Elevated plasma protein C levels correlate with the presence of fatty liver (NASH and NAFLD). 2005 , 54, 729	9
1982	Reinforcing the mucus: a new therapeutic approach for ulcerative colitis?. 2005 , 54, 900-3	34
1981	Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening?. 2005 , 54, 891	1
1980	Adalimumab use in pregnancy. 2005 , 54, 890	113
1979	Insulin resistance and steatosis in hepatitis C virus infection. 2005 , 54, 903-6	44
1978	Epithelial cells disseminate into the bone marrow of colorectal adenoma patients. 2005 , 54, 1045-6	8
1977	Ferroportin disease due to the A77D mutation in Australia. 2005 , 54, 1048-9	20
1976	Diagnostic radiation exposure and cancer risk. 2005 , 54, 889-90	8
1975	Immunsuppressive und biologische Therapieoptionen bei chronisch entzündlichen Darmerkrankungen. 2005 , 1, 145-160	

1974	HHV-8 positive, HIV negative disseminated Kaposi's sarcoma complicating steroid dependent ulcerative colitis: a successfully treated case. 2005 , 54, 1049-50	19
1973	Protein Therapeutics. 2005 , 429-446	
1972	The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. 2005 , 17, 1023-34	93
1971	Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. 2005 , 21, 1741-54	100
1970	EUS assessment of response to chemoradiation in esophageal cancer patients. 2005 , 100, 496-7; author reply 497-9	3
1969	Response to Letter. 2005 , 100, 497-499	
1968	Managing complicated Crohn's disease in children and adolescents. 2005 , 2, 572-9	13
1967	Infliximab for the treatment of chronic anemia in Crohn's disease. 2005 , 100, 496	17
1966	Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. 2005 , 100, 2031-5	82
1965	Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time. 2005 , 100, 1435-8	8
1964	5-ASA therapy and renal function in inflammatory bowel disease. 2005 , 100, 501	8
1963	Chemokines as attractive targets in liver carcinogenesis. 2005 , 100, 499-501	6
1962	Reflux esophagitis and ectopic columnar epithelium (Barrett's esophagus) in the esophageal stump after cervical gastropasty. 2005 , 100, 499	10
1961	What next after infliximab?. 2005 , 100, 80-3	16
1960	Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. 2005 , 100, 1121-5	62
1959	Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease. 2005 , 100, 1438-9	4
1958	Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy. 2005 , 100, 1433-5	13
1957	Evaluation of vascular signal in pancreatic ductal carcinoma using contrast enhanced ultrasonography: effect of systemic chemotherapy. 2005 , 54, 1047	11

1956	Coexistent chronic idiopathic intestinal pseudo obstruction and inflammatory bowel disease. 2005 , 54, 729-30	10
1955	Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. 2005 , 64, 1150-7	495
1954	CORRECTION. 2005 , 54, 734-734	78
1953	Ozone. 2005 ,	2
1952	Inflammatory bowel disease stimulates formation of carcinogenic N-nitroso compounds. 2005 , 54, 731	30
1951	Severe and steroid-resistant Crohn's disease. 2005 , 71, 19-25	14
1950	Maintenance of remission in Crohn's disease. 2005 , 71, 41-8	12
1949	Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed. 2005 , 72, 124-8	15
1948	Hepatocellular carcinoma occurring after successful treatment of childhood cancer with high dose chemotherapy and radiation. 2005 , 54, 732	14
1947	Genotypes 677TT and 677CT+1298AC of methylenetetrahydrofolate reductase are associated with the severity of ulcerative colitis in central China. 2005 , 54, 733-4	14
1946	Gastric ulceration due to chronic mesenteric ischaemia treated by stenting of the inferior mesenteric artery. 2005 , 54, 888-9	10
1945	Erosions or not in GORD? The potential role of oesophageal cell proliferation. 2005 , 54, 887-8	2
1944	Mechanism of TNF- α modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. 2005 , 288, G422-30	310
1943	Biologic and Novel Therapy of the Inflammatory Bowel Diseases. 2005 , 4, 319-331	1
1942	Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade. 2005 , 44, 17-23	6
1941	Workshop report: prevention of postoperative recurrence in Crohn's disease. 2005 , 41, 145-51	12
1940	Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. 2005 , 330, 716-20	22
1939	Infliximab use in Crohn's disease. 2005 , 5, 589-99	7

1938	Can we alter the natural history of Crohn disease in children?. 2005 , 40, 262-72	29
1937	Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. 2005 , 40, 220-2	113
1936	Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. <i>Lancet, The</i> , 2005 , 366, 1367-74	40 850
1935	A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. 2005 , 100, 2239-47	138
1934	Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. 2005 , 34, 353-8	106
1933	The use of systemic immune moderators in dermatology: an update. 2005 , 23, 259-300	43
1932	[Desensitisation to infliximab in patients with Crohn's disease]. 2005 , 22, 239-46	19
1931	Medical Biometrics Handbook. 2005 ,	2
1930	Enteral nutrition in the management of Crohn's disease. 2005 , 29, S108-12; discussion S112-7, S184-8	33
1929	Does <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> cause Crohn's disease?. 2005 , 54, 896-8	122
1928	Probiotics and barrier function in colitis. 2005 , 54, 898-900	18
1927	Infliximab for the treatment of early rheumatoid arthritis. 2005 , 5, 405-17	9
1926	Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy. 2005 , 40, 1423-30	11
1925	Treatment-resistant lingual Crohn's disease disappears after infliximab. 2005 , 40, 1255-9	6
1924	Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. 2005 , 34, 178-90	43
1923	Economic implications of biological therapies for Crohn's disease: review of infliximab. 2005 , 23, 875-88	23
1922	Peacekeeping in Crohn's disease: maintenance of remission. 2005 , 21, 7-11	
1921	Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNF α inhibitors?. 2005 , 19, 211-31	51

1920	Genetic testing in Crohn disease: utility in individualizing patient management. 2005 , 5, 213-22	10
1919	New insights into the biological therapy of Crohn's disease. 2005 , 15, 409-419	4
1918	Infliximab for the treatment of ankylosing spondylitis. 2005 , 5, 1095-109	9
1917	Infliximab treatment for refractory Kawasaki syndrome. 2005 , 146, 662-7	201
1916	Protective effect of tumor necrosis factor alpha antibody on experimental necrotizing enterocolitis in the rat. 2005 , 40, 1440-5	21
1915	Pediatric gastrointestinal diseases: are drugs the answer?. 2005 , 5, 604-9	
1914	Advances in medical therapy of inflammatory bowel disease. 2005 , 5, 566-72	20
1913	[GETECCU-2005 recommendations for the use of infliximab (Remicade) in inflammatory bowel disease]. 2005 , 28, 126-34	8
1912	[What should Lalonde think on the decision taking in health care?]. 2005 , 125, 158-9	
1911	[Treatment of severe refractory psoriasis with infliximab. Clinical outcomes after one year of therapy]. 2005 , 125, 159	0
1910	[Refractory psoriasis treatment with etanercept]. 2005 , 125, 371-3	4
1909	Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. 2005 , 65, 2179-208	63
1908	Biologic therapy for inflammatory bowel disease. 2005 , 65, 2253-86	199
1907	Affesis leucocitaria en el tratamiento de la enfermedad inflamatoria intestinal. 2005 , 4, 227-232	
1906	A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. 2005 , 129, 807-18	491
1905	Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. 2005 , 37, 407-17	26
1904	Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. 2005 , 37, 577-83	65
1903	The use of immunosuppressive drugs in IBD: RAND or random choice?. 2005 , 37, 391-3	

1902	Prediction of response to infliximab in Crohn's disease. 2005 , 37, 559-63	8
1901	Early or late guided missile in the treatment of Crohn's disease?. 2005 , 37, 973-9	12
1900	The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. 2005 , 100, 1134-42	79
1899	Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. 2005 , CD003715	77
1898	The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. 2005 , 2, 580-6	94
1897	Euroconference on tissue repair and ulcer/wound healing: molecular mechanisms, therapeutic targets and future directions. 2005 , 14, 743-9	6
1896	Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. 2005 , 100, 75-9	141
1895	Infliximab for induction and maintenance therapy for ulcerative colitis. 2005 , 353, 2462-76	2906
1894	Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. 2005 , 34, 387-91	72
1893	Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. 2006 , 8, R114	90
1892	Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. 2006 , 4, 621-30	724
1891	Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. 2006 , 4, 325-34	145
1890	Exploring utilities and outcomes with infliximab therapy. 2006 , 4, 976-8	3
1889	Infusion reactions and their management. 2006 , 35, 857-66	40
1888	Infliximab use in luminal Crohn's disease. 2006 , 35, 775-93	5
1887	Economics of the use of biologics in the treatment of inflammatory bowel disease. 2006 , 35, 867-82	23
1886	Toxicity of infliximab in the course of treatment of Crohn's disease. 2006 , 5, 9-16	26
1885	Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. 2006 , 101, 1030-8	174

1884	Risks and benefits of infliximab for the treatment of Crohn's disease. 2006 , 4, 1017-24; quiz 976	115
1883	Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?. 2006 , 4, 1135-42	47
1882	Ankylosing Spondylitis. 2006 ,	5
1881	The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. 2006 , 6, 453-66	34
1880	Spotlight on infliximab in Crohn disease and rheumatoid arthritis. 2006 , 20, 67-70	11
1879	Current therapy of inflammatory bowel disease in children. 2006 , 8, 279-302	79
1878	Immune Mechanisms in Inflammatory Bowel Disease. 2006 ,	6
1877	Update in the treatment of paediatric ulcerative colitis. 2006 , 7, 1907-18	3
1876	Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. 2006 , 41, 1064-72	71
1875	Tratamiento de la enfermedad de Crohn corticodependiente y corticorrefractaria. 2006 , 13, 150-158	
1874	Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. 2006 , 130, 323-33; quiz 591	1305
1873	Problems encountered during anti-tumour necrosis factor therapy. 2006 , 20, 757-90	169
1872	Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab. 2006 , 35, 883-93	18
1871	Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies. 2006 , 35, 743-56	15
1870	Infliximab in ulcerative colitis. 2006 , 35, 821-36	13
1869	Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. 2006 , 4, 1030-4	42
1868	Safety of infliximab and other biologic agents in the inflammatory bowel diseases. 2006 , 35, 837-55	64
1867	New therapies for the treatment of inflammatory bowel disease. 2006 , 86, 1045-64	11

1866	General principles and pharmacology of biologics in inflammatory bowel disease. 2006 , 35, 757-73	24
1865	Medical therapy for refractory pediatric Crohn's disease. 2006 , 4, 1199-213	7
1864	Infusion services in the gastroenterology practice. 2006 , 16, 727-42	2
1863	Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. 2006 , 4, 888-93	58
1862	Medical Management of Surgical Inflammatory Bowel Disease? Current Concepts and Future Possibilities. 2006 , 17, 50-54	
1861	American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. 2006 , 130, 940-87	351
1860	Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. 2006 , 130, 1054-61	318
1859	Infliximab and azathioprine: bridge or parachute?. 2006 , 130, 1354-7	9
1858	Adalimumab induction for Crohn's disease. 2006 , 130, 1929	12
1857	American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. 2006 , 131, 283-311	117
1856	The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. 2006 , 131, 410-9	107
1855	Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date. 2006 , 66, 2059-65	12
1854	[Recommendations on tuberculosis and treatment of inflammatory bowel disease with infliximab. 2006 update]. 2006 , 29, 81-4	23
1853	Treatment of rheumatoid arthritis. 2006 , 63, 2451-65	118
1852	Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. 2006 , 4, 1248-54	508
1851	Mechanisms underlying inflammatory bowel disease. 2006 , 3, 457-462	8
1850	Putting the puzzle together: inherited cancer risk in Crohn's disease patients. 2006 , 38, 8-9	
1849	Lessons for inflammatory bowel disease from rheumatology. 2006 , 38, 157-62	13

1848	Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. 2006 , 63, 433-42; quiz 464	464
1847	Mucosal healing in Crohn's disease: what you see is what you get?. 2006 , 63, 443-4	6
1846	Bioequivalence of Biologics. 2006 , 189-208	1
1845	Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. 2006 , 3, 220-8	39
1844	«Anticorps anti-TNF, quelles applications, quels effets secondaires?». 2006 , 46, 261-266	1
1843	Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. 2006 , 118, 11-9	88
1842	Rheumatoid arthritis in dermatology. 2006 , 24, 430-7	33
1841	Cytokine pharmacogenetics. 2006 , 33, 362-6	
1840	Serum sickness-like reactions in patients receiving intravenous infliximab. 2006 , 30, 41-4	59
1839	Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. 2006 , 55, 47-53	369
1838	Favorable response to high-dose infliximab for refractory childhood uveitis. 2006 , 113, 860-4.e2	179
1837	Medical Treatment of Inflammatory Bowel Disease. 2006 , 49, 1164	
1836	Conventional therapy for Crohn's disease. 2006 , 12, 4794-806	12
1835	Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll" ?. 2006 , 12, 1829-41	102
1834	Inflammatory Bowel Diseases: Ulcerative Colitis and Crohn's Disease. 2006 , 713-728	
1833	Canadian consensus on medically acceptable wait times for digestive health care. 2006 , 20, 411-23	96
1832	Dealing With Infusion Reactions. 67-69	
1831	. 2006 ,	0

1830 Infliximab and Surgery: Health Or Hazard?. 74-76

1829 Bacteria in the pathogenesis of inflammatory bowel disease. **2006**, 19, 475-84

55

1828 Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. **2006**, 40, 55-63

68

1827 Complications of biological therapy for inflammatory bowel diseases. **2006**, 22, 30-43

30

1826 The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. **2006**, 16, 727-34

29

1825 Place des anti-TNF dans le traitement de la maladie de Crohn. **2006**, 1, 1-6

1824 Infliximab, Adalimumab and Certolizumab. **2006**, 12, S6

1

1823 Infliximab dependency in a national cohort of children with Crohn's disease. **2006**, 42, 40-5

51

1822 Infliximab for induction and maintenance therapy for ulcerative colitis. **2006**, 42, 589-90

3

1821 Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. **2006**, 18, 11-6

44

1820 Infliximab for hospitalized patients with severe ulcerative colitis. **2006**, 40, 476-81

54

1819 Safety issues with biological therapies for inflammatory bowel disease. **2006**, 22, 370-6

20

1818 Infliximab as first-line therapy in severe pediatric Crohn disease. **2006**, 43, 388-90

16

1817 Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. **2006**, 16, 911-4

65

1816 Crohn's Disease. **2006**,

1815 [Cytokine targetting therapy for inflammatory bowel diseases]. **2006**, 95, 1781-6

1814 Management consensus of inflammatory bowel disease for the Asia-Pacific region. **2006**, 21, 1772-82

78

1813 CLINICAL AND ENDOSCOPIC HEALING AFTER INFLIXIMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE. **2006**, 18, 29-33

11

1812	Infliximab (Remicade [®]): from bench to clinical practice. A paradigm shift in rheumatology practice. 2006 , 9, 107-118	3
1811	Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. 2006 , 3, 171-9	83
1810	Review article: Infliximab therapy for inflammatory bowel disease--seven years on. 2006 , 23, 451-63	189
1809	CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. 2006 , 23, 617-28	35
1808	The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. 2006 , 24, 319-30	148
1807	Infliximab therapy in Crohn's disease: a pragmatic approach?. 2006 , 24, 351-9	10
1806	Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn's disease. 2006 , 24, 343-50	22
1805	Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. 2006 , 24, 851-8	31
1804	Review article: biological drugs in Crohn's disease. 2006 , 24 Suppl 3, 80-9	13
1803	Adherence rates with infliximab therapy in Crohn's disease. 2006 , 24, 1099-103	44
1802	Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: A randomized-controlled trial. 2006 , 24, 1333-40	208
1801	Systematic review: Infliximab therapy in ulcerative colitis. 2007 , 25, 19-37	100
1800	Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies. 2007 , 25, 3-12	80
1799	Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. 2006 , 12, 692-6	32
1798	A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. 2006 , 12, 558-65	80
1797	Genetic variants in TNF-alpha but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort. 2006 , 12, 178-84	31
1796	Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. 2006 , 12, 1087-9	21
1795	Symptomatic hypokalemia associated with infliximab in a patient with Crohn's disease. 2006 , 12, 1010-1	1

1794	Anti-TNF drugs in psoriasis and IBD - Where are we going?. 2006 , 7, 14-20	
1793	Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. 2006 , 1072, 98-113	16
1792	Apoptosis as a therapeutic tool in IBD?. 2006 , 1072, 62-77	38
1791	Inflammatory bowel disease: Pandora's box, present and future. 2006 , 1072, 365-78	16
1790	Current limitations of IBD treatment: where do we go from here?. 2006 , 1072, 1-8	28
1789	Anorectal carcinoma after infliximab therapy in Crohn's disease: report of a case. 2006 , 49, 1228-33	10
1788	Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. 2006 , 49, 1837-41	135
1787	The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. 2006 , 298, 309-19	85
1786	Successful retreatment with infliximab in patients with prior severe infusion reactions. 2006 , 25, 540-1	12
1785	Immunogenicity, efficacy and adverse events of adalimumab in RA patients. 2007 , 27, 269-74	116
1784	Novel biological therapies for inflammatory bowel disease. 2006 , 9, 201-10	4
1783	Safety of biologics in inflammatory bowel disease. 2006 , 9, 221-33	9
1782	Diagnostik und Therapie chronisch-entzündlicher Darmerkrankungen. 2006 , 1, 147-156	
1781	Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. 2006 , 8, 499-505	10
1780	Advances in biologic therapy for ulcerative colitis and Crohn's disease. 2006 , 8, 506-12	37
1779	Prévention des récurrences de la maladie de Crohn : pourquoi et comment?. 2006 , 36, 713-723	
1778	Ankylosing spondylitis and bowel disease. 2006 , 20, 451-71	131
1777	Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. 2006 , 30, 247-52	13

1776	Analysis of linkage between lymphotoxin alpha haplotype and polymorphisms in 5'-flanking region of tumor necrosis factor alpha gene associated with efficacy of infliximab for Crohn's disease patients. 2006 , 602, 170-4	11
1775	Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease. 2006 , 21, 249-51	10
1774	Natalizumab: a promising treatment for Crohn's disease. 2006 , 2, 677-89	1
1773	Dynamic contrast-enhanced MRI of the bowel wall for assessment of disease activity in Crohn's disease. 2006 , 186, 1384-92	149
1772	Infliximab and ulcerative colitis. 2006 , 6, 401-8	10
1771	Recent advances in the etiology and treatment of inflammatory bowel disease. 2006 , 2, 245-56	
1770	Bislang kein wirklicher Durchbruch - Biologika bei chronisch entzündlichen Darmerkrankungen. 2006 , 35, 50-55	
1769	Diagnosis and treatment of pyoderma gangrenosum. 2006 , 333, 181-4	152
1768	Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?. 2006 , 55, 437-41	28
1767	Crohn's disease. 2006 , 785-801	
1766	Anti-TNF-alpha antibody therapies in autoimmune diseases. 2006 , 6, 1707-14	60
1765	TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. 2006 , 1, 1100-7	25
1764	European evidence based consensus on the diagnosis and management of Crohn's disease: current management. 2006 , 55 Suppl 1, i16-35	443
1763	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. 2006 , 65 Suppl 3, iii2-15	50
1762	TNF-alpha Inhibitors. 2006 ,	3
1761	Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. 2006 , 17, 1243-52	49
1760	Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. 2006 , 55, 228-33	104
1759	Shortening infusion times for infliximab administration. 2006 , 45, 485-6	26

1758	6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. 2006 , 73, 25-31	58
1757	Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease. 2006 , 55, 1056	13
1756	Inflammatory bowel disease: current therapeutic options. 2006 , 73 Suppl 1, 67-76	55
1755	Infliximab. 2006 , 1747-1753	
1754	Medical management of Crohn's disease: current therapy and recent advances. 2006 , 2, 109-20	1
1753	Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. 2006 , 101, 1012-23	210
1752	Life events and inflammatory bowel disease relapse: a prospective study of patients enrolled in remission. 2006 , 101, 775-81	62
1751	European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. 2006 , 55 Suppl 1, i1-15	416
1750	Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. 2007 , 56, 1232-9	715
1749	Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte/monocyte apheresis. 2007 , 23, 2715-28	13
1748	Crohn's disease or abdominal tuberculosis?. 2007 , 56, 1757-8	
1747	Medical Management of Ulcerative Colitis in 2006: What's on the Horizon?. 2007 , 102, S7-S13	3
1746	Medical Management of Crohn's Disease in 2006: What's on the Horizon?. 2007 , 102, S2-S6	2
1745	Response to the article: McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101:812-22. 2007 , 102, 201-2	16
1744	Do black and Hispanic Americans with inflammatory bowel disease (IBD) receive inferior care compared with white Americans? Uneasy questions and speculations. 2007 , 102, 1343-9	34
1743	Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. 2008 , 57, 549-58	134
1742	Crohn's disease, relapsing polychondritis and epidermolysis bullosa acquisita: an immune-mediated inflammatory syndrome. 2008 , 47, 380-1	8
1741	Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. 2007 , 42, 221-7	38

1740	Are we ready for top-down therapy for inflammatory bowel diseases: pro. 2007 , 1, 243-8	4
1739	Risks and benefits of biologic therapy for inflammatory bowel diseases. 2007 , 56, 725-32	59
1738	Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. 2007 , 83, 251-60	199
1737	Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. 2007 , 3, 1909-24	68
1736	Treatment with biologic therapies and the risk of cancer in patients with IBD. 2007 , 4, 78-91	35
1735	The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease. 2007 , 42, 464-70	22
1734	Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. 2007 , 66, 1252-4	98
1733	Editor's quiz: iron deficiency anaemia 10 years after small bowel resection in infancy. 2007 , 56, 463, 488	4
1732	EDITOR'S QUIZ: GI SNAPSHOT. 2007 , 56, 1231-1231	
1731	Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?. 2007 , 56, 1181-3	38
1730	Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. 2007 , 44, 312-7	48
1729	Anti-TNF therapy in Crohn's disease: a balance between a targeted therapeutic approach and drug-induced immunogenicity. 2007 , 1, 233-237	
1728	Anti-TNF antibodies for Crohn's disease--in pursuit of the perfect clinical trial. 2007 , 357, 296-8	16
1727	Ernährung bei chronisch-entzündlichen Darmerkrankungen. 2007 , 22, 117-120	
1726	Medical management of Crohn's disease. 2007 , 20, 269-81	9
1725	New concepts in the management of adverse drug reactions. 2007 , 28, 517-24	6
1724	Current and future therapies for inflammatory bowel disease. 2007 , 1, 89-100	
1723	Crohn's disease: drug therapy or surgery?. 2007 , 1, 187-92	2

1722	Treatment of Crohn's disease with certolizumab pegol. 2007 , 3, 683-94	3
1721	Emerging biologics in the treatment of uveitis. 2007 , 3, 781-96	3
1720	Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. 2007 , 102, 2804-12; quiz 2803, 2813	85
1719	Maintenance therapy with certolizumab pegol for Crohn's disease. 2007 , 357, 239-50	892
1718	The role of TNFalpha in ulcerative colitis. 2007 , 47, 930-41	105
1717	Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. 2007 , 42, 1312-20	98
1716	Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. 2007 , 7, 1051-9	38
1715	Inflammatory bowel diseases: meeting of the European Crohn's Colitis Organization, 1-3 March 2007, Innsbruck, Austria. 2007 , 11, 853-6	2
1714	Crohn's disease and its mucocutaneous involvement. 2007 , 6, 179-85	14
1713	Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. 2007 , 56, 293-303	87
1712	TREM-1--expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. 2007 , 117, 3097-106	262
1711	Severe and steroid-resistant Crohn's disease. 2007 , 76, 99-108	4
1710	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. 2007 , 66 Suppl 3, iii2-22	85
1709	Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. 2007 , 1, 101-12	5
1708	Management of inflammatory bowel disease. 2007 , 46, 359-64	1
1707	In vivo single-photon emission computed tomography imaging of apoptosis in Crohn's disease and anti-tumour necrosis factor therapy. 2007 , 56, 461-3	3
1706	The classics in perspective. 2007 , 56, 1184-6	1
1705	Maintenance of medically induced remission of Crohn's disease. 2007 , 76, 116-29	3

1704	Treatment of inflammatory immunologic disease 2. Anti-cytokine therapies in inflammatory bowel disease. 2007 , 46, 1307-9	1
1703	Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. 2007 , 146, 621-30	345
1702	Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease. 2007 , 22, 20-5	16
1701	Benign Neoplasms of the Colon and Rectum. 2007 , 475-512	
1700	Inflammatory bowel disease in the elderly. 2007 , 3, 77-84	5
1699	GAIN for loss: adalimumab for infliximab-refractory Crohn disease. 2007 , 146, 888-90	7
1698	Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. 2007 , 146, 829-38	704
1697	Disease presentation and clinical course in black and white children with inflammatory bowel disease. 2007 , 44, 555-60	37
1696	Anti-tumor necrosis factor-alpha (TNF-alpha) treatment strategies in Crohn's disease. 2007 , 1, 21-34	4
1695	A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone. 2007 , 41, 677-81	5
1694	Biological therapies in inflammatory bowel disease: top-down or bottom-up?. 2007 , 23, 395-9	42
1693	Infliximab use in children and adolescents with inflammatory bowel disease. 2007 , 45, 3-14	28
1692	Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. 2007 , 7, 393-403	33
1691	"Mind the Gap": an unmet need for new therapy in IBD. 2007 , 41, 799-809	16
1690	The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. 2007 , 19, 789-94	33
1689	Maladie de Crohn de l'adulte. 2007 , 2, 1-18	1
1688	[Biologic therapies in inflammatory bowel disease: anti-TNF and new therapeutic targets]. 2007 , 28, 852-61	4
1687	Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials. 2007 , 61, 75-80	60

1686	Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. 2007 , 144, 844-849		103
1685	Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). 2007 , 56, e55-79		88
1684	Ankylosing spondylitis. <i>Lancet, The</i> , 2007 , 369, 1379-1390	40	1210
1683	Inflammatory bowel disease: clinical aspects and established and evolving therapies. <i>Lancet, The</i> , 2007 , 369, 1641-57	40	1301
1682	Diagnosis and management of inflammatory bowel disease in children. 2007 , 16, 164-71		30
1681	Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. 2007 , 56, 1226-31		437
1680	[Infliximab therapy for inflammatory bowel disease: seven years on]. 2007 , 67, 344-51		1
1679	Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. 2007 , 102, 2737-46		40
1678	Certolizumab pegol for the treatment of Crohn's disease. 2007 , 357, 228-38		935
1677	Inflammatory bowel diseases in the elderly. 2007 , 23, 809-21, vi		9
1676	Biologics in General Medicine. 2007 ,		1
1675	Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. 2007 , 48, 1410-3		45
1674	Certolizumab Pegol in Crohn's Disease. 2007 , 21, 202-203		
1673	Infliximab therapy for pediatric Crohn's disease. 2007 , 7, 1869-80		11
1672	Emerging drugs to treat Crohn's disease. 2007 , 12, 49-59		13
1671	Biological response modifier therapy for refractory childhood uveitis. 2007 , 91, 1341-4		73
1670	Tumor necrosis factor-alpha and the early vein graft. 2007 , 45, 169-76		15
1669	Current medical therapy for chronic inflammatory bowel diseases. 2007 , 87, 697-725		15

1668	The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease. 2007 , 8, 67-77	30
1667	[Infliximab-induced skin reaction with visceral manifestations and high levels of anti-DNA antibodies]. 2007 , 134, 268-71	2
1666	Trends in hospitalization rates for inflammatory bowel disease in the United States. 2007 , 5, 597-601	118
1665	Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor necrosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis. 2007 , 150, 223-32	16
1664	[Common errors in the management of the seriously ill patient with inflammatory bowel disease]. 2007 , 30, 294-314	0
1663	[Infliximab therapy in ulcerative colitis: initial experience in two referral centers]. 2007 , 30, 449-53	2
1662	Clinical pharmacokinetics and use of infliximab. 2007 , 46, 645-60	180
1661	Infliximab therapy in children and adolescents with inflammatory bowel disease. 2007 , 67, 1703-23	30
1660	Crohn's disease: a review of current treatment with a focus on biologics. 2007 , 67, 2511-37	53
1659	Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. 2007 , 132, 52-65	1668
1658	Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. 2007 , 132, 863-73; quiz 1165-6	621
1657	Timing infliximab therapy in pediatric Crohn's disease. 2007 , 132, 1167-70	5
1656	American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. 2007 , 133, 312-39	167
1655	Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. 2007 , 133, 412-22	862
1654	Diagnostics of inflammatory bowel disease. 2007 , 133, 1670-89	285
1653	Importance of the Australian Crohn's disease antibiotic study. 2007 , 133, 1744-5; author reply 1745-6	12
1652	Infliximab in paediatric inflammatory bowel disease. 2007 , 1, 2-9	7
1651	Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. 2007 , 39, 811-7	25

1650	Biologics in Crohn's disease: searching indicators for outcome. 2007 , 7, 1233-43	4
1649	Treatment of arthralgias and spondyloarthropathy associated with inflammatory bowel disease. 2007 , 2, 423-431	1
1648	Enteral nutrition for maintenance of remission in Crohn's disease. 2007 , CD005984	62
1647	Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients. 2007 , 21, 637-42	36
1646	Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease. 2007 ,	
1645	Lactobacillus plantarum inhibits epithelial barrier dysfunction and interleukin-8 secretion induced by tumor necrosis factor-alpha. 2007 , 13, 1962-5	64
1644	The fundamental basis of inflammatory bowel disease. 2007 , 117, 514-21	946
1643	Traitement des maladies inflammatoires chroniques de l'intestin. 2007 , 191, 1125-1141	
1642	Special issues in pediatric inflammatory bowel disease. 2008 , 14, 413-20	48
1641	Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. 2007 , 57, 639-47	139
1640	Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy. 2007 , 13, 65-70	20
1639	Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. 2007 , 13, 2-11	101
1638	Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. 2007 , 13, 372-9	54
1637	Safety of biologic therapy. 2007 , 13, 769-96	30
1636	"New drugs: kids come first": children should be included in trials of new biological treatments. 2007 , 13, 1165-9; discussion 1176-7	9
1635	Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. 2007 , 13, 129-34	54
1634	Predictors of early response to infliximab in patients with ulcerative colitis. 2007 , 13, 123-8	134
1633	Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. 2007 , 13, 424-30	101

1632	Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: response to infliximab. 2007 , 13, 509-10	11
1631	Infliximab and the risk of latent viruses reactivation in active Crohn's disease. 2007 , 13, 896-902	73
1630	Fulminant Crohn's colitis: when only an antibody will do. 2007 , 13, 971-4	4
1629	Restoration of soluble CD146 in patients with Crohn's disease treated with the TNF-alpha antagonist infliximab. 2007 , 13, 1315-7	8
1628	Infliximab dose intensification in Crohn's disease. 2007 , 13, 1093-9	105
1627	New drugs: kids come first; con: first adults, then children. 2007 , 13, 1170-5; discussion 1176-7	1
1626	Look before you leap. 2007 , 13, 1176-1177	
1625	Should we be CHARMed?. 2007 , 13, 1308-9	
1624	Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. 2007 , 13, 1395-400	36
1623	Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?. 2007 , 13, 1299-307	86
1622	Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. 2007 , 13, 1323-32	352
1621	What predicts mucosal inflammation in Crohn's disease patients?. 2007 , 13, 1567-72	29
1620	Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. 2007 , 13, 1379-84	47
1619	Drug therapy for inflammatory bowel disease in pregnancy and the puerperium. 2007 , 21, 835-47	23
1618	Biologic therapies in rheumatology: lessons learned, future directions. 2007 , 6, 75-92	141
1617	Tumor necrosis factor blockade: mechanism of action. 2007 , 12, 1-4	28
1616	Invasive Escherichia coli are a feature of Crohn's disease. 2007 , 87, 1042-54	192
1615	Identification of ligands binding specifically to inflammatory intestinal mucosa using phage display. 2007 , 34, 286-9	12

1614	Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. 2007, 22, 1671-7	15
1613	Infliximab: getting the most for your money. 2007, 22, 1559-61	1
1612	Management of inflammatory bowel disease in adults. 2007, 8, 65-71	22
1611	Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID). 2007, 150, 306-11	65
1610	Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies. 2007, 25, 111-22	44
1609	Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. 2007, 25, 419-27	43
1608	Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. 2007, 25, 409-18	73
1607	Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. 2007, 25, 557-67	64
1606	Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study. 2007, 25, 787-96	36
1605	Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. 2007, 25, 675-80	58
1604	Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment. 2007, 25, 925-32	7
1603	Review article: appropriate use of corticosteroids in Crohn's disease. 2007, 26, 313-29	56
1602	A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. 2007, 26, 411-9	108
1601	A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. 2007, 26, 421-30	25
1600	Resource use in patients with Crohn's disease treated with infliximab. 2007, 26, 1313-23	32
1599	Review article: the evidence base for interventions used to maintain remission in Crohn's disease. 2008, 27, 11-8	33
1598	Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. 2007, 26, 1509-20	71
1597	Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. 2008, 27, 19-30	77

1596	Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. 2008 , 27, 220-7	68
1595	The use of adalimumab in the management of refractory Crohn's disease. 2008 , 27, 308-15	53
1594	Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. 2007 , 204, 956-62; discussion 962-3	254
1593	Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. 2007 , 12, 125-31	52
1592	[Current status of treatment of inflammatory bowel disease]. 2007 , 82, 254-9	3
1591	Steroid-sparing effect of wormwood (<i>Artemisia absinthium</i>) in Crohn's disease: a double-blind placebo-controlled study. 2007 , 14, 87-95	76
1590	Pharmacogénétique de l'infliximab dans la maladie de Crohn. 2007 , 37, 521-530	
1589	L'infliximab dans le traitement prolongé de la maladie de Crohn non fistulisante. 2007 , 37, 271-283	
1588	Biologische Therapie chronisch entzündlicher Darmerkrankungen. 2007 , 155, 118-126	
1587	Review article: multiple myeloma and inflammatory bowel disease. 2007 , 52, 2022-8	13
1586	Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. 2007 , 52, 1798-805	18
1585	Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn's disease. 2007 , 52, 1438-41	11
1584	Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn's disease. 2007 , 52, 3329-33	28
1583	Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. 2007 , 50, 672-6	32
1582	Patient preferences between surgical and medical treatment in Crohn's disease. 2007 , 50, 586-97	34
1581	Rectovaginal fistula in Crohn's disease. 2007 , 50, 2215-22	83
1580	Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?. 2007 , 50, 1754-60	85
1579	Inflammatory bowel disease: past, present, and future. 2007 , 42, 16-25	210

1578	Interleukin-18 is increased only in a minority of patients with active Crohn's disease. 2007 , 22, 1013-20	5
1577	Administration of infliximab in general practitioners' offices is safe. 2007 , 26, 1863-6	4
1576	Chronisch-entzündliche Krankheiten. 2007 , 19, 5-9	
1575	Esophageal, gastric, and duodenal manifestations of IBD and the role of upper endoscopy in IBD diagnosis. 2007 , 9, 475-8	26
1574	Biologic therapy for inflammatory bowel disease comes of age. 2007 , 9, 485-488	3
1573	Optimizing drug therapy in inflammatory bowel disease. 2007 , 9, 513-20	10
1572	Positioning biologic therapy for Crohn's disease and ulcerative colitis. 2007 , 9, 521-7	24
1571	Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis. 2007 , 10, 171-7	8
1570	Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease. 2007 , 10, 178-84	16
1569	Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. 2007 , 10, 185-94	12
1568	Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease. 2007 , 10, 195-207	20
1567	Clinical factors contributing to rapid reoperation for Crohn's disease patients undergoing resection and/or strictureplasty. 2007 , 11, 1692-8; discussion 1698	12
1566	Tumour necrosis factor alpha in segmental colitis associated with diverticula. 2008 , 53, 1865-8	16
1565	Long-term durability of Crohn's disease treatment with infliximab. 2008 , 53, 1033-41	49
1564	Chronisch-entzündliche Darmerkrankungen [neue Therapieansätze]. 2008 , 30, 123-138	
1563	Advances in the diagnosis and immunotherapy for ocular inflammatory disease. 2008 , 30, 145-64	23
1562	[Inflammatory bowel diseases--new therapeutic options]. 2008 , 103, 90-101; quiz 102-3	2
1561	Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. 2008 , 12, 1730-6; discussion 1736-7	187

1560	Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. 2008 , 12, 1738-44	212
1559	Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease. 2008 , 10, 302-7	2
1558	Optimizing treatment of inflammatory bowel diseases with biologic agents. 2008 , 10, 591-6	16
1557	Maladies Inflammatoires Chroniques Intestinales (MICI): quelle place pour les traitements conventionnels?. 2008 , 38, 359-374	
1556	Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey. 2008 , 51, 916-23	15
1555	Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. 2008 , 23, 289-96	43
1554	P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. 2008 , 5, 22	48
1553	Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription. 2008 , 5, 4	13
1552	TNF-mediated inflammatory disease. 2008 , 214, 149-60	1196
1551	Biological agents for ulcerative colitis: hypes and hopes. 2008 , 28, 201-18	21
1550	Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis. 2008 , 38, 1318-25	24
1549	Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care. 2008 , 14, 106-13	23
1548	Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. 2008 , 14, 1-6	47
1547	Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. 2008 , 14, 40-6	338
1546	GRIM-19 mutations are not associated with Crohn's disease. 2008 , 14, 434-5	1
1545	Infliximab dose intensification by shortening infusion intervals. 2008 , 14, 432-4	8
1544	Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis. 2008 , 14, 213-6	72
1543	Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception. 2008 , 14, 435-6	19

1542	Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. 2008 , 14, 353-8	51
1541	Another anti-TNF therapy for patients with Crohn's disease. 2008 , 14, 425-7	
1540	The fungus among us. 2008 , 14, 721-2	2
1539	Guidelines for the management of growth failure in childhood inflammatory bowel disease. 2008 , 14, 839-49	142
1538	Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. 2008 , 14, 1197-204	29
1537	Patterns of infliximab use among Crohn's disease patients in a community setting. 2008 , 14, 1265-72	8
1536	Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. 2008 , 14, 1392-8	178
1535	Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. 2008 , 14, 1387-91	34
1534	Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice. 2008 , 14, 1483-90	16
1533	Management of the pregnant IBD patient. 2008 , 14, 1736-50	74
1532	Short-term response to adalimumab in childhood inflammatory bowel disease. 2008 , 14, 1683-7	36
1531	Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. 2008 , 58, 947-52	44
1530	Hépatite induite par l'infliximab : absence de toxicité croisée avec le bñanercept. 2008 , 75, 1280-1282	
1529	Hépatotoxicité des anti-TNF. 2008 , 75, 1208-1210	1
1528	Is there a role for multidrug therapy in active Crohn's disease?. 2008 , 14 Suppl 2, S257-8	
1527	What is the optimal maintenance treatment for Crohn's disease?. 2008 , 14 Suppl 2, S255-6	
1526	How do you judge relapse in Crohn's disease?. 2008 , 14 Suppl 2, S253-4	
1525	How have animal models of IBD contributed to advance IBD therapy?. 2008 , 14 Suppl 2, S134-5	1

1524	Is it always therapeutically important to distinguish between Crohn's disease and ulcerative colitis?. 2008 , 14 Suppl 2, S202-3	2
1523	From model cell line to in vivo gene expression: disease-related intestinal gene expression in IBD. 2008 , 9, 240-8	14
1522	Decoy oligodeoxynucleotide targeting activator protein-1 (AP-1) attenuates intestinal inflammation in murine experimental colitis. 2008 , 88, 652-63	37
1521	Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease. 2008 , 83, 70-6	54
1520	Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective. 2008 , 11, 820-9	23
1519	Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease. 2008 , 27, 765-70	53
1518	Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. 2008 , 27, 885-94	39
1517	Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. 2008 , 27, 1210-23	16
1516	Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults. 2008 , 28, 76-87	69
1515	The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. 2008 , 28, 221-7	31
1514	Anti-mycobacterials and Crohn's disease. 2008 , 28, 373-4	4
1513	Anti-mycobacterials and Crohn's disease: author's reply. 2008 , 28, 374-5	
1512	Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. 2008 , 28, 674-88	76
1511	Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. 2008 , 28, 1122-6	169
1510	Infliximab vs. Adalimumab for Crohn's disease. 2008 , 28, 1265-6; author reply 1266-7	2
1509	Infliximab vs. Adalimumab for Crohn's disease: authors' reply. 2008 , 28, 1266-1267	1
1508	Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited?. 2008 , 32, 153-7	10
1507	[Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases]. 2008 , 32, 467-77	

1506	[Anti-TNF therapy and Crohn's disease]. 2008 , 32, 478-81	3
1505	[Hepatotoxicity of immunosuppressants. Diagnostic approach]. 2008 , 32, S194-204	8
1504	Spondyloarthropathies: progress and challenges. 2008 , 22, 325-37	1
1503	Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. 2008 , 75, 737-9	47
1502	Liver toxicity of TNFalpha antagonists. 2008 , 75, 636-8	11
1501	Cellular and molecular mechanisms that mediate basal and tumour necrosis factor-alpha-induced regulation of myosin light chain kinase gene activity. 2008 , 12, 1331-46	82
1500	Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. 2008 , 68, 747-70	21
1499	Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. 2008 , 31, 1135-44	34
1498	Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. 2008 , 31, 421-6	21
1497	Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. 2008 , CD006893	119
1496	Risk factors for opportunistic infections in patients with inflammatory bowel disease. 2008 , 134, 929-36	756
1495	Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. 2008 , 134, 1861-8	390
1494	Combination therapy with infliximab and immunomodulators: is the glass half empty?. 2008 , 134, 2161-3	6
1493	A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. 2008 , 135, 1130-41	614
1492	Genome-wide association analysis in sarcoidosis and Crohn's disease unravels a common susceptibility locus on 10p12.2. 2008 , 135, 1207-15	66
1491	Current directions in IBD therapy: what goals are feasible with biological modifiers?. 2008 , 135, 1442-7	86
1490	Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. 2008 , 40 Suppl 2, S236-46	7
1489	Infliximab in Crohn's disease: early and long-term treatment. 2008 , 40 Suppl 2, S271-9	12

1488 CHARM: un anàlisi crític. **2008**, 7, 241-243

1487	Efficacy of Infliximab treatment in patients with severe Fistulizing Hidradenitis Suppurativa. 2008 , 2, 241-5	14
1486	Long-term outcome after infliximab for refractory ulcerative colitis. 2008 , 2, 219-25	163
1485	Management of loss of response to anti-TNF drugs: Change the dose or change the drug?. 2008 , 2, 348-51	10
1484	Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease?. 2008 , 2, 322-6	15
1483	Recent advances in the management of Crohn's disease. 2008 , 40, 709-16	10
1482	Novel therapeutic targets in the treatment of IBD. 2008 , 12, 553-63	25
1481	Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. 2008 , 103, 944-8	134
1480	Terapia biologiczna nieswoistych zapaleń jelit u dzieci. 2008 , 83, 691-696	
1479	Improving patients' QoL: how the success of treatment can improve workability. 2008 , 2, 17-18	1
1478	New developments in biologics therapy: what about from the medical point of view?. 2008 , 2, 25-26	
1477	[Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab]. 2008 , 31, 629-32	6
1476	Tratamiento médico de la enfermedad de Crohn. 2008 , 10, 298-306	
1475	Initial combination therapy in early Crohn's disease. <i>Lancet, The</i> , 2008 , 371, 635-636	40 7
1474	Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. <i>Lancet, The</i> , 2008 , 371, 660-667	40 957
1473	Crohn's disease: beyond antagonists of tumour necrosis factor. <i>Lancet, The</i> , 2008 , 372, 67-81	40 80
1472	Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. 2008 , 103, 3123-31	33
1471	Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. 2008 , 6, 644-53	462

1470	Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. 2008 , 6, 1212-7; quiz 1176	123
1469	Fungal Infections Complicating Tumor Necrosis Factor Blockade Therapy. 2008 , 83, 181-194	40
1468	Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. 2008 , 6, 1378-84	89
1467	Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. 2008 , 6, 1370-7	236
1466	Frequency and pattern of endoscopic recurrence in Crohn's disease patients with ileocolonic resection using a laparoscopic versus laparotomic approach: a prospective longitudinal study. 2008 , 103, 809-11	7
1465	The probiotic Escherichia coli strain Nissle 1917 induces gammadelta T cell apoptosis via caspase- and FasL-dependent pathways. 2008 , 20, 829-40	39
1464	Adalimumab for the treatment of Crohn's disease. 2008 , 8, 1011-9	7
1463	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. 2008 , 67 Suppl 3, iii2-25	81
1462	Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy. 2008 , 23, 551-6	29
1461	Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults. 2008 , 2, 163-76	10
1460	Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. 2008 , 76, 275-82	59
1459	STAT4 isoforms differentially regulate Th1 cytokine production and the severity of inflammatory bowel disease. 2008 , 181, 5062-70	27
1458	Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. 2008 , 31 Suppl 3, 505-9	25
1457	Pharmacogenetics of Crohn's disease. 2008 , 9, 881-93	5
1456	Pneumococcal vaccination in adults. 2008 , 168, 666-7	3
1455	Frequency and clinical correlations of granulomas in children with Crohn disease. 2008 , 46, 392-8	77
1454	Inflammatory Bowel Disease in Older People. 2008 , 38, 234-238	1
1453	Medical management of Crohn's disease. 2008 , 336, 1062-6	44

1452	Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. 2008 , 21, 367-74	24
1451	Therapeutic options in acute severe ulcerative colitis. 2008 , 2, 357-70	12
1450	New therapeutic strategies for treatment of inflammatory bowel disease. 2008 , 1, 175-82	62
1449	Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. 2008 , 7, 617-32	35
1448	Ankylosing spondylitis and other spondyloarthropathies: extra-articular manifestations and their management. 2008 , 3, 457-473	
1447	The impact of medical therapy for inflammatory bowel disease on pregnancy outcome. 2008 , 103, 805-6	2
1446	Phosphate nephropathy. 2008 , 103, 807	3
1445	Response to Schiano et al. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. 2008 , 103, 808-9	4
1444	Inflammatory bowel disease: lessons from animal models. 2008 , 103, 802	
1443	Blood cultures of 19 Crohn's disease patients. 2008 , 103, 802-3	10
1442	Low colorectal cancer screening rates and primary care physicians' behavior. 2008 , 103, 804-5	2
1441	Hiccups: an unrecognized symptom of esophageal cancer?. 2008 , 103, 801	15
1440	Septic pylephlebitis mimicking biliary obstruction. 2008 , 103, 807-8	5
1439	Polyflex or ultraflex stents to treat peptic refractory esophageal strictures?. 2008 , 103, 803-4	
1438	Colorectal cancer screening in Latin America: the Panama experience. 2008 , 103, 806-7	
1437	Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. 2008 , 103, 1210-6	85
1436	Nonmetastatic cancer of the colon associated with pyogenic liver abscess. 2008 , 103, 798-9	17
1435	The appropriateness of colorectal cancer screening by fecal occult blood tests. 2008 , 103, 800-1	

1434	Acute phosphate nephropathy--comment on Sica et al. 2008 , 103, 800	0
1433	Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. 2008 , 67, 189-94	321
1432	Susceptibility to nontuberculous mycobacterial lung disease. 2008 , 31, 1322-33	111
1431	Long-term management of generalized pustular psoriasis with infliximab: case series. 2008 , 12, 184-8	14
1430	Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. 2008 , 299, 1690-7	190
1429	Autoantibody production in patients treated with anti-TNF-alpha. 2008 , 4, 275-80	34
1428	Pathogenesis and Clinical Practice in Gastroenterology. 2008 ,	
1427	A patient with systemic lupus erythematosus and Crohn's disease complicated with massive lower gastrointestinal bleeding, mimicking intestinal vasculitis. 2008 , 17, 1049-50	11
1426	Is there a role for bowel rest in nutrition management of Crohn's disease?. 2008 , 23, 309-17	7
1425	Moderate-to-Severe Psoriasis. 2008 ,	
1424	Crohn's disease: current treatment options. 2008 , 93, 787-92	32
1423	Efficacy and safety of adalimumab in Crohn's disease. 2008 , 1, 43-50	19
1422	Myeloid-derived suppressor cells in cancer cachexia syndrome: a new explanation for an old problem. 2008 , 32, 651-5	15
1421	[Clinical practice guideline on diagnosis and treatment of Crohn's disease]. 2008 , 46, 1094-146	96
1420	[Perianal fistulas in Crohn's disease--biologicals and surgery: is it worthwhile?]. 2008 , 46, 1376-83	2
1419	Specific considerations in the treatment of pediatric inflammatory bowel disease. 2008 , 2, 105-24	9
1418	How have animal models of ibd contributed to advance ibd therapy?. 2008 , 14, S134-S135	
1417	How do you judge relapse in Crohn's disease?. 2008 , 14, S253-S254	

- 1416 Is it always therapeutically important to distinguish between Crohn's disease and ulcerative colitis?. **2008**, 14, S202-S203
- 1415 What is the optimal maintenance treatment for Crohn's disease?. **2008**, 14, S255-S256
- 1414 Safety and efficacy of adalimumab in pediatric patients with Crohn disease. **2008**, 47, 19-25 39
- 1413 Thalidomide for maintenance of remission in Crohn's disease. **2008**,
- 1412 Methotrexate for maintenance of remission in Crohn's disease. **2008**,
- 1411 Crohn's disease in an African-American population. **2008**, 336, 389-92 24
- 1410 IMMUNOMODULATORS CAN BE DISCONTINUED IN PATIENTS ON SCHEDULED INFLIXAMAB TREATMENT. **2008**, 9, 75-77
- 1409 Is there a role for multidrug therapy in active Crohn's disease?. **2008**, 14, S257-S258
- 1408 Fungal Infections Complicating Tumor Necrosis Factor Blockade Therapy. **2008**, 83, 181-194 245
- 1407 Hypersensitivity reactions to last generation chimeric, humanized [correction of umanized] and human recombinant monoclonal antibodies for therapeutic use. **2008**, 14, 2883-91 27
- 1406 MAINTENANCE THERAPY WITH CERTOLIZUMAB PEGOL FOR CROHN'S DISEASE: A BETTER MOUSETRAP?. **2008**, 9, 13-15
- 1405 FIRST DO NO HARM??? RISK FACTORS FOR OPPORTUNISTIC INFECTIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. **2008**, 9, 41-42
- 1404 12-month follow-up after successful infliximab therapy in pediatric crohn disease. **2008**, 46, 293-8 35
- 1403 Molecular pathogenesis of inflammatory bowel disease: relevance for novel therapies. **2008**, 5, 609-626 2
- 1402 Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. **2008**, 24, 462-8 39
- 1401 Biologic therapy in Crohn's disease: state of the art. **2008**, 24, 475-81 5
- 1400 CERTOLIZUMAB PEGOL REDUCES SYMPTOMS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE. **2008**, 9, 32-33
- 1399 The direct and indirect cost burden of Crohn's disease and ulcerative colitis. **2008**, 50, 1261-72 135

1398	Review and clinical perspectives for the use of infliximab in ulcerative colitis. 2008 , 22, 261-72	7
1397	Treatment of Ulcerative Colitis; Update. 2008 , 3,	
1396	Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. 2008 , 3, e2629	80
1395	Inflammatory Bowel Disease and the Short Bowel Syndrome. 99-106	1
1394	Thalidomide for induction of remission in Crohn's disease. 2008 ,	
1393	Treatment of inflammatory bowel disease: a review of medical therapy. 2008 , 14, 354-77	163
1392	Oropharyngeal Crohn's disease. 2008 , 1, 15-8	6
1391	Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease. 2009 , 104, 760-767	
1390	New biologics in the management of Crohn's disease: focus on certolizumab pegol. 2009 , 61	
1389	Patient choice in administering anti-TNF for severe, active Crohn's disease in adults. 2009 , 7, 16-22	1
1388	Lower Gastrointestinal Disorders. 301-320	
1387	. 2009 ,	3
1386	Inflammatory bowel disease in the geriatric population. 2009 , E3, 945	
1385	[Efficacy of infliximab in the treatment of korean patients with crohns disease]. 2009 , 54, 108-16	12
1384	Infliximabe na doenã de crohn: experiãcia clãnica de um centro terciãrio paulista. 2009 , 29, 38-45	3
1383	Biologic targeting in the treatment of inflammatory bowel diseases. 2009 , 77	1
1382	Tratamento da doenã de Crohn com infliximabe: primeira opãõ?. 2009 , 22, 101-104	1
1381	[Biologics in current therapy for inflammatory bowel disease]. 2009 , 32, 168-79	

1380 Infliximab: A Review of its Use in the Treatment of Crohn's Disease. **2009**, 1, CMT.S2250

- 1379 Análise de custo-minimizaçã entre o Infliximabe (IFX) e o Adalimumabe (ADA) no tratamento da doenã de Crohn (DC). **2009**, 29, 158-168 5
- 1378 Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. **2009**, 23, 348-52 29
- 1377 Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. **2009**, 23, 185-202 33
- 1376 Anti-tumour necrosis factor-alpha therapies in Crohn's disease. **2009**, 70, 644-7
- 1375 Maintenance treatment with infliximab for the management of Crohn's disease in adults. **2009**, 39
- 1374 Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. **2009**, 58, 492-500 399
- 1373 Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection?. **2009**, 6, 638-47 95
- 1372 An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. **2009**, 68, 1433-9 95
- 1371 Anti-TNF Therapy in Inflammatory Bowel Diseases. **2009**, 95-107 1
- 1370 Biological therapies for inflammatory bowel disease: controversies and future options. **2009**, 2, 391-403 15
- 1369 Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. **2009**, 58, 1427-36 54
- 1368 Selecting appropriate anti-TNF agents in inflammatory bowel disease. **2009**, 3, 235-48 15
- 1367 Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. **2009**, 104, 2768-73 61
- 1366 Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. **2009**, 104, 1976-83 32
- 1365 Duodenopancreatic fistula complicating upper gastrointestinal Crohn's disease: successful treatment with infliximab. **2009**, 104, 1863-4 11
- 1364 The true culprit within the SPINK1 p.N34S-containing haplotype is still at large. **2009**, 58, 478-80 10
- 1363 Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. **2009**, 79, 30-5 26

1362	Predicting response to Anti-TNF Agents for the treatment of crohn's disease. 2009 , 2, 245-51	61
1361	Severe acute ulcerative colitis: the pediatric perspective. 2009 , 27, 322-6	15
1360	Mild to moderate Crohn's disease: still room for step-up therapies?. 2009 , 27, 347-50	5
1359	Anti-tumor necrosis factor nonresponders in Crohn's disease: therapeutic strategies. 2009 , 27, 351-7	7
1358	Early inflammatory bowel disease: different treatment response to specific or all medications?. 2009 , 27, 358-65	15
1357	Targeted therapies in inflammatory bowel disease. 2009 , 27, 465-9	20
1356	How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease. 2009 , 27 Suppl 1, 80-4	7
1355	Drug-induced lupus associated with infliximab and adalimumab in an adolescent with Crohn disease. 2009 , 49, 355-8	8
1354	Rapid infliximab infusions in pediatric inflammatory bowel disease. 2009 , 49, 151-4	18
1353	Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. 2009 , 21, 71-5	32
1352	Curcumin has bright prospects for the treatment of inflammatory bowel disease. 2009 , 15, 2087-94	137
1351	Can ELISpot replace the tuberculin skin test for latent tuberculosis?. 2009 , 18, 1248-54	5
1350	TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. 2009 , 16, 3152-67	202
1349	TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. 2009 , 9, 295-314	25
1348	Psoriasis comorbidities. 2009 , 13 Suppl 2, S77-87	26
1347	Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. 2009 , 296, G850-9	109
1346	Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. 2009 , 58, 501-8	313
1345	Balancing the risks and benefits of prolonged use of infliximab. 2009 , 58, 477-8	3

1344	Certolizumab pegol for the management of Crohn's disease in adults. 2009 , 31, 1158-76	30
1343	Incidence and nature of infectious disease in patients treated with anti-TNF agents. 2009 , 9, 67-81	52
1342	The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. 2009 , 78, 1214-23	58
1341	Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. 2009 , 33, 31-40	16
1340	TNF antagonists in the treatment of inflammatory bowel disease: results of a survey of gastroenterologists in the French region of Lorraine. 2009 , 33, 23-30	7
1339	Methotrexate: the best choice for second-line maintenance treatment in active Crohn's disease?. 2009 , 33, 21-2	0
1338	[Which place for methotrexate in treatment of luminal Crohn's disease?]. 2009 , 33, 18-20	
1337	Liver and inflammatory bowel disease. 2009 , 33, 370-81	15
1336	Ten years of infliximab (remicade) in clinical practice: the story from bench to bedside. 2009 , 623 Suppl 1, S1-4	5
1335	Infliximab therapy for patients with inflammatory bowel disease: 10 years on. 2009 , 623 Suppl 1, S17-25	19
1334	Biological markers in inflammatory bowel disease: practical consideration for clinicians. 2009 , 33 Suppl 3, S158-73	83
1333	Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?. 2009 , 33 Suppl 3, S202-8	5
1332	Anti-TNF-alpha treatment strategies: results and clinical perspectives. 2009 , 33 Suppl 3, S209-16	8
1331	Esophageal ulcer of Crohn's disease: disappearance in 1 week with infliximab. 2009 , 15, 1121-2	6
1330	Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. 2009 , 15, 375-82	118
1329	Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis. 2009 , 15, 422-8	4
1328	Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. 2009 , 15, 388-94	77
1327	Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. 2009 , 15, 816-22	141

1326	Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease. 2009 , 15, 1240-4	26
1325	Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. 2009 , 15, 1264-75	98
1324	Gastroenterologists' prescribing of infliximab for Crohn's disease: a national survey. 2009 , 15, 1467-75	8
1323	Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. 2009 , 15, 1460-6	96
1322	Positioning biologic agents in the treatment of Crohn's disease. 2009 , 15, 1570-82	12
1321	Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. 2009 , 15, 1295-301	499
1320	Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. 2009 , 15, 1476-84	47
1319	Differential expression of leukocyte functions associated antigen-1 (LFA-1) on peripheral blood mononuclear cells in patients with Crohn's disease. 2009 , 15, 1379-84	
1318	Adalimumab safety in global clinical trials of patients with Crohn's disease. 2009 , 15, 1308-19	98
1317	Durability of infliximab in Crohn's disease: a single-center experience. 2009 , 15, 1837-43	14
1316	Factors predicting the outcome of disease activity assessment in Crohn's disease. 2009 , 15, 1859-66	13
1315	Anti-IL-12/23: the next big thing in IBD?. 2009 , 15, 1927-8	3
1314	Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. 2009 , 15, 1599-604	84
1313	Lack of TNFR2 expression by CD4(+) T cells exacerbates experimental colitis. 2009 , 39, 1743-53	31
1312	Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: a case report. 2009 , 15, 682-5	19
1311	Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. 2009 , 61, 560-8	150
1310	Immunomodulation does not alter histology in resected Crohn's disease. 2009 , 13, 295-300	4
1309	XXVIIIe congrès du CREGG, 25-26 septembre 2009, Marne-la-Vallée. 2009 , 39, 265-321	

1308	Use of double-balloon enteroscopy in the management of patients with Crohn's disease: feasibility and diagnostic yield in a high-volume centre for inflammatory bowel disease. 2009 , 23, 2790-5	47
1307	Effectiveness of IkappaB kinase inhibitors in murine colitis-associated tumorigenesis. 2009 , 44, 935-43	35
1306	Drug-induced lupus erythematosus. 2009 , 301, 99-105	175
1305	The precision of health state valuation by members of the general public using the standard gamble. 2009 , 18, 509-18	7
1304	Esophageal, gastric, and duodenal manifestations of IBD and the role of upper endoscopy in IBD diagnosis. 2009 , 11, 234-7	31
1303	Natural history and complications of IBD. 2009 , 11, 481-7	44
1302	Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease). 2009 , 11, 504-8	8
1301	Managing the risks of IBD therapy. 2009 , 11, 509-17	5
1300	Effect of acupuncture-moxibustion on TNF- α /sTNFR-I and sTNFR-II of rats with Crohn's disease. 2009 , 7, 29-32	1
1299	Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. 2009 , 26, 936-46	76
1298	Infliximab treatment for Crohn's disease in a patient with IgA nephropathy. 2009 , 2, 380-383	6
1297	Crohn's disease clinical issues and treatment: what the radiologist needs to know and what the gastroenterologist wants to know. 2009 , 34, 297-302	6
1296	Increased plasma ghrelin following infliximab in Crohn's disease. 2009 , 29, 83-9	9
1295	Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. 2009 , 29, 273-8	35
1294	The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. 2009 , 29, 286-97	105
1293	Infliximab treatment for symptomatic Crohn's disease strictures. 2009 , 29, 279-85	66
1292	Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). 2009 , 29, 527-34	48
1291	Infliximab dependency in children with Crohn's disease. 2009 , 29, 792-9	19

1290	Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease. 2009 , 29, 605-14	34
1289	Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. 2009 , 29, 1106-13	64
1288	The tolerance and efficacy of a postponed retreatment with infliximab in Crohn's disease primary responders. 2009 , 29, 1240-8	11
1287	Clinical trial: cyclophosphamide pulse therapy - a promising therapeutic alternative in refractory Crohn's disease. 2009 , 29, 1230-9	12
1286	Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. 2009 , 30, 210-26	161
1285	Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. 2009 , 30, 265-74	96
1284	Review article: diet and inflammatory bowel disease--epidemiology and treatment. 2009 , 30, 99-112	87
1283	Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. 2009 , 30, 977-86	37
1282	Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45 years: a proposed method. 2009 , 30, 1078-86	6
1281	Safety and tolerability of omalizumab. 2009 , 39, 788-97	183
1280	Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. 2009 , 24, 1252-7	24
1279	Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?. 2009 , 24, 1160-2	6
1278	Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. 2009 , 68, 1863-9	137
1277	Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. 2009 , 20, 100-8	215
1276	Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. 2009 , 68, 1177-83	109
1275	Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. 2009 , 104, 2100-9	155
1274	TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. 2009 , 46, 222-7	62
1273	CT enterography: principles, technique and utility in Crohn's disease. 2009 , 69, 393-7	65

1272	Medical management of Crohn's disease: a guide for radiologists. 2009 , 69, 371-4	2
1271	Inflammatory bowel disease. 2009 , 108, e1-10	28
1270	[Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología]. 2009 , 100, 103-12	10
1269	[Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab]. 2009 , 70, 271-7	2
1268	Talking about life and IBD: A paradigm for improving patient-physician communication. 2009 , 3, 1-3	11
1267	Public awareness of Crohn's disease and ulcerative colitis: A national survey. 2009 , 3, 157-61	6
1266	Pulmonary Crohn's disease: A rare extra-intestinal manifestation treated with infliximab. 2009 , 3, 207-11	12
1265	Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel - EPACT II. 2009 , 3, 241-9	4
1264	Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel-EPACT II. 2009 , 3, 232-40	11
1263	Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. 2009 , 3, 271-6	20
1262	Clinical course of Crohn's disease first diagnosed at surgery for acute abdomen. 2009 , 41, 269-76	36
1261	Use of colonoscopy in the management of patients with Crohn's disease: appropriateness and diagnostic yield. 2009 , 41, 653-8	3
1260	Segmental colitis associated with diverticula: a rare clinical entity and a new challenge for the gastroenterologist. 2009 , 41, 794-7	13
1259	Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent. 2009 , 229-254	4
1258	Reactions to Infliximab Infusions in Dermatologic Patients: Consensus Statement and Treatment Protocol. 2009 , 100, 103-112	
1257	Biological therapies for inflammatory bowel diseases. 2009 , 136, 1182-97	306
1256	Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. 2009 , 137, 1628-40	403
1255	P205 - Outcome of patients with Crohn's disease and primary sclerosing cholangitis in CHARM and GAIN. 2009 , 3, S91-S92	0

1254	P206 - Which patient population profits best from a high dose, once daily treatment with 3.0g mesalazine for maintaining clinical remission in ulcerative colitis? A subgroup analysis of a double-blind, double-dummy, randomised, controlled, dose-ranging study. 2009 , 3, S92	
1253	P207 - Infliximab use in adolescents with IBD. 2009 , 3, S92	
1252	Can we modulate the clinical course of inflammatory bowel diseases by our current treatment strategies?. 2009 , 27, 516-21	22
1251	Overview of biologic therapy for Crohn's disease. 2009 , 9, 967-74	17
1250	Overview of stem cell therapy for Crohn's disease. 2009 , 9, 841-7	34
1249	Medical management of Crohn's disease: treatment algorithms 2009. 2009 , 27, 536-41	9
1248	Mucosal healing: impact on the natural course or therapeutic strategies. 2009 , 27, 470-5	17
1247	Molecular Mechanisms of Spondyloarthropathies. 2009 ,	2
1246	How to manage difficult Crohn's disease: optimum delivery of anti-TNFs. 2009 , 3, 407-15	4
1245	Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. 2009 , 6, 433-6	34
1244	Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. 2009 , 44, 774-81	120
1243	Budesonide for Crohn's disease. 2009 , 5, 971-9	14
1242	Hepatosplenic T-cell lymphoma and TNF- α inhibitors. 2009 , 2, 611-4	9
1241	Advances in surgical approaches to Crohn's disease: minimally invasive surgery and biologic therapy. 2009 , 5, 463-70	4
1240	Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. 2009 , 27, 609-21	36
1239	Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. 2009 , 104, 760-7	486
1238	Management of Crohn's disease in adults. 2009 , 104, 465-83; quiz 464, 484	691
1237	Therapy of spondyloarthritides. 2009 , 649, 133-47	9

1236	Pregnancy and inflammatory bowel disease. 2009 , 38, 629-49	10
1235	Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. 2009 , 7, 874-81	395
1234	Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. 2009 , 38, 577-94	19
1233	Safety profile of IBD: lymphoma risks. 2009 , 38, 669-89	11
1232	A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab. 2009 , 21, 1042-8	12
1231	Development of antibodies against humanized antitumor necrosis factor and loss of efficacy in a black spider monkey with inflammatory bowel disease. 2009 , 15, 39	
1230	Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. 2009 , 21, 283-8	36
1229	Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy. 2009 , 32, 327-39	12
1228	Anti Tumor Necrosis Factor Alpha (TNFα) Therapy in Ankylosing Spondylitis - Asian Perspective. 2009 , 5, 158-164	
1227	Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. 2009 , 43, 950-6	18
1226	[Management and treatment of Crohn's disease. 2. Anti-cytokine therapy]. 2009 , 98, 88-93	
1225	Thalidomide and thalidomide analogues for induction of remission in Crohn's disease. 2009 , CD007350	14
1224	Immunogenicity Assessment of Antibody Therapeutics. 20-42	
1223	Methotrexate for maintenance of remission in Crohn's disease. 2009 , CD006884	29
1222	Severe neutropenia following a single infliximab infusion in a child with Crohn disease. 2009 , 15, S10	
1221	[Targeting therapy for inflammatory diseases by anti-TNFalpha biologics]. 2009 , 129, 19-24	7
1220	Infliximab in the treatment of pediatric Crohn's disease. 2009 , 6, 15-22	2
1219	OP-Indikation: Wie oft zuviel und zu frh. operiert?. 2009 , 25, 219-224	2

1218	Immunosuppression in inflammatory bowel disease: traditional, biological or both?. 2009 , 25, 323-8	8
1217	Making therapeutic decisions in inflammatory bowel disease: the role of patients. 2009 , 25, 334-8	19
1216	Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. 2009 , 49, 183-90	49
1215	Biotechnological Approaches for the Treatment of Inflammatory Diseases. 2009 , 8, 51-71	1
1214	Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. 2009 , CD007351	13
1213	Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies?. 2009 , 48, 257-67	31
1212	Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update. 2010 , 22, 779-86	11
1211	Efficacy of anti-TNF in Crohn's disease: how does it work?. 2010 , 11, 138-42	14
1210	Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?. 2010 , 11, 179-86	31
1209	Mucosal healing and anti TNFs in IBD. 2010 , 11, 227-33	44
1208	Anti-TNF and Crohn's disease: when should we start?. 2010 , 11, 143-7	8
1207	Anti-TNF and fistulizing perianal Crohn's disease: use in clinical practice. 2010 , 11, 187-97	7
1206	Anti TNF-alpha treatment for Crohn' disease: "mhage a trois". 2010 , 11, 136-7	3
1205	Concomitant use of immunomodulators with anti-TNF in Crohn's disease: yes or no?. 2010 , 11, 176-8	9
1204	A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn disease. 2010 , 51, 714-7	21
1203	Listeria meningitis after infliximab treatment of ulcerative colitis. 2010 , 50, 337-9	22
1202	Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. 2010 , 50 Suppl 1, S14-34	39
1201	Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. 2010 , 50 Suppl 1, S1-13	108

1200	Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen. 2010 , 44, 34-7	30
1199	Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. 2010 , 22, 334-9	13
1198	Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients. 2010 , 22, 1196-203	12
1197	Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use. 2010 , 50, 628-33	11
1196	Trends in surgery for Crohn's disease in the era of infliximab. 2010 , 252, 307-12	108
1195	Takayasu's arteritis in a patient with Crohn's disease: an unexpected association during infliximab therapy. 2010 , 49, 179-82	20
1194	3) Antibody Therapy for Inflammatory Bowel Disease.. 2010 , 99, 2172-2176	
1193	Scheduled maintenance therapy with infliximab improves the prognosis of Crohn's disease: a single center prospective cohort study in Japan. 2010 , 220, 207-15	1
1192	Inflammatory bowel disease in children: current trends. 2010 , 45, 673-82	30
1191	Dynamic MRI of the small bowel: usefulness of quantitative contrast-enhancement parameters and time-signal intensity curves for differentiating between active and inactive Crohn's disease. 2010 , 35, 646-53	58
1190	[Serious course of a miliary tuberculosis in a 34-year-old patient with ulcerative colitis and HIV infection under concomitant therapy with infliximab]. 2010 , 105, 314-8	4
1189	The role of infection in the aetiology of inflammatory bowel disease. 2010 , 45, 266-76	93
1188	The impact of disease activity of Crohn's disease during pregnancy on fetal growth. 2010 , 3, 179-81	6
1187	Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. 2010 , 38, 82-9	122
1186	Infliximab-related hepatitis: discussion of a case and review of the literature. 2010 , 5, 193-200	95
1185	Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. 2010 , 55, 1413-20	17
1184	Response to medical treatment in patients with Crohn's disease: the role of NOD2/CRAD15, disease phenotype, and age of diagnosis. 2010 , 55, 1674-80	14
1183	Circulating cytokines reflect mucosal inflammatory status in patients with Crohn's disease. 2010 , 55, 2316-26	13

1182	Surgery for intestinal Crohn's disease recurrence. 2010 , 148, 936-46	27
1181	Genetic ablation of Tnfalpha demonstrates no detectable suppressive effect on inflammation-related mouse colon tumorigenesis. 2010 , 184, 423-30	18
1180	Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. 2010 , 16, 243-9	87
1179	Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center. 2010 , 16, 830-5	71
1178	Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey. 2010 , 16, 933-8	23
1177	Perianal fistulae in Crohn's Disease: current and future approaches to treatment. 2010 , 16, 870-80	12
1176	Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. 2010 , 16, 881-95	100
1175	Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease. 2010 , 16, 1173-9	14
1174	Methotrexate for maintenance of remission in chronic active Crohn's disease: long-term single-center experience and meta-analysis of observational studies. 2010 , 16, 1195-202	15
1173	Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. 2010 , 16, 1357-66	105
1172	To TNF or not to TNF: that is the question. 2010 , 16, 1993-5	
1171	Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease. 2010 , 16, 1708-16	34
1170	CCL2 (pM levels) as a therapeutic agent in Inflammatory Bowel Disease models in mice. 2010 , 16, 1496-504	13
1169	Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. 2010 , 16, 1898-904	43
1168	Nonfistulizing perianal Crohn's disease: clinical features, epidemiology, and treatment. 2010 , 16, 1431-42	44
1167	Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. 2010 , 16, 1912-21	40
1166	Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?. 2010 , 16, 1922-5	15
1165	Safety of infliximab in Crohn's disease: a large single-center experience. 2010 , 16, 2109-16	28

1164	Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. 2010 , 16, 2168-72	21
1163	Bacterial induction of proinflammatory cytokines in inflammatory bowel disease. 2010 , 16, 2173-9	21
1162	Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. 2010 , 16 Suppl 1, S1-11	14
1161	Pain from Abdominal Organs. 2010 , 174-193	
1160	Prevention of acute adverse events related to infliximab infusions in pediatric patients. 2010 , 62, 785-90	20
1159	Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation. 2010 , 224, 316-26	15
1158	Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists. 2010 , 41, 723-7	61
1157	Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections?. 2010 , 60, 386-96	22
1156	Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease. 2010 , 13, 188-95	14
1155	Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study. 2010 , 37, 708-13	42
1154	Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. 2010 , 31, 20-34	83
1153	The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. 2010 , 31, 92-101	94
1152	Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. 2010 , 31, 553-60	47
1151	Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. 2010 , 31, 1296-309	78
1150	Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease. 2010 , 32, 313-23	12
1149	Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. 2010 , 32, 1129-34	74
1148	The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. 2010 , 32, 1228-39	112
1147	Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. 2010 , 32, 1357-63	28

1146	Therapeutic antibodies for autoimmunity and inflammation. 2010 , 10, 301-16	654
1145	Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease. 2010 , 25, 810-6	26
1144	Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. 2010 , 25, 886-91	17
1143	Western-style diets induce macrophage infiltration and contribute to colitis-associated carcinogenesis. 2010 , 25, 1785-94	34
1142	Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. 2010 , 25, 1732-8	63
1141	Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia. 2010 , 40, 139-49	10
1140	Advances in the management of inflammatory bowel disease. 2010 , 40, 258-64	14
1139	Tumor necrosis factor- β signaling in macrophages. 2010 , 20, 87-103	783
1138	Sargramostim (GM-CSF) for induction of remission in Crohn's disease. 2010 ,	
1137	Crohn Disease. 2010 , 225-235	
1136	Sclerosing mesenteritis successfully treated with a TNF antagonist. 2010 , 2010,	10
1135	Infliximab therapy in pediatric Crohn's disease: a review. 2010 , 57	
1134	TNF superfamily - mechanisms of action, biologic functions and therapeutic possibilities. 2010 , 6, 303-309	3
1133	Risk assessment for new therapies in inflammatory bowel disease. 2010 , 8, 551-555	1
1132	Tried and tested: Ten years' experience of infliximab in inflammatory bowel disease. 2010 , 8, 16-23	
1131	Consensus guidelines for the management of inflammatory bowel disease. 2010 , 47, 313-25	23
1130	Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet. 2010 , 16, 2484-95	136
1129	Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. 2010 , 16, 616-28	49

1128	The Principles of Drug Therapy of Crohn's Disease in Child and Adolescent. 2010 , 13, S59	4
1127	The safety of infliximab infusions in the community setting. 2010 , 24, 307-11	22
1126	Advances in Understanding the Pathogenesis of Inflammatory Bowel Disease. 2010 , 2945-2957	
1125	Impact of pain on health-related quality of life in patients with inflammatory bowel disease. 2010 , 16, 3168-77	91
1124	Locking the Door to Leukocytes: Use of Integrin Inhibitors for the Treatment of Crohn's Disease. 2010 , 2, CMT.S4013	
1123	Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer. 2010 , 2, 347-65	8
1122	Natural killer cell lymphoma in a pediatric patient with inflammatory bowel disease. 2010 , 126, e977-81	11
1121	Review of the safety and efficacy of ustekinumab. 2010 , 3, 321-8	29
1120	Decision-making in ileocecal Crohn's disease management: surgery versus pharmacotherapy. 2010 , 4, 181-9	11
1119	Probiotics promote gut health through stimulation of epithelial innate immunity. 2010 , 107, 454-9	247
1118	Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. 2010 , 105, 1811-9	119
1117	Anti-TNF treatment in Crohn's disease: toward tailored therapy?. 2010 , 105, 1140-1	8
1116	Biological therapies of inflammatory bowel disease. 2010 , 2, 727-42	9
1115	Infliximab, azathioprine or combination therapy in the treatment of active Crohn's disease. 2010 , 4, 709-12	1
1114	Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. 2010 , 105, 1133-9	380
1113	Racial disparities in utilization of specialist care and medications in inflammatory bowel disease. 2010 , 105, 2202-8	53
1112	A population-based study of health-care resource use among infliximab users. 2010 , 105, 2009-16	17
1111	Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. 2010 , 6, 621-31	31

1110	Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update. 2010 , 6, 543-50	35
1109	Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. 2010 , 94, 284-8	80
1108	Current directions of biologic therapies in inflammatory bowel disease. 2010 , 3, 99-106	25
1107	Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease. 2010 , 7, 174-7	14
1106	The pharmacoeconomics of biologic therapy for IBD. 2010 , 7, 103-9	20
1105	Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. 2010 , 25, 3307-14	62
1104	Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. 2010 , 116, 6123-32	128
1103	Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases. 2010 , 29, 4-37	9
1102	Clinically validated approaches to the treatment of autoimmune diseases. 2010 , 19, 195-213	21
1101	Optimal use of biologics in the management of Crohn's disease. 2010 , 3, 179-89	27
1100	Optimizing the safety of biologic therapy for IBD. 2010 , 7, 93-101	40
1099	NICE guidance for anti-tumour necrosis factor therapy in Crohn's disease: what does it mean for the inflammatory bowel disease community?. 2010 , 1, 144-146	4
1098	The Large Bowel. 2010 , 661-677	2
1097	Suspected intestinal tuberculosis might be Crohn's disease. 2010 , 2010, 695461	
1096	What options do we have for induction therapy for Crohn's disease?. 2010 , 28, 543-7	5
1095	Biological nurse specialist: goodwill to good practice. 2010 , 19, 477-80	12
1094	Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. 2010 , 6, 607-20	18
1093	Chemokines in inflammatory bowel diseases. 2010 , 28, 386-94	44

1092	Inflammatory bowel disease and pregnancy: an update. 2010 , 6, 643-57	28
1091	State-of-the-art: Immunosuppression and biologic therapy. 2010 , 28, 536-42	26
1090	[Treatment of Crohn's disease: step-up or top-down?]. 2010 , 135, 1694-8	0
1089	[Biologics in gastroenterology: TNF-blockers]. 2010 , 135, 2243-52	1
1088	Current therapeutic approaches in inflammatory bowel disease. 2010 , 16, 3668-83	25
1087	Emerging drugs to treat Crohn's disease. 2010 , 15, 309-22	1
1086	Efficacy and safety of drugs for ulcerative colitis. 2010 , 9, 573-92	24
1085	The cost effectiveness and budget impact of natalizumab for formulary inclusion. 2010 , 13, 63-9	20
1084	Pregnancy and inflammatory bowel disease. 2010 , 94, 53-73	6
1083	Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECISE 4 Study. 2010 , 8, 696-702.e1	61
1082	The complex clinical picture of side effects to biologics. 2010 , 94, 791-804, xi-ii	28
1081	Anti-tumor necrosis factor therapy in Crohn's disease: more information and more questions about the long term. 2010 , 8, 556-8	4
1080	The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. 2010 , 8, 655-9	39
1079	Tumor necrosis factor- α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. 2010 , 39, 543-57	33
1078	Innovative uses of tumor necrosis factor alpha inhibitors. 2010 , 28, 559-75	34
1077	Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. 2010 , 8, 600-9	91
1076	What is the optimal therapy for Crohn's disease: step-up or top-down?. 2010 , 4, 167-80	31
1075	Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. 2010 , 24 Suppl 1, 3-14	71

1074	Hepatotoxicity of agents used in the management of inflammatory bowel disease. 2010 , 28, 508-18	57
1073	Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. 2010 , 94, 1-18	26
1072	Orally administered <i>L. lactis</i> secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. 2010 , 3, 49-56	183
1071	Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECISE 2 randomized maintenance trial data. 2010 , 105, 1574-82	165
1070	Ineffectiveness of infliximab therapy in severe infantile Crohn's disease. 2010 , 4, 106-9	1
1069	A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. 2010 , 4, 221-56	68
1068	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. 2010 , 4, 28-62	1071
1067	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. 2010 , 4, 7-27	808
1066	Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. 2010 , 4, 329-33	23
1065	Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies. 2010 , 4, 594-8	17
1064	Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. 2010 , 4, 355-66	227
1063	Hepatosplenic T-cell lymphoma and inflammatory bowel disease. 2010 , 4, 511-22	78
1062	5-aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study. 2010 , 4, 575-81	18
1061	Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. 2010 , 105, 501-23; quiz 524	917
1060	Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach. 2010 , 70, 109-20	16
1059	E20 EBV and lymphoma in IBD. 2010 , 4, 15-16	
1058	E21 Why do treatments fail? [Basic]. 2010 , 4, 16	
1057	E22 Why failure of medical treatment (clinical aspects). 2010 , 4, 16-17	

1056	Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. 2010 , 138, 463-8; quiz e10-1	625
1055	Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. 2010 , 138, 2282-91	194
1054	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. 2010 , 36, 1185-206	360
1053	Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. 2010 , 8, 1048-55	127
1052	Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. 2010 , 59, 49-54	404
1051	Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. 2010 , 62, 205-17	288
1050	[Must immunomodulators be added to biological treatment in inflammatory bowel disease?]. 2010 , 33, 43-53	2
1049	[Hepatotoxicity induced by new immunosuppressants]. 2010 , 33, 54-65	14
1048	[Markers of the course of inflammatory bowel disease treated with immunomodulators or biological agents]. 2010 , 33, 449-60	
1047	[Perianal herpes simplex in a patient with Crohn's disease treated with infliximab]. 2010 , 33, 758-9	2
1046	Infliximab, azathioprine, or combination therapy for Crohn's disease. 2010 , 362, 1383-95	2198
1045	Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. 2010 , 6, 659-66	19
1044	Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. 2010 , 59, 1363-8	132
1043	The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases. 2010 , 4, 1-3	
1042	Combined treatment with adalimumab and surgery in a patient with steroid-dependent Crohn's disease complicated by perianal disease. 2010 , 4, 34-37	
1041	Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. 2010 , 105, 162-9	380
1040	The potential for disease modification in Crohn's disease. 2010 , 7, 79-85	72
1039	Genomic Assessment of Inflammatory Bowel Disease. 2010 , 575-589	0

1038	Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. 2010 , 8, 688-695.e2	126
1037	Safety profile of IBD: lymphoma risks. 2010 , 94, 93-113	2
1036	Anorectal abscess and fistula-in-ano: evidence-based management. 2010 , 90, 45-68, Table of Contents	74
1035	Clinical implications of mucosal healing for the management of IBD. 2010 , 7, 15-29	347
1034	Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease. 2010 , 81, 78-85	18
1033	Anorectal stenosis after treatment with tumor necrosis factor alpha antibodies: a case series. 2010 , 4, 226	0
1032	Inflammatory bowel disease in the elderly. 2010 , 27, 617-24	25
1031	The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. 2010 , 12, 217	76
1030	Clinical evaluation of natalizumab for formulary consideration. 2010 , 10, 1279-87	1
1029	Tumour necrosis factor (TNF) inhibitors are an effective option in the management of Crohn's disease. 2010 , 26, 15-18	
1028	Perceptions of medication safety among patients with inflammatory bowel disease. 2010 , 45, 1076-83	7
1027	Anti-adhesion molecule therapy for inflammatory bowel disease. 2010 , 3, 239-58	86
1026	Patient outcomes after anti TNF-alpha drugs for Crohn's disease. 2010 , 10, 163-75	14
1025	Investigational agents for Crohn's disease. 2010 , 19, 1147-59	10
1024	[Biological agents in ulcerative colitis. When to prescribe]. 2011 , 34 Suppl 3, 36-42	
1023	Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis. 2011 , 106, 2009-17	41
1022	Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?. 2011 , 7, 507-16	15
1021	Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. 2011 , 9, 670-678.e3	117

1020	Doenā de Crohn intestinal: manejo. 2011 , 57, 10-13	3
1019	Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. 2011 , 9, 421-7.e1	153
1018	Intestinal Crohn's disease: management. 2011 , 57, 10-13	
1017	A Crohn's disease patient who does not respond to infliximab: what is next?. 2011 , 9, 1033-8	3
1016	Appendicitis, diverticulitis, and colitis. 2011 , 29, 347-68, ix	9
1015	Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. 2011 , 9, 395-9	15
1014	Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. 2011 , 43 Suppl 1, S40-8	28
1013	Anti-tumor necrosis factor- α antibodies induce regulatory macrophages in an Fc region-dependent manner. 2011 , 140, 221-30	144
1012	In favour of early surgery in Crohn's disease: a hypothesis to be tested. 2011 , 5, 1-4	17
1011	The clinical implication of drug dependency in children and adults with inflammatory bowel disease: a review. 2011 , 5, 81-90	6
1010	Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. 2011 , 5, 301-16	30
1009	Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience. 2011 , 5, 324-31	19
1008	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. 2011 , 43, 1-20	101
1007	Tumour necrosis factor-alpha expression in segmental colitis associated with diverticulosis is related to the severity of the endoscopic damage. 2011 , 43, 374-9	7
1006	Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. 2011 , 73, 1174-80	60
1005	An evidence-based systematic review on medical therapies for inflammatory bowel disease. 2011 , 106 Suppl 1, S2-25; quiz S26	205
1004	Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. 2011 , 106, 644-59, quiz 660	437
1003	Cost effectiveness of treatments for inflammatory bowel disease. 2011 , 29, 387-401	26

1002	Medical management of Crohn's disease. 2011 , 12, 2505-25	15
1001	Assessing response and loss of response to biological therapies in IBD. 2011 , 106, 685-98	236
1000	Current management of small bowel obstruction. 2011 , 45, 1-29	40
999	A practical, evidence-based guide to the use of adalimumab in Crohn's disease. 2011 , 27, 1803-13	6
998	Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. 2011 , 46, 310-8	151
997	Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. 2011 , 13, R82	31
996	Mechanisms of drug toxicity or intolerance. 2011 , 29, 172-6	4
995	Retinoic acid attenuates ileitis by restoring the balance between T-helper 17 and T regulatory cells. 2011 , 141, 1821-31	58
994	[Long-term outcome of infliximab therapy in pediatric Crohn disease]. 2011 , 18, 863-9	6
993	Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. 2011 , 124, e1-18	5
992	[Ten major publications in 2010 with implications for clinical practice in gastroenterology]. 2011 , 34, 289-304	
991	[Ustekinumab in a patient with Crohn's disease and anti-TNF-induced psoriasis]. 2011 , 34, 546-50	14
990	Guidelines for the management of inflammatory bowel disease in adults. 2011 , 60, 571-607	927
989	[Inflammatory bowel diseases: gynecological and obstetrical considerations]. 2011 , 40, 612-9	2
988	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. 2011 , 106, 199-212; quiz 213	291
987	The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. 2011 , 106, 1594-602; quiz 1593, 1603	60
986	Adverse effects of biologics: a network meta-analysis and Cochrane overview. 2011 , CD008794	353
985	Infliximab: A Review of Its Use in the Treatment of Inflammatory Bowel Disease. 2011 , 3, CMT.S1978	

984	Cytokine therapies in Crohn's disease: where are we now and where should we go?. 2011 , 10, 47-53	7
983	Crohn's disease and hyperbaric oxygen therapy. 2011 , 26 Suppl 2, 129-32	13
982	Treatment of Psoriasis in the Setting of Excessive Alcohol Intake: From the Medical Board of the National Psoriasis Foundation. 2011 , 17a, 119-130	
981	Inflammatory bowel disease in the geriatric population. 2011 , 3, 945-54	1
980	Is Certolizumab Pegol an Effective Longterm Maintenance Treatment for Moderate to Severe Crohn's Disease?. 2011 , 58, 121	
979	Efficacy and safety of biological treatment in Crohn's disease: our experience. 2011 , 5, 304-309	
978	Treatment costs for the group of patients with non-specific inflammatory bowel disease during acute exacerbation and further annual observation. 2011 , 1, 36-44	1
977	[Approved indications and other possible utilizations of anti-TNF biologic drugs]. 2005 , 57, 30-3	1
976	[Incidence and management of infusion reactions to infliximab in 186 italian patients with rheumatoid arthritis: the Padua experience]. 2005 , 57, 44-51	6
975	Medical management of inflammatory bowel disease among Canadian gastroenterologists. 2011 , 25, 565-9	4
974	[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary]. 2011 , 152, 1433-42	1
973	Health care resource use and costs in Crohn's disease before and after infliximab therapy. 2011 , 25, 497-502	22
972	Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease. 2011 , 48, 112-6	44
971	Mind the gaps: confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease. 2011 , 45, 240-5	47
970	Safety of infliximab in 10 years of clinical practice. 2011 , 23, 603-6	23
969	Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease. 2011 , 23, 1100-10	38
968	Surgery, Crohn's disease, and the biological era: has there been an impact?. 2011 , 45, 691-3	16
967	Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. 2011 , 45, 113-8	97

966	Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis. 2011 , 12, 1467-77	
965	Exploring the role of monitoring anti-TNF drug and antibody levels in the management of inflammatory bowel disease. 2011 , 4, 145-51	5
964	Sargramostim (GM-CSF) for induction of remission in Crohn's disease. 2011 , CD008538	9
963	[Progress in management of Crohn's disease]. 2011 , 100, 85-95	
962	Faecal diversion in the management of perianal Crohn's disease. 2011 , 13, 171-6	48
961	Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. 2011 , 71, 7-19	22
960	The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. 2011 , 33, 349-57	69
959	Review article: the role of non-biological drugs in refractory inflammatory bowel disease. 2011 , 33, 417-27	24
958	Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. 2011 , 33, 541-50	37
957	Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience. 2011 , 33, 857-69	60
956	A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. 2011 , 33, 946-53	79
955	Review article: loss of response to anti-TNF treatments in Crohn's disease. 2011 , 33, 987-95	378
954	Review article: the effects of antitumour necrosis factor- α on bone metabolism in inflammatory bowel disease. 2011 , 33, 1261-72	50
953	Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF therapy. 2011 , 34, 1-10	94
952	A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. 2011 , 34, 181-7	28
951	Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. 2011 , 34, 125-45	390
950	Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. 2011 , 34, 306-17	33
949	Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. 2011 , 34, 911-22	123

948	Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. 2011 , 34, 1318-27	141
947	Elevated levels of tumour necrosis factor (TNF)- α interleukin (IL)-1 β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF- α and IL-1 β 2011 , 164, 1292-8	293
946	The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. 2011 , 163, 50-8	65
945	Use of biological molecules in the treatment of inflammatory bowel disease. 2011 , 270, 15-28	26
944	A humanized monoclonal antibody targeting the $\alpha 4 \beta 7$ integrin selectively blocks intestinal homing of T lymphocytes. 2011 , 162, 1855-70	64
943	Immunoregulatory effects of adsorptive granulocyte and monocyte apheresis in patients with drug refractory Crohn's disease. 2011 , 15, 367-73	10
942	Risk factors that predict the requirement of aggressive therapy among Chinese patients with Crohn's disease. 2011 , 12, 99-104	20
941	Short-term study of infliximab treatment for Crohn's disease in China. 2011 , 12, 105-9	5
940	Efficacy and safety of adalimumab in Crohn's disease: meta-analysis of placebo-controlled trials. 2011 , 12, 165-72	9
939	Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab. 2011 , 12, 379-83	17
938	Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies. 2011 , 100, 451-5	37
937	Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn's disease. 2011 , 372, 177-86	42
936	Outcomes of pediatric inflammatory bowel disease: socioeconomic status disparity in a universal-access healthcare system. 2011 , 158, 960-967.e1-4	60
935	Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. 2011 , 33, 946-64	198
934	The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn's disease treated with Infliximab. 2011 , 30, 86-91	35
933	The effect of pentoxifylline and its metabolite-1 on inflammation and fibrosis in the TNBS model of colitis. 2011 , 662, 47-54	19
932	Anti-TNF therapy: safety aspects of taking the risk. 2011 , 10, 563-8	100
931	Crohn's Disease. 2011 , 472-489.e6	

930	Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. 2011 , 56, 1489-95	10
929	Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn's Disease: an open-label pilot study. 2011 , 56, 1806-10	19
928	Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn's disease: a US national practice survey comparing experts and non-experts. 2011 , 56, 1160-4	15
927	Inflammatory bowel disease characteristics and treatment in Hispanics and Caucasians. 2011 , 56, 1476-81	14
926	Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses. 2011 , 56, 3525-33	4
925	Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease. 2011 , 56, 3610-5	39
924	Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. 2011 , 31, 243-5	47
923	A meta-analysis of the therapeutic effects of tumor necrosis factor- β blockers on ulcerative colitis. 2011 , 67, 759-66	27
922	Inflammatory bowel disease associated arthropathy. 2011 , 4, 123-31	73
921	Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs. 2011 , 28, 671-83	40
920	A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. 2011 , 15, 267-76	53
919	Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. 2011 , 6 Suppl 1, 17-27	15
918	Exploring the differential diagnosis of joint complaints in pediatric patients with inflammatory bowel disease. 2011 , 13, 271-8	3
917	Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. 2011 , 20, 838-48	25
916	T-cell targeted therapies in autoimmune diseases. 2011 , 72, 585-597	1
915	Anti-tumor necrosis factor- β therapies for immune-mediated and inflammatory skin diseases. 2011 , 72, 615-622	0
914	Leukocytoclastic vasculitis: A rare adverse effect secondary to infliximab. 2011 , 17, E4-5	8
913	Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. 2011 , 17, 141-51	62

912	QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. 2011 , 17, 77-83	54
911	Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF- α antibody-treated patients with inflammatory bowel disease. 2011 , 17, 91-8	60
910	Successful use of infliximab for perianal Crohn's disease in pregnancy. 2011 , 17, 868-9	9
909	Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. 2011 , 17, 99-104	30
908	Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. 2011 , 17, 758-66	33
907	Endoscopic monitoring of infliximab therapy in Crohn's disease. 2011 , 17, 947-53	24
906	Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. 2011 , 17, 1603-9	99
905	Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. 2011 , 17, 152-9	28
904	Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. 2011 , 17, 1530-9	20
903	Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. 2011 , 17, 1846-54	135
902	Development and validation of the Crohn's disease perceived work disability questionnaire. 2011 , 17, 2350-7	19
901	Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. 2011 , 17, 2144-52	74
900	Practical application of anti-TNF therapy for luminal Crohn's disease. 2011 , 17, 2366-91	15
899	Comparative effectiveness research in inflammatory bowel disease. 2011 , 17, E46-7	1
898	Severe agranulocytosis following first infliximab infusion in Crohn's disease. 2011 , 17, E147-8	1
897	[Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology]. 2011 , 49, 534-42	
896	Low dose endoluminal photodynamic therapy improves murine T cell-mediated colitis. 2011 , 43, 604-16	9
895	[IBD ahead 2010--Answering important questions in Crohn's disease treatment]. 2011 , 49, 1246-54	2

894	Inflammatory Bowel Disease. 2011,	2
893	IBD and arthropathies: a practical approach to its diagnosis and management. 2011, 60, 1426-35	34
892	Establishing a biologics service for patients with inflammatory bowel disease. 2011, 2, 133-139	2
891	Interleukin 37 expression protects mice from colitis. 2011, 108, 16711-6	248
890	Interferon γ release assays for detecting latent tuberculosis infection in patients scheduled for anti-TNF α therapy. 2011, 2, 26-31	2
889	Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment. 2011, 95, 205-8	30
888	Cytokine blockade in inflammatory bowel diseases. 2011, 3, 1341-52	64
887	Acute infusion reactions induced by monoclonal antibody therapy. 2011, 7, 55-63	82
886	Peripheral Blood CD64 Levels Decrease in Crohn's Disease following Granulocyte and Monocyte Adsorptive Apheresis. 2011, 5, 667-71	2
885	Infliximab to treat Crohn's disease: an update. 2011, 4, 227-38	11
884	Premedications for infliximab infusions do not impact the risk of acute adverse drug reactions. 2011, 2, 249-254	2
883	Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. 2011, 60, 930-6	177
882	Current misunderstandings in the management of ulcerative colitis. 2011, 60, 1294-9	29
881	The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. 2011, 60, 1068-75	114
880	Azathioprine and Infliximab: Monotherapy or Combination Therapy in the Treatment of Crohn's Disease. 2011, 4, CGast.S5256	1
879	Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. 2011, 106, 778-85	29
878	Adalimumab for the treatment of inflammatory bowel disease. 2011, 5, 679-84	11
877	Primary treatment of Crohn's disease: combined antibiotics taking center stage. 2011, 7, 751-60	20

876	Infliximab in drug-naïve patients with failed ileorectal anastomosis for Crohn's disease: a new chance for sparing the rectum?. 2011 , 46, 163-8	19
875	Surgery for adult Crohn's disease: what is the actual risk?. 2011 , 60, 1178-81	158
874	Evidence-based use of anti-TNF therapy in Crohn's disease; where are we in 2011?. 2011 , 2, 144-150	4
873	Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease. 2011 , 95, 549-52	28
872	Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years. 2011 , 4, 9-17	9
871	Biologics in paediatric Crohn's disease. 2011 , 2011, 287574	4
870	Animal models of colitis-associated carcinogenesis. 2011 , 2011, 342637	70
869	Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review. 2011 , 14, 397-402	8
868	Certolizumab pegol for the treatment of Crohn's disease. 2011 , 4, 375-89	48
867	Readministration of calcineurin inhibitors for ulcerative colitis. 2012 , 46, 1315-21	5
866	The EGF receptor and HER2 participate in TNF-dependent MAPK activation and IL-8 secretion in intestinal epithelial cells. 2012 , 2012, 207398	25
865	Stability of infliximab in polyvinyl chloride bags. 2012 , 69, 1509-12	15
864	Management and evaluation of extra-articular manifestations in spondyloarthritis. 2012 , 4, 413-22	37
863	Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease. 2012 , 47, 662-8	63
862	Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. 2012 , 61, 459-65	64
861	Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. 2012 , 4, 883-98	67
860	Infliximab for the treatment of pediatric ulcerative colitis. 2012 , 6, 659-65	1
859	Infusion reactions related to infliximab therapy are not usually associated with drug discontinuation. 2012 , 39, 1500-2	1

- 858 Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. **2012**, 107, 1409-22 513
- 857 A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. **2012**, 107, 1051-63 153
- 856 Efficacy of certolizumab pegol in Crohn's disease: response to Ford et al. **2012**, 107, 321; author reply 321-2
- 855 Lymphoma in inflammatory bowel disease and treatment decisions. **2012**, 107, 964-70 14
- 854 Response to Kayhan et al.. **2012**, 107, 321-322
- 853 Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn's disease. **2012**, 66, 1219-23 29
- 852 Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease. **2012**, 15, 45-52 10
- 851 Endoscopic Assessment of Disease Activity and Mucosal Healing in Inflammatory Bowel Disease. **2012**, 321-331
- 850 Autoimmune diseases in gastroenterology. **2012**, 18, 4542-5 2
- 849 Infliximab- and immunosuppressant-resistant Crohn's disease successfully treated with adsorptive granulocyte apheresis combined with prednisolone. **2012**, 6, 118-23 3
- 848 Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study. **2012**, 2, e000823 62
- 847 Medical therapy and mucosal healing. **2012**, 13, 1294-9 6
- 846 Trial discontinuation: lessons for future trial design?. **2012**, 2, 147-152
- 845 The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn's disease. **2012**, 13, 1273-9 3
- 844 Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. **2012**, 97, 529-33 18
- 843 Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colorectal Surgeons, and the American Society of Colorectal Surgeons Evidence Based Reviews in Surgery [Colorectal Surgery]. **2012**, 55, 727-731
- 842 Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. **2012**, 24, 762-9 77
- 841 Mycobacterium avium ss paratuberculosis-associated diseases: piecing the Crohn's puzzle together. **2012**, 46, 649-55 15

840	Randomized Controlled Clinical Trials in Mild-Moderate Ulcerative Colitis. 2012 , 7, 256-269	
839	Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. 2012 , 18, 5058-64	19
838	Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis. 2012 , 18, 872-81	67
837	Sonography for surveillance of patients with Crohn disease. 2012 , 31, 1147-52	9
836	Actualizaci3n del tratamiento m3dico de la enfermedad de Crohn. 2012 , 11, 284-292	
835	Current advantages in the application of proteomics in inflammatory bowel disease. 2012 , 57, 2755-64	14
834	Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNF3 agents. 2012 , 10, 889-97	27
833	Tratamiento del brote de enfermedad de Crohn. 2012 , 11, 309-313	
832	Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. 2012 , 61, 229-34	100
831	Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. 2012 , 36, 650-9	33
830	eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn's disease. 2012 , 36, 840-9	71
829	Immunotherapy in inflammatory bowel disease. 2012 , 96, 525-44, x	27
828	Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?. 2012 , 12, 179-92	23
827	Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. 2012 , 71, 1955-60	95
826	Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy. 2012 , 56, 536-43	12
825	Treatment of experimental ulcerative colitis. 2012 , 153, 889-92	1
824	[Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis]. 2012 , 139 Suppl 2, S58-67	16
823	Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease. 2012 , 47, 649-57	15

822	Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor agents for inflammatory bowel disease. 2012 , 41, 411-28	7
821	Ustekinumab en la artritis psoriásica y la enfermedad de Crohn. 2012 , 103, 65-72	
820	Optimizing immunomodulators and anti-TNF agents in the therapy of Crohn disease. 2012 , 41, 393-409, ix	7
819	Biologic Therapy in Inflammatory Bowel Disease: A Gastrointestinal Perspective. 2012 , 23, 81-88	
818	Individualized treatment with infliximab therapy in children with Crohn's disease support shorter time intervals between infusions. 2012 , 1, 20-3	
817	Comparative effectiveness research in inflammatory bowel disease: prospects and challenges. 2012 , 6, 405-7	
816	Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. 2012 , 8, 43-52; quiz 53-4	60
815	Key insights from therapeutic drug monitoring in Crohn's disease patients. 2019 , 15, 399-406	8
814	Indications and Preoperative Medical Management of Ulcerative Colitis Patients Undergoing Pouch Surgery. 2019 , 17-28	
813	Systematic review: outcomes and adverse events from randomised trials in Crohn's disease. 2019 , 49, 978-996	8
812	Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. 2019 , 34, 1523-1532	12
811	Thalidomide-induced sinus bradycardia in Crohn's disease: case report and literature review. 2019 , 47, 2228-2233	1
810	Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. 2019 , 34, 1296-1315	18
809	Is the need for inflammatory bowel disease surgery diminishing in the biologic era?. 2019 , 21, 259-260	1
808	Long-term prognosis of Japanese patients with biologic-naïve Crohn's disease treated with anti-tumor necrosis factor- α antibodies. 2019 , 17, 94-106	6
807	Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists. 2019 , 64, 1952-1958	3
806	Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. <i>Lancet, The</i> , 2019 , 393, 1699-1707	40 90
805	GI Surgery Annual. 2019 ,	0

804	ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases. 2019 , 34, 1727-1735	4
803	Wirkmechanismen und Wirkung von Biologika und JAK-Inhibitoren bei CED. 2019 , 6, 26-37	2
802	Clinical Impact of Sonographic Transmural Healing After Anti-TNF Antibody Treatment in Patients with Crohn's Disease. 2019 , 64, 2600-2606	13
801	Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?. 2019 , 26, 248-258	3
800	Low-dose biologics to treat inflammatory bowel disease. Ready for prime time?. 2019 , 51, 609-610	
799	Surgery in the age of biologics. 2019 , 7, 77-90	32
798	Infliximab in inflammatory bowel disease. 2019 , 10, 2040622319838443	47
797	Application of Pharmacometrics and Systems Pharmacology to Current and Emerging Biologics in Inflammatory Bowel Diseases. 2019 , 209-242	
796	Quantitative Pharmacology Assessment Strategy Therapeutic Proteins in Pediatric Subjects □ Challenges and Opportunities. 2019 , 315-336	
795	Model-Based Meta-Analysis Use in the Development of Therapeutic Proteins. 2019 , 93-124	
794	Cytomegalovirus reactivation in inflammatory bowel disease: an uncommon occurrence related to corticosteroid dependence. 2019 , 32, 1210-1216	7
793	Targeting anti-fibrotic pathways in Crohn's disease - The final frontier?. 2019 , 38-39, 101603	6
792	IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?. 2019 , 38-39, 101604	16
791	Treatment sequence network meta-analysis in Crohn's disease: a methodological case study. 2019 , 35, 733-756	9
790	Impact of therapeutic drug level monitoring on outcomes of patients with Crohn's disease treated with Infliximab: real world data from a retrospective single centre cohort study. 2019 , 10, 330-336	8
789	Therapy for Crohn's Disease. 2019 , 150-172	
788	Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. 2019 , 49, 880-889	24
787	Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. 2019 , 25, 1532-1540	11

786	Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation?. 2019 , 197, 308-318	34
785	Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. 2019 , 1,	2
784	The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth. 2019 , 7, S388	
783	Paediatric onset inflammatory bowel disease is a distinct and aggressive phenotype: a comparative population-based study. 2019 , 1, 266-273	7
782	Uhrf1-Mediated Tnf- α Gene Methylation Controls Proinflammatory Macrophages in Experimental Colitis Resembling Inflammatory Bowel Disease. 2019 , 203, 3045-3053	14
781	. 2019 ,	
780	Benzofuran and pyrrole derivatives as cannabinoid receptor modulators with efficacy against ulcerative colitis. 2019 , 11, 3139-3159	2
779	Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. 2019 , 21, 292	17
778	Tracheobronchitis in ulcerative colitis: a case report of therapeutic response with infliximab and review of the literature. 2019 , 19, 171	4
777	Influence of previous corticosteroid treatment on the efficacy and safety of infliximab therapy in Crohn disease. 2019 , 98, e15189	
776	Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn's Disease: Real-World Data from a German IBD Cohort. 2019 , 8,	16
775	Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. 2019 , 31, 478-485	17
774	Time to antibody detection and associated factors for presence of anti-drug antibodies in pediatric inflammatory bowel disease patients treated with anti-TNF therapy. 2019 , 31, 1228-1233	2
773	Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies. 2019 , 10, 2726	26
772	Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?. 2019 , 62, 1352-1362	14
771	Performance of Interferon-Gamma Release Assays for Tuberculosis Screening in Pediatric Inflammatory Bowel Disease. 2019 , 69, e111-e116	1
770	Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease. 2019 , 12, CD012804	7
769	Infliximab Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease. 2019 , 69, 189-193	14

768	Top-100 highest-cited original articles in inflammatory bowel disease: A bibliometric analysis. 2019 , 98, e15718	12
767	Serum IgG and albumin concentrations predict secondary loss of response to anti-TNF in inflammatory bowel disease patients. 2019 , 31, 1563-1568	2
766	Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis. 2019 , 17, 79	13
765	Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. 2019 , 13, 50-57	39
764	A 10-Year Follow-up Study of the Natural History of Perianal Crohn's Disease in a Danish Population-Based Inception Cohort. 2019 , 25, 1227-1236	28
763	Loss of response to scheduled infliximab therapy for Crohn's disease in adults: A systematic review and meta-analysis. 2019 , 20, 65-72	9
762	Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease. 2019 , 64, 1622-1631	6
761	Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies. 2019 , 18, 123-128	18
760	Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study. 2019 , 13, 578-584	24
759	Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. 2019 , 80, 27-40	177
758	Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease. 2019 , 25, 925-936	6
757	Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients. 2019 , 39, 118-128	4
756	Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. 2019 , 25, 1169-1186	37
755	Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. 2019 , 49, 147-154	25
754	A Novel Predictive Nomogram for Early Endoscopic Recurrence after Intestinal Resection for Crohn's Disease. 2019 , 100, 269-276	5
753	Characteristics of biological therapy in pediatric patients with Crohn's disease. 2019 , 19, 181-196	2
752	Evaluating the effectiveness of infliximab on perianal fistulizing Crohn's disease by magnetic resonance imaging. 2019 , 7, 50-56	4
751	Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation. 2019 , 17, 1515-1524.e4	12

750	Diverting Stoma for Refractory Ano-perineal Crohn's Disease: Is It Really Useful in the Anti-TNF Era? A Multivariate Analysis in 74 Consecutive Patients. 2019 , 13, 572-577	8
749	Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan. 2019 , 21, 2	20
748	Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. 2019 , 25, 328-335	3
747	Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort. 2019 , 49, 753-760	5
746	Localization of TNF alpha in ileocolonic biopsies of patients with inflammatory bowel disease. 2019 , 38, 20-25	4
745	Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease. 2019 , 64, 60-67	1
744	Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes. 2019 , 64, 1660-1667	21
743	Strategies toward rheumatoid arthritis therapy; the old and the new. 2019 , 234, 10018-10031	134
742	Current Medical Therapies for Ulcerative Colitis. 2019 , 1-15	
741	Interesting Case of Infliximab IV Type Hypersensitivity. 2019 , 25, e49-e51	0
740	Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study. 2019 , 51, 112-119	11
739	Targeting IL-10 Family Cytokines for the Treatment of Human Diseases. 2019 , 11,	67
738	Inflammatory Cytokine Profile in Crohn's Disease Nonresponders to Optimal Antitumor Necrosis Factor Therapy. 2019 , 53, 210-215	6
737	Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). 2019 , 68, 40-48	75
736	Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. 2020 , 69, 274-282	74
735	The Role of Immunomodulators and Biologics in the Medical Management of Strictureing Crohn's Disease. 2020 , 14, 557-566	11
734	Small Bowel Healing Detected by Endoscopy in Patients With Crohn's Disease After Treatment With Antibodies Against Tumor Necrosis Factor. 2020 , 18, 1545-1552	9
733	Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. 2020 , 14, 542-556	22

732	Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis. 2020 , 55, 133-141	11
731	Crohn's Disease. 2020 , 739-753	
730	Will the Placebo Effect Disappear With New Targets For Treatment of Inflammatory Bowel Diseases?. 2020 , 18, 1030-1032	1
729	Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease. 2020 , 65, 1445-1452	10
728	Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan. 2020 , 35, 593-600	6
727	Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan. 2020 , 23, 80-85	2
726	Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases. 2020 , 18, 257-258	6
725	Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials. 2020 , 26, 125-131	7
724	Understanding the Cause of Weight Gain in Patients With IBD on Anti-TNF Medications. 2020 , 26, 132-133	
723	Immunosuppressants. 2020 , 248-266	
722	Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus. 2020 , 101, 683-691	8
721	HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease. 2020 , 51, 356-363	22
720	Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. 2020 , 65, 1436-1444	5
719	UK Patients of Bangladeshi Descent with Crohn's Disease Respond Less Well to TNF Antagonists Than Caucasian Patients. 2020 , 65, 1790-1799	0
718	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. 2020 , 14, 4-22	320
717	Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. 2020 , 115, 128-137	14
716	The Impact of Anti-Tumor Necrosis Factor Alpha Therapy on Postoperative Complications in Pediatric Crohn's Disease. 2020 , 30, 27-32	2
715	Implementation of infliximab standardized doses after pharmacokinetic modelization in a cohort of patients with Crohn's disease. 2020 , 52, 408-413	

714	Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease. 2020 , 70, 310-317	6
713	Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China. 2020 , 37, 431-449	2
712	Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. 2020 , 42, 102-110	4
711	Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. 2020 , 20, 151-161	2
710	Real-world Safety and Effectiveness of Infliximab in Pediatric Patients With Acute Kawasaki Disease: A Postmarketing Surveillance in Japan (SAKURA Study). 2020 , 39, 41-47	9
709	Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study. 2020 , 20, 205-213	4
708	Rate of Reoperation Decreased Significantly After Year 2002 in Patients With Crohn's Disease. 2020 , 18, 898-907.e5	11
707	Interrogating host immunity to predict treatment response in inflammatory bowel disease. 2020 , 17, 9-20	46
706	Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease. 2020 , 18, 628-636	6
705	Long-Term Prognosis of Japanese Patients with Crohn's Disease Treated by Switching Anti-Tumor Necrosis Factor-Antibodies. 2020 , 5, 11-19	1
704	The Efficacy of Antihistamines in Preventing Reactions to Infliximab in Patients With Crohn Disease/Ulcerative Colitis: A Review of the Evidence. 2020 , 43, 345-349	1
703	The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. 2021 , 33, 1008-1023	3
702	Time Trends of Crohn's Disease in Catalonia from 2011 to 2017. Increasing Use of Biologics Correlates with a Reduced Need for Surgery. 2020 , 9,	3
701	The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab. 2020 , 52, 1148-1155	5
700	Medikamentöse Therapie des Morbus Crohn. 2020 , 229-258	
699	Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease. 2021 , 19, 2082-2092.e10	2
698	Clearing of the Clouds in Inflammatory Bowel Disease Management. 2020 , 65, 3411-3417	1
697	Clinical course of Crohn's disease in a population-based cohort in Uppsala County followed for 10 years. 2020 , 55, 1301-1307	1

696	Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. 2021 , 66, 3548-3554	2
695	Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn's Disease: A Retrospective Cohort Study. 2020 , 2,	1
694	IBD considerations in spondyloarthritis. 2020 , 12, 1759720X20939410	6
693	Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK - a retrospective observational study. 2020 , 55, 907-916	2
692	Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor- α Inhibitor Induction Therapy among Patients with Crohn's Disease. 2020 , 5, 78-83	1
691	Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. 2021 , 19, 1366-1376.e2	22
690	Highly bioavailable curcumin derivative ameliorates Crohn's disease symptoms: A randomized, double-blind, multicenter study. 2020 ,	17
689	Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapy-the Danish IBD Biobank Project: protocol for a multicentre prospective cohort study. 2020 , 10, e035756	1
688	Follow-Up Ileocolonoscopy Is Underused in Crohn's Disease Patients after Ileocecal Resection despite Higher Total and Inpatient Health-Care Costs Compared to Controls. 2020 , 5, 100-108	
687	Infliximab Therapy in Very Early Onset Crohn's Disease: Real-World Experience in China. 2021 , 66, 3555-3562	1
686	Mesenchymal stem cells and acellular products attenuate murine induced colitis. 2020 , 11, 515	12
685	Acute Venous Thromboembolism Risk in Patients With Inflammatory Bowel Diseases. 2020 , 18, 3058-3059	
684	Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. 2020 , 115, 1236-1245	7
683	Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further?. 2020 , 14, 807-817	5
682	The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study. 2020 , 99, e21226	1
681	Inhibitors of Tumoral Necrosis Factor Alpha in Inflammatory Bowel Disease. 2020 ,	
680	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease. 2020 , 63, 1028-1052	11
679	Is Polymorphism in the Apoptosis and Inflammatory Pathway Genes Associated With a Primary Response to Anti-TNF Therapy in Crohn's Disease Patients?. 2020 , 11, 1207	3

678	Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring. 2020 , 2, otaa050	4
677	Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial. 2020 , 13, 1756284820938960	5
676	Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand. 2020 , 23, 1302-1310	1
675	Biologics and surgical outcomes in Crohn's disease: is there a direct relationship?. 2020 , 13, 1756284820931738	
674	Lysophosphatidic Acid-Mediated GPR35 Signaling in CX3CR1 Macrophages Regulates Intestinal Homeostasis. 2020 , 32, 107979	22
673	Monocytes from infliximab-resistant patients with Crohn's disease exhibit a disordered cytokine profile. 2020 , 10, 12238	4
672	Clinical Follow-up of Patients with Behçet Uveitis after Discontinuation of Infliximab Therapy. 2020 , 1-5	2
671	Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study. 2020 , 11, e00217	1
670	Potential for Targeting Myeloid Cells in Controlling CNS Inflammation. 2020 , 11, 571897	5
669	Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study. 2020 ,	5
668	Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?. 2020 , 17, 702-710	19
667	Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India. 2020 , 39, 388-397	2
666	Biosimilars in inflammatory bowel disease. 2020 , 21, 610-620	0
665	A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis. 2020 , 10, 1121-1135	1
664	Adding Thiopurine After Loss of Response to Infliximab Versus Early Combination in Treating Crohn's Disease: A Retrospective Study. 2021 , 66, 3124-3131	1
663	Ulcerative colitis. 2020 , 6, 74	182
662	Therapiealgorithmen für die Behandlung des Morbus Crohn im klinischen Alltag. 2020 , 1, 51-64	
661	Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases. 2020 , 26, 1451-1462	6

660	Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the Microbiota. 2020 , 26, 1543-1553	5
659	Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy. 2020 , 10,	8
658	Rapid weight gain in infliximab treated Crohn's disease patients is sustained over time: real-life data over 12 months. 2020 , 55, 1411-1418	4
657	Utility of bowel ultrasound in assessing disease activity in Crohn's disease. 2020 , 39, 495-502	1
656	Infliximab-related weight gain in inflammatory bowel disease: associations and financial impacts. 2020 , 50, 1134-1138	2
655	Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease. 2020 , 39, 3543-3553	3
654	Endoscopic Activity and Serum TNF- α Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease Patients. 2020 , 26, 1669-1681	2
653	Adalimumab for maintenance of remission in Crohn's disease. 2020 , 5, CD012877	1
652	Dynamic pH barrage junction focusing of amino acids, peptides, and digested monoclonal antibodies in capillary electrophoresis-mass spectrometry. 2020 , 41, 1832-1842	6
651	Reversal of anti-drug antibodies against tumor necrosis factor inhibitors with addition of immunomodulators: A systematic review and meta-analysis. 2020 , 39, 153-160	3
650	Histologic evaluation of disease activity in inflammatory bowel disease. 2020 , 221-233	
649	The treatment approach to inflammatory bowel disease in 2020. 2020 , 36, 247-256	7
648	Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. 2020 , 36, 1457-1463	23
647	Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. 2020 , 10,	21
646	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. 2020 , 32, 588-596	2
645	The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. 2020 , 22, 36	9
644	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. 2020 , 33,	32
643	Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. 2020 , 14, 1274-1281	0

642	Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients With Inflammatory Bowel Disease Showing Lost Response to Infliximab. 2020 , 14, 1264-1273	5
641	Novel candidate drugs in anti-tumor necrosis factor refractory Crohn's diseases: in silico study for drug repositioning. 2020 , 10, 10708	3
640	An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases. 2020 , 12, 609-623	1
639	The New Proactive Approach and Precision Medicine in Crohn's Disease. 2020 , 8,	4
638	Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. 2020 , 11, e00177	7
637	Optimal strategies to prevent recrudescence Crohn's disease after resection. 2020 , 31, 100746	
636	Are Biologics Safe in the Immediate Postoperative Period? A Single-Center Evaluation of Consecutive Crohn's Surgical Patients. 2020 , 63, 934-943	3
635	The voltage-gated potassium channel K1.3 as a therapeutic target for venom-derived peptides. 2020 , 181, 114146	23
634	Optimal use of biologics with endoscopic balloon dilatation for repeated intestinal strictures in Crohn's disease. 2020 , 4, 532-540	2
633	Anti-TNF-induced lupus in patients with inflammatory bowel disease. 2020 , 4, 507-510	7
632	Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease. 2020 , 55, 178-183	6
631	Human α -Defensin 2 Mediated Immune Modulation as Treatment for Experimental Colitis. 2020 , 11, 93	28
630	Evaluation of ileal Crohn's disease response to TNF antagonists: Validation of MR enterography for assessing response. Initial results. 2020 , 7, 100217	4
629	Inflammatory bowel disease and targeted oral anti-TNF α therapy. 2020 , 119, 157-198	6
628	Intestinal Organoids as a Tool for Inflammatory Bowel Disease Research. 2019 , 6, 334	25
627	Associations Between Obesity and the Effectiveness of Anti-Tumor Necrosis Factor- α Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis. 2020 , 54, 729-741	10
626	Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease. 2020 , 42, 500-507	8
625	Efficacy of anti-TNF α drugs in patients with stricturing Crohn's disease. 2020 , 14, 347-353	4

624	Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies. 2020 , 34, 513-528	5
623	Surgery for Inflammatory Bowel Disease in the Era of Biologics. 2020 , 24, 1430-1435	4
622	Emerging medical treatments for hidradenitis suppurativa. 2020 , 83, 554-562	11
621	Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. 2020 , 72, 486-526	62
620	Vagotomy and subsequent risk of inflammatory bowel disease: a nationwide register-based matched cohort study. 2020 , 51, 1022-1030	8
619	Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. 2020 , 51, 1031-1038	36
618	Infliximab levels and antibodies in IBD-related peripheral arthralgia. 2020 , 35, 1141-1148	4
617	Strictureplasty for Crohn's disease of the small bowel in the biologic era: long-term outcomes and risk factors for recurrence. 2020 , 24, 711-720	6
616	Mucosal healing in Crohn's disease: new insights. 2020 , 14, 335-345	8
615	COVID-19 and immunomodulation in IBD. 2020 , 69, 1335-1342	153
614	Association between preoperative tumor necrosis factor alpha inhibitor and surgical site infection after surgery for inflammatory bowel disease: a systematic review and meta-analysis. 2021 , 51, 32-43	1
613	Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab. 2021 , 19, 721-731.e1	6
612	Plasma Oncostatin M, TNF- α /IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop. 2021 , 39, 1-9	3
611	A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's Disease. 2021 , 4, 48	5
610	Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. 2021 , 87, 106-118	7
609	Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis. 2021 , 19, 238-245.e4	6
608	Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn's Disease. 2021 , 66, 1658-1668	5
607	The Impact of Preoperative Anti-TNF α Therapy on Postoperative Outcomes Following Ileocolectomy in Crohn's Disease. 2021 , 25, 467-474	5

606	Smoking May Reduce the Effectiveness of Anti-TNF Therapies to Induce Clinical Response and Remission in Crohn's Disease: A Systematic Review and Meta-analysis. 2021 , 15, 74-87	1
605	A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease. 2021 , 51, 341-347	2
604	Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review. 2021 , 36, 344-361	5
603	Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease. 2021 , 19, 1200-1208.e1	5
602	No Change in Surgical and Hospitalization Trends Despite Higher Exposure to Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease in the Qubec Provincial Database From 1996 to 2015. 2021 , 27, 655-661	2
601	Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach. 2021 , 35, 329-337	3
600	Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. 2021 , 214, 128-133	6
599	Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. 2021 , 56, 145-154	19
598	Ustekinumab is effective against small bowel lesions in Crohn's disease: two case reports. 2021 , 14, 129-135	1
597	Elemental diet therapy plays a significant role in preventing surgical recurrence of Crohn's disease in the era of biologics. 2021 , 51, 250-257	2
596	Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn's Disease: A Post Hoc Analysis of the IM-UNITI Trial. 2021 , 27, 848-854	6
595	Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease. 2021 , 36, 990-998	0
594	Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings. 2021 , 51, 739-745	4
593	Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: A Review of Existing Literature and Best Practices. 2021 , 3,	3
592	How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. 2021 , 8, 640813	7
591	Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases. 2020 , 11, 623691	7
590	Rates of inflammatory bowel disease in Hispanics comparable to non-Hispanic Whites: results of a cohort study. 2021 , 36, 1043-1051	0
589	Differential relieving effects of shikonin and its derivatives on inflammation and mucosal barrier damage caused by ulcerative colitis. 2021 , 9, e10675	4

588 Crohn Disease. **2021**, 461-473.e8

587	Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis. 2021 , 12, 20406223211041927	0
586	OUP accepted manuscript.	
585	Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn's Disease. 2021 , 15, 92-99	0
584	Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn's disease. 2021 , 13, 1-18	18
583	Pharmacoeconomical Impacts of Crohn's Disease.	
582	A systematic review of the quality of reporting of interventions in the surgical treatment of Crohn's anal fistula: an assessment using the TIDiER and Blencowe frameworks. 2021 , 25, 359-369	0
581	Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases. 2021 , 5, 364-370	7
580	High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study. 2021 , 21, 77	0
579	Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease: A retrospective cohort study. 2021 , 100, e24731	0
578	Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register - a validation study. 2021 , 56, 410-421	1
577	Self-Assembling Nanofibers Inhibit Inflammation in a Murine Model of Crohn's-Disease-Like Ileitis. 2021 , 4, 2000274	1
576	Fibrotic Strictures in Crohn's Disease: Mechanisms and Predictive Factors. 2021 , 22, 241-251	3
575	Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD. 2021 , 21, 63	1
574	Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort. 2021 , 22, 66-72	0
573	Location is important: differentiation between ileal and colonic Crohn's disease. 2021 , 18, 544-558	13
572	Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn's Disease during One-Year Follow-Up. 2021 , 13,	3
571	Association of Anti-Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease. 2021 , 4, e210313	0

570	Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study. 2021 , 25, 1-138	1
569	Intestinal Mucosal Wound Healing and Barrier Integrity in IBD-Crosstalk and Trafficking of Cellular Players. 2021 , 8, 643973	9
568	De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months. 2021 , 1	0
567	Cortical Vein Thrombosis after Infliximab Treatment for Crohn's Disease. 2021 , 13, 120-124	0
566	Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort. 2021 , 36, 2067-2075	4
565	Omics data integration identifies 'ELOVL7' and 'MMD' gene regions as novel loci for adalimumab response in patients with Crohn's disease. 2021 , 11, 5449	0
564	Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis. 2021 , 15, 1649-1657	0
563	Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients. 2021 , 12, 654985	0
562	Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease. 2021 , 12, 655865	2
561	Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. 2021 ,	2
560	Advances in the Comprehensive Management of Postoperative Crohn's Disease. 2021 ,	5
559	Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study. 2021 , 180, 3029-3038	1
558	The brain-gut axis, inflammatory bowel disease and bioelectronic medicine. 2021 , 33, 349-356	2
557	The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. 2021 , 1-28	0
556	Infliximab in inflammatory bowel disease. Is premedication necessary?. 2021 , 44, 321-321	
555	Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease. 2021 ,	4
554	Impact of rapid infliximab infusions on access at a large academic tertiary medical center. 2021 , 78, 2046-2052	
553	B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment. 2021 , 53, 574-580	5

552	Infliximab in inflammatory bowel disease. Is premedication necessary?. 2021 , 44, 321-329	1
551	Fecal Microbiota Transplantation is a Promising Switch Therapy for Patients with Prior Failure of Infliximab in Crohn's Disease. 2021 , 12, 658087	1
550	Calibrating Real-World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn's Disease. 2021 ,	1
549	Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. 2021 , 325, 1744-1754	20
548	Perioperative safety of tofacitinib in surgical ulcerative colitis patients. 2021 , 23, 2085-2090	2
547	Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study. 2021 , 45, 165-165	1
546	Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of $\alpha\alpha$, in Healthy Volunteers. 2021 , 10, 1263-1278	5
545	Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post-marketing surveillance in Japan. 2021 , 36, 3069-3076	1
544	Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated. 2021 , 27, 2031-2033	1
543	Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. 2021 , 54, 667-677	3
542	Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease. 2021 , 54, 249-266	2
541	A quinazoline-based bromodomain inhibitor, CN210, ameliorates indomethacin-induced ileitis in mice by inhibiting inflammatory cytokine expression. 2021 , 82, 1235-1246	1
540	Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring.	
539	Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: medical treatment.. 2022 , 13, 168-170	0
538	Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. 2021 , 53, 1571-1579	0
537	What is the best method of rectovaginal fistula repair? A 25-year single-center experience. 2021 , 25, 1037-1044	0
536	Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. 2021 , 20, 102832	8
535	AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. 2021 , 160, 2512-2556.e9	11

534	Position Statement. Recommendations of the Spanish Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of strictures in Crohn's disease. 2021 ,	
533	From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases. 2021 , 12, 685280	3
532	An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. 2021 , 54, 678-688	1
531	Prognostic biomarkers to identify patients likely to develop severe Crohn's disease: a systematic review. 2021 , 25, 1-66	1
530	Targeting Purinergic Receptor P2RX1 Modulates Intestinal Microbiota and Alleviates Inflammation in Colitis. 2021 , 12, 696766	1
529	Ultra-proactive therapeutic drug monitoring of infliximab based on point-of-care-testing in inflammatory bowel disease: results of a pragmatic trial. 2021 ,	6
528	A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn's Disease. 2021 , 12, 646673	0
527	Insurance Type Influences Access to Biologics and Healthcare Utilization in Pediatric Crohn's Disease. 2021 , 3,	
526	Early Start of Infliximab in Crohn's Disease Increases Rates of Endoscopic Remission and Decreases Stenosis Formation: Experiences From a Single Center Cohort. 2021 , 3,	
525	Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020). 2021 , 1-15	1
524	Management Decisions in Crohn's Disease Are Changed by Knowledge of Proactive and Reactive Testing of Antitumor Necrosis Factor Drug Levels. 2021 , 3,	1
523	Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register. 2021 , 54, 931-943	1
522	Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology. 2021 , 54, 779-791	2
521	Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease. 2021 , 54, 1052-1060	2
520	Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction. 2021 , 3,	1
519	Twenty-five years of biologics in IBD: What's all the hype about?. 2021 , 290, 806-825	5
518	Inflammatory Bowel Disease in Children and Adolescents. 2021 , 68, 121-142	4
517	A literature review on large intestinal hyperelastic constitutive modeling. 2021 , 88, 105445	1

516	Long-term Disease Course of Crohn's Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors. 2021 ,	0
515	Stopping Anti-TNF in CD Remitters: Cons.. 2022 , 7, 59-63	
514	High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature. 2021 , 60, 2677-2681	2
513	Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNF β therapy in inflammatory bowel disease patients: a report from the epi-IIRN. 2021 ,	5
512	Histoplasmosis Related to Immunosuppression in a Patient with Crohn's Disease: A Diagnostic Challenge. 2021 , 22, e925345	2
511	Will the Inducing and Maintaining Remission of Non-biological Agents and Biological Agents Differ for Crohn's Disease? The Evidence From the Network Meta-Analysis. 2021 , 8, 679258	0
510	Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies. 2021 , 64, 605-613	1
509	Inflammatory Bowel Disease and Neutrophil-Lymphocyte Ratio: A Systematic Scoping Review. 2021 , 10,	3
508	Role of hospitalization for inflammatory bowel disease in the post-biologic era. 2021 , 9, 7632-7642	
507	Bacterial Translocation as Inflammatory Driver in Crohn's Disease. 2021 , 9, 703310	3
506	Machine learning gene expression predicting model for ustekinumab response in patients with Crohn's disease. 2021 , 9, 1529-1540	1
505	Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor- β Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study. 2021 , 15, 752-762	1
504	Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention. 2021 , 22,	2
503	Takayasu's Arteritis Diagnosed in an Adolescent Patient with Crohn's Disease: Management of Biologicals. 2021 , 11,	
502	Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. 2021 , 8, 737256	3
501	Epithelial wound healing in inflammatory bowel diseases: the next therapeutic frontier. 2021 , 236, 35-51	2
500	Efficacy and Safety of Vedolizumab and Infliximab Treatment for Immune-Mediated Diarrhea and Colitis in Cancer Patients: A Multi-Center Study.	
499	25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. 2021 , 70, 1396-1405	23

498	Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment. 2021 , 5, e13888	
497	The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease. 2021 , 36, 1231-1241	3
496	Enteral nutrition for maintenance of remission in Crohn's disease. 2018 , 8, CD005984	10
495	From immunogenic mechanisms to novel therapeutic approaches in inflammatory bowel disease. 2006 , 579, 227-42	8
494	Surgery for Crohn's Disease. 2007 , 584-600	4
493	Cytokines and Inflammatory Bowel Disease. 2008 , 31-41	1
492	Cytokines and Inflammatory Bowel Disease. 2013 , 25-33	2
491	Inflammatory bowel disease: a model of chronic inflammation-induced cancer. 2009 , 511, 193-233	33
490	The New Economic Reality in the World of IBD. 2011 , 295-313	1
489	Therapeutic human monoclonal antibodies in inflammatory diseases. 2014 , 1060, 37-59	39
488	From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic. 2008 , 169-185	1
487	The Clinical Application of Ozonotherapy. 2010 , 97-232	8
486	First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. 2020 , 22, 7	10
485	Management of ankylosing spondylitis. 2011 , 1157-1177.e3	2
484	Crohn's Disease. 2010 , 1941-1973.e9	4
483	Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease. 2021 , 27, 482-492	13
482	Intermittent Appearance of Antibodies to Infliximab Is Not Associated With Reduced Efficacy in Patients With Inflammatory Bowel Diseases. 2022 , 56, e47-e51	1
481	Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Infliximab in Pediatric Inflammatory Bowel Disease: A Systematic Review and Revised Dosing Considerations. 2020 , 70, 763-776	12

480	Mucosal and Histologic Healing in Children With Inflammatory Bowel Disease Treated With Antitumor Necrosis Factor-Alpha. 2021 , 72, 728-735	2
479	Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. 2009 , 102, 1133-40	32
478	Natural naphthoquinones isolated from <i>Lithospermum erythrorhizon</i> suppress dextran sulfate sodium-induced murine experimental colitis.	1
477	Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers. 2021 , 53, 471-483	7
476	The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies. 2021 , 70, 2076-2084	7
475	SARS-CoV-2 Virus Manifestations in the Gastrointestinal Tract: Therapeutic Implications. 2021 , 37, 63-69	0
474	An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. 2011 , 121, 985-97	677
473	Clinical Potential of <i>Lactococcus lactis</i> Mediated Delivery of Human Interleukin-10 and Trefoil Factors. 2006 , 25, 81-97	2
472	Dietary eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor- α . 2011 , 6, e24031	32
471	Downregulation of the NHE3-binding PDZ-adaptor protein PDZK1 expression during cytokine-induced inflammation in interleukin-10-deficient mice. 2012 , 7, e40657	31
470	Probiotic bacteria regulate intestinal epithelial permeability in experimental ileitis by a TNF-dependent mechanism. 2012 , 7, e42067	83
469	Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease. 2017 , 12, e0172916	10
468	Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. 2017 , 12, e0175099	21
467	Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. 2017 , 12, e0186575	13
466	Discontinuation of Scheduled Infliximab in Crohn's Patients With Clinical Remission: A Retrospective Single-Center Study. 2017 , 10, 92-99	4
465	BIOLOGICAL THERAPY PENETRATION FOR INFLAMMATORY BOWEL DISEASE IN LATIN AMERICA: CURRENT STATUS AND FUTURE CHALLENGES. 2019 , 56, 318-322	7
464	Reindução da remissão clínica com adalimumabe após interrupção do tratamento: uma alternativa no manejo da doença de Crohn. 2010 , 30, 135-140	1
463	[Long-term infliximab therapy for ulcerative colitis in real clinical practice]. 2016 , 88, 46-52	4

462	Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months. 2018 , 110, 564-570	9
461	Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches. 2021 , 21, 270-283	8
460	Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. 2016 , 29, 127-36	5
459	Current and emerging drugs for the treatment of inflammatory bowel disease. 2011 , 5, 185-210	173
458	Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870). 2007 , 2, 39-47	15
457	Infliximab in the treatment of Crohn's disease. 2007 , 3, 301-8	28
456	Are Surgical Rates Decreasing in the Biological Era In IBD?. 2019 , 20, 1356-1362	10
455	Medical-surgical Combined Approach in Perianal Fistulizing Crohn's Disease (CD): Doing it Together. 2019 , 20, 1373-1383	2
454	The Role of TNF- α as a Proinflammatory Cytokine in Pathological Processes. 2019 , 13, 332-338	10
453	Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients. 2017 , 11, 75-87	12
452	Biomarkers in Enteropathic Arthritis. 2020 , 4, 039-044	1
451	Changes of energy metabolism, nutritional status and serum cytokine levels in patients with Crohn's disease after anti-tumor necrosis factor- α therapy. 2013 , 53, 122-7	8
450	Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF- α) inhibitors [LISA-TRACKER \square enzyme-linked immunosorbent assay (ELISA) kits, TNF- α Blocker ELISA kits and Promonitor \square ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. 2016 , 20, 1-288	17
449	Change in the treatment strategy for pediatric Crohn's disease. 2010 , 53, 830-3	7
448	Long-term Outcomes and Risk Factors for Reoperation After Surgical Treatment for Gastrointestinal Crohn Disease According to Anti-tumor Necrosis Factor- α Antibody Use: 35 Years of Experience at a Single Institute in Korea. 2015 , 31, 144-52	7
447	A comprehensive review of inflammatory bowel disease focusing on surgical management. 2012 , 28, 121-31	5
446	Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. 2008 , 14, 5512-8	32
445	Are we giving biologics too late? The case for early versus late use. 2008 , 14, 5523-7	19

444	Are we giving biologics too much time? When should we stop treatment?. 2008 , 14, 5528-31	3
443	Postoperative Crohn's disease recurrence: a practical approach. 2008 , 14, 5540-8	38
442	Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. 2009 , 15, 4449-52	26
441	Adenosine: an immune modulator of inflammatory bowel diseases. 2009 , 15, 4491-8	49
440	IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. 2005 , 11, 1187-92	58
439	Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. 2006 , 12, 4628-35	85
438	Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. 2006 , 12, 7568-77	40
437	Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?. 2006 , 12, 974-6	129
436	Recent advances in basic and clinical aspects of inflammatory bowel disease: which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease?. 2007 , 13, 2145-9	13
435	Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. 2007 , 13, 5238-44	42
434	Practical guidelines for the treatment of inflammatory bowel disease. 2007 , 13, 1149-55	30
433	Efficacy of early treatment with infliximab in pediatric Crohn's disease. 2010 , 16, 1776-81	20
432	Role of endoscopy in predicting the disease course in inflammatory bowel disease. 2010 , 16, 2626-32	56
431	Prevention of recurrence after surgery for Crohn's disease: efficacy of infliximab. 2010 , 16, 5405-10	18
430	Serum immune-activation potency and response to anti-TNF- α therapy in Crohn's disease. 2010 , 16, 5845-51	3
429	Current treatment of ulcerative colitis. 2011 , 17, 3204-12	72
428	Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases. 2011 , 17, 547-56	41
427	Epidemiology and clinical course of Crohn's disease: results from observational studies. 2012 , 18, 1723-31	81

426	Crucial steps in the natural history of inflammatory bowel disease. 2012 , 18, 3790-9	77
425	Impact of medical therapies on inflammatory bowel disease complication rate. 2012 , 18, 3823-7	15
424	Surgery for Crohn's disease in the era of biologicals: a reduced need or delayed verdict?. 2012 , 18, 3828-32	34
423	Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. 2012 , 18, 197-204	30
422	Use of the tumor necrosis factor-blockers for Crohn's disease. 2012 , 18, 4823-54	27
421	Effectiveness of infliximab after adalimumab failure in Crohn's disease. 2012 , 18, 5219-24	22
420	Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. 2012 , 18, 6967-73	18
419	Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients. 2013 , 19, 2676-82	10
418	Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care. 2013 , 19, 6375-82	8
417	Time of infliximab therapy initiation and dose escalation in Crohn's disease. 2014 , 20, 214-8	6
416	Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. 2014 , 20, 3516-24	23
415	Utility of serum TNF- α infliximab trough level, and antibody titers in inflammatory bowel disease. 2014 , 20, 5031-5	24
414	Postprandial response of bone turnover markers in patients with Crohn's disease. 2014 , 20, 9534-40	6
413	Impact of medical therapy on patients with Crohn's disease requiring surgical resection. 2014 , 20, 11808-14	6
412	Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy. 2014 , 20, 14479-87	16
411	Temporal trends in inflammatory bowel disease publications over a 19-years period. 2014 , 20, 16745-9	4
410	Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. 2014 , 20, 17352-9	43
409	When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease. 2014 , 20, 1139-46	9

408	Therapy with stem cells in inflammatory bowel disease. 2014 , 20, 1211-27	48
407	What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?. 2014 , 20, 1248-58	7
406	Real-life outcome of anti-tumor necrosis factor in the ambulatory treatment of ulcerative colitis. 2015 , 21, 3282-90	15
405	Effect of tumor necrosis factor-antagonists on oxidative stress in patients with Crohn's disease. 2015 , 21, 10208-14	3
404	Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. 2015 , 21, 12519-43	19
403	Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective. 2016 , 22, 10103-10117	29
402	Estimation of quality of life in Cypriot patients with inflammatory bowel disease. 2017 , 23, 121-126	7
401	Biosimilars in inflammatory bowel disease: A review of post-marketing experience. 2017 , 23, 197-203	11
400	Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease. 2017 , 23, 414-425	14
399	Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?. 2017 , 23, 6385-6402	31
398	Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease. 2017 , 23, 1489-1496	7
397	Mucosa repair mechanisms of Tong-Xie-Yao-Fang mediated by CRH-R2 in murine, dextran sulfate sodium-induced colitis. 2018 , 24, 1766-1778	6
396	Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. 2018 , 24, 3567-3582	27
395	Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability. 2020 , 26, 5437-5449	2
394	First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. 2020 , 26, 6710-6769	4
393	Development of a prognostic model for one-year surgery risk in Crohn's disease patients: A retrospective study. 2020 , 26, 524-534	4
392	Biologic Management of Fistulizing Crohn's Disease. 2004 , 1, 17-24	13
391	Inflammatory bowel diseases. 2006 , 35, 268-74	0

390	Infliximab treatment in a hemodialysis patient with relapse of Crohn's disease after a 40-year interval. 2009 , 42, 905-910	2
389	[Use of TNFalpha antibodies in treatment of inflammatory bowel disease]. 2010 , 130, 273-7	3
388	Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF- α Antibodies after a Single Injection in Mice. 2017 , 199, 418-424	13
387	A Saudi Gastroenterology association position statement on the use of tumor necrosis factor- α antagonists for the treatment of inflammatory bowel disease. 2015 , 21, 185-97	4
386	Therapeutic efficacy of an elemental diet for patients with crohn's disease and its association with amino acid metabolism. 2017 , 23, 20-27	5
385	A health economic analysis of combination therapy with infliximab plus elemental diet for moderately to severely active Crohn's disease. 2014 , 06, 107-114	3
384	Early surgery in Crohn's disease a benefit in selected cases. 2016 , 8, 492-500	18
383	Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. 2017 , 9, 613-626	16
382	Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases. 2020 , 11, 114-130	5
381	Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. 2015 , 6, 181-92	18
380	Henoch-Schönlein purpura complicating adalimumab therapy for Crohn's disease. 2010 , 1, 119-22	19
379	Combination therapy for inflammatory bowel disease. 2017 , 8, 103-113	21
378	Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study. 2017 , 8, 131-136	2
377	Infliximab therapy impacts the peripheral immune system of immunomodulator and corticosteroid naïve patients with Crohn's disease. 2011 , 5, 37-45	18
376	Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. 2017 , 11, 55-61	20
375	Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. 2019 , 13, 604-616	35
374	2019 Expert opinion on biological treatment use in inflammatory bowel disease management. 2019 , 30, S913-S946	2
373	Comparison of Infliximab and Infliximab/Azathioprine for Maintenance Therapy in Korean Patients with Luminal Crohn's Disease. 2011 , 9, 189	0

372	Guidelines for the Management of Crohn's Disease. 2012 , 10, 26	9
371	Long-term clinical outcomes of Korean patient with Crohn's disease following early use of infliximab. 2014 , 12, 281-6	15
370	Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy. 2017 , 15, 524-528	5
369	Risk of surgery in patients with stricturing type of Crohn's disease at the initial diagnosis: a single center experience. 2019 , 17, 357-364	7
368	Improving the quality of care for inflammatory bowel disease. 2019 , 17, 45-53	10
367	Ustekinumab is effective in biological refractory Crohn's disease patients-regardless of approval study selection criteria. 2019 , 17, 340-348	12
366	Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn's disease: the Indian experience. 2020 , 18, 184-191	4
365	Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases. 2020 , 18, 34-44	6
364	The reasons for discontinuation of infliximab treatment in patients with Crohn's disease: a review of practice at NHS teaching hospital. 2011 , 2011, 672017	2
363	Assessing wildfire occurrence probability in Pinus pinaster Ait. stands in Portugal. 2012 , 21, 111	18
362	Differential diagnosis of inflammatory bowel disease: what is the role of colonoscopy?. 2012 , 45, 254-62	11
361	Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. 2020 , 9,	24
360	TNF-inhibitors and psychiatric adverse drug reactions in the spectrum of bipolar (manic) or psychotic disorders: Analysis from the French pharmacovigilance database. 2021 , 76, 449-454	
359	Abdominopelvic CT-scan in emergency departments for patients with suspected complications of Crohn's disease: a single tertiary center experience. 2021 , 21, 113	1
358	Therapie-Update Morbus Crohn 2021. 2021 , 8, 26-33	
357	Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. 2021 , 6, 1002-1014	13
356	Tumor necrosis factor inhibitors as therapeutic agents for recurrent spontaneous abortion (Review). 2021 , 24,	2
355	Basistherapeutika und Immunsuppressiva. 2003 , 706-749	

- 354 Gastrointestinal Complications. **2004**, 259-278
- 353 Pharmacotherapy of inflammatory bowel disease: Novel therapeutic approaches. **2004**, 17-49
- 352 Chronisch-entzündliche Darmkrankheiten. **2004**, 25,
- 351 [Anti tumor necrosis factor-alpha antibody: biological significance and therapeutic target for Crohn's disease]. **2004**, 27, 16-21
- 350 Autoimmunity in Inflammatory Bowel Disease. **2005**, 525-542
- 349 CED richtig behandeln!.
- 348 Biologicals: old and new ones. **2006**, 71-77
- 347 Tratamiento farmacológico de la enfermedad intestinal inflamatoria. **2006**, 492-495
- 346 Medical Therapy of Fistulizing Crohn's Disease. **2006**, 171-179
- 345 Biologic Therapies in Spondyloarthritis-The Current State. **2006**, 169-185
- 344 Treatment of Inflammatory Bowel Diseases in Children. **2006**, 653-660
- 343 Medical Management of Inflammatory Bowel Disease. **2007**, 555-566
- 342 Control of mucosal immune responses by transforming growth factor- β . **2007**, 29-34
- 341 VALIDATION OF TNF AS A DRUG TARGET IN INFLAMMATORY BOWEL DISEASE. **2007**, 83-102
- 340 Medical Management of Ulcerative Colitis in 2006. **2007**, 102, 7-13
- 339 Medical Management of Crohn's Disease in 2006. **2007**, 102, 2-6
- 338 [Medical therapy of inflammatory bowel diseases: Crohn's disease]. **2007**, 148, 1107-14
- 337 CLINICAL UTILITY OF INFLIXIMAB TREATMENT IN CROHN'S DISEASE PATIENTS-REOPERATION RATE, PATIENTS' SATISFACTION AND COST-BENEFIT ANALYSIS-. **2008**, 69, 3061-3068

- 336 Clinical Features of Pouch Related Complications Following Ileal Pouch-anal Anastomosis for Ulcerative Colitis and Outcomes of Salvage Surgery. **2008**, 61, 16-21 1
- 335 Long-term Result of Surgical Treatment for Crohn's Enteritis. **2008**, 24, 409
- 334 Complementary Medicine & Mucosal Immunology -Recent Topics around Inflammatory Bowel Disease. **2008**, 5, 85-101
- 333 Biologicals for treatment of patients with inflammatory bowel diseases [quite in fashion or really necessary?]. **2008**, 26-43
- 332 CROHN'S DISEASE: AETIOLOGY, PATHOLOGY, DIAGNOSIS AND MEDICAL TREATMENT. **2008**, 1783-1862
- 331 Infliximabe no tratamento inicial da retocolite ulcerativa moderada e grave. Terapia top down: relato preliminar. **2008**, 28, 289-293
- 330 Complications h patiques du traitement des MICI. **2009**, 13-18
- 329 INFLAMMATORY BOWEL DISEASES. **2009**, 487-503 1
- 328 INFLAMMATION AND IMMUNOMODULATION. **2009**, 157-172
- 327 Spondyloarthropathies. **2009**, 1067-1083
- 326 Inflammatory Bowel Disease. **2009**, 1040-1055
- 325 A CASE OF CROHN'S DISEASE COMPLICATED BY A MESENTERIC ABSCESS AND A LIVER ABSCESS DURING INFLIXIMAB REGIMEN. **2009**, 70, 2762-2766 2
- 324 Therapy of inflammatory bowel disease: bottom-up or top-down?. **2009**, 67-69
- 323 Chronisch-entz ndliche Darmerkrankungen. **2009**, 421-439
- 322 Biologic Therapies For Inflammatory Bowel Disease. **2009**,
- 321 [TNF-alpha blocking therapy in chronic inflammatory bowel disease]. **2009**, 150, 1773-9
- 320 Immunogenicity Assessment of Antibody Therapeutics. **2010**, 271-291
- 319 New Therapies. **2010**, 123-130

- 318 Nouveautés dans la stratégie thérapeutique des maladies inflammatoires chroniques de l'intestin. **2010**, 181-188
- 317 Crohn's Disease and Cancer. **2010**, 259-273
- 316 Medical Treatment and Prevention for Intestinal Complications in Crohn's Disease. **2010**, 63, 869-874
- 315 La cicatrisation muqueuse endoscopique est-elle un nouvel objectif thérapeutique dans les MICI?. **2010**, 173-180
- 314 GLUCOCORTICOIDS AND DISEASE MODIFYING ANTIRHEUMATIC DRUGS. **2010**, 371-667
- 313 [When should anti-TNF-alpha treatment in Crohn disease be terminated?]. **2010**, 130, 474
- 312 Gene therapy for the treatment of inflammatory bowel disease. **2010**, 19-37
- 311 Biothérapies et anticorps monoclonaux. **2010**, 667-677
- 310 Drug Therapy for Inflammatory Bowel Disease. **2010**, 403-406
- 309 MONOCLONAL ANTIBODIES. **2010**, 457-489
- 308 An Update on the Treatment of Crohn's Disease. **2010**, 63, 863-868
- 307 Crohn's Disease. **2010**, 211-231
- 306 State-of-the-Art Management of the Pediatric IBD Patient. **2011**, 151-164
- 305 IBD: Medical Management. **2011**, 463-478
- 304 Intestinal Crohn's disease: management. **2011**, 57, 10-13
- 303 State-of-the-Art Medical Treatment of the Adult Patient with IBD: The Biological Therapies. **2011**, 111-121
- 302 [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period]. **2011**, 152, 951-7
- 301 Inflammatory bowel disease. **2011**, 86-92

- 300 Biologic Therapy of Crohn's Disease: Infliximab. **2012**, 413-432
- 299 Biologic Treatment of Crohn's Disease: Adalimumab. **2012**, 397-405
- 298 Surgery for Small Bowel Crohn's Disease. **2012**, 293-309
- 297 Targeted Therapy in Inflammatory Bowel Disease; Current Status and Future Perspectives. **2012**, 32, 94
- 296 Recent Trends of Infliximab Treatment for Crohn's Disease. **2012**, 15, 19
- 295 What can we do with Crohn's Patients who Fail or Lose Response to Anti-TNF Therapy?. 124-128
- 294 Are all Anti-TNF Agents the Same?. 107-112
- 293 Biological Therapy for Inflammatory Bowel Disease in Children. **2012**, 15, 13 2
- 292 Safety of Biotherapeutics. 585-601 0
- 291 Mathematical Models of Anti-TNF Therapies and their Correlation with Tuberculosis. 83-104 1
- 290 Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. **2013**, 345-355
- 289 6-Mercaptopurine Therapy. **2013**, 331-337
- 288 Inflammatory Bowel Disease. **2013**, 1961-1981
- 287 Natural Course of Crohn's Disease and Novel Treatment Drugs. **2013**, 85, 578
- 286 Two Cases of Ulcerative Colitis Followed up Endoscopically after Administration of Infliximab. **2013**, 66, 234-240
- 285 Chronisch-entzündliche Darmerkrankungen. **2013**, 475-495
- 284 Azathioprine/6-Mercaptopurine Metabolism in Ulcerative Colitis: A Guide to Metabolite Assessment—An Evidence-Based Approach. **2014**, 145-151
- 283 Step-Up Versus Top-Down Therapy in Ulcerative Colitis. **2014**, 457-467

282 Crohn's disease. **2014**, 141-166

281 Safety Considerations in the Medical Therapy of Ulcerative Colitis. **2014**, 297-311

280 The Evaluation, Diagnosis, and Treatment of Inflammatory Bowel Diseases over the Past 100 Years: A Brief Review. **2015**, 3-28

279 The Relationship Between miR-29, NOD2 and Crohn's Disease. **2015**, 185-196

278 Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model. **2015**, 21, 12576-85 o

277 Further Developments. **2015**, 69-74

276 Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis. **2014**, 2, 131-146

275 Crohn's Disease: Clinical Manifestations and Management. 1418-1449

274 Infliximab. **2016**, 73-97

273 Inflammatory Bowel Disease. **2016**, 183-201

272 Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study). **2016**, 10, 391-8 8

271 Monitoring Anti-Tnf Drug Treatment in Inflammatory Bowel Disease. Is it Useful in Clinical Practice?. **2016**, 5,

270 Tumor Necrosis Factor-alpha Antibodies in Fistulizing Crohn's Disease: An Updated Systematic Review and Meta-analysis. **2017**, 6, 135-144 1

269 Cytokines and Inflammatory Bowel Disease. **2017**, 31-43

268 Inflammatory Bowel Disease. **2017**, 177-182

267 Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. **2017**, 389-400

266 6-Mercaptopurine Therapy. **2017**, 375-381

265 Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. **2017**, 417-424

- 264 Inflammatory Bowel Disease. **2017**,
- 263 EFFICACY AND SAFETY OF VEDOLIZUMAB IN CROHN'S DISEASE (review). **2017**, 71-79
- 262 Dietary Treatment for Crohn's Disease. *Old Therapy, New Insights*. **2017**, 2, 1-8
- 261 Anti-TNF versus chirurgie dans la maladie de Crohn. **2018**, 12, 114-116 1
- 260 DIFFICULT ISSUES OF THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES PATIENTS. **2018**, 21, 94-100 3
- 259 Is there a beneficial effect of adding azathioprine to adalimumab in Crohn's disease patients?. **2018**, 6, 278 2
- 258 IMPACT OF ANTIRHEUMATIC THERAPY ON THE LEVEL OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. **2018**, 56, 328-332 1
- 257 Surgery for Crohn Disease. **2019**, 1941-1950
- 256 Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease. **2019**, 111, 431-436 1
- 255 Medical Management 3: Biologicals. **2019**, 91-98
- 254 A Primer on IBD: Phenotypes, Diagnosis, Treatment, and Clinical Challenges. **2019**, 3-24 0
- 253 Management of Enterovesical Fistula. **2019**, 219-226
- 252 One Size Does Not Fit All: The Case for Translational Medicine. **2019**, 10,
- 251 VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY. **2019**, 56, 312-317 3
- 250 Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report. **2020**, 12, 12-18 1
- 249 Efficacy of Infliximab and Adalimumab for Crohn's Disease:. **2019**, 45, 674-681
- 248 Ameliorative effect of a quinazoline-based bromodomain inhibitor, CN210, on experimentally-induced Crohn's disease-like murine ileitis via inhibition of inflammatory cytokine expression.
- 247 Absorption and Secretion, General Symptoms, and Pharmacology. **2020**, 1-6

- 246 Lysophosphatidic acid-mediated GPR35 signaling in CX3CR1+macrophages regulates the intestinal cytokine milieu. 1
- 245 Dose Augmentation of Tumor Necrosis Factor Inhibitors is Frequently Performed in Persons With Inflammatory Bowel Disease in the Absence of Objective Evidence of Active Inflammation. **2021**, 55, 602-608 0
- 244 GPR35 in Intestinal Diseases: From Risk Gene to Function. **2021**, 12, 717392 4
- 243 Changes in the Crohn's Disease Activity Index and Safety of Administering in Patients with Crohn's Disease in Clinical Remission: A Single Hospital-based Retrospective Cohort Study. **2020**, 76, 314-321 1
- 242 Medikamentöse Therapie der chronisch entzündlichen Darmerkrankungen (CED). **2020**, 49, 550-558
- 241 INDUCTION THERAPEUTIC DRUG MONITORING REGIMEN WITH INFLIXIMAB: A SIMPLIFIED EVIDENCE-BASED ALGORITHM FOR INFLAMMATORY BOWEL DISEASE. **2020**, 57, 507-510
- 240 Encyclopedia of Behavioral Medicine. **2020**, 1190-1191
- 239 Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study. **2021**, 113, 110-115 1
- 238 Crohn's disease. **2020**, 2925-2936
- 237 Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease. **2020**, 112, 360-366 0
- 236 Evaluation of Invasive Intra-abdominal Candidiasis in Crohn Disease at the Time of Surgery. **2020**, 36, 12-16 0
- 235 State-of-the-art surgery for Crohn's disease: Part I-small intestine/ileal disease. **2021**, 1 0
- 234 Mucosal Healing in Crohn's Disease: Bull's Eye or Bust? "The Pro Position".. **2022**, 7, 36-41
- 233 Mechanism-based Drug Therapy of Inflammatory Bowel Disease With Special Reference to Rheumatic Disease. **2020**, 27, 128-135
- 232 Optimizing the use of current drugs for inflammatory bowel disease. 180-185
- 231 Diffuse jejunoileitis in an adolescent. 189-195
- 230 Treatment of inflammatory bowel disease: Early hit or stepwise escalation. 299-304
- 229 Gastrointestinale Komplikationen. **2005**, 211-245 3

- 228 Infliximab in dermatology, gastroenterology, and off-label use. **2006**, 83-99
- 227 Biological Approach in the Treatment of Crohn's Disease. **2006**, 157-170
- 226 Crohn's Disease of the Colon. **2006**, 191-203
- 225 6-Mercaptopurine Therapy. **2008**, 371-378
- 224 Infliximab Therapy. **2008**, 387-401
- 223 Medical therapy of small bowel Crohn's disease. 181-188
- 222 Can Asia afford new and emerging therapies in inflammatory bowel disease?. 218-227
- 221 Are biological drugs effective enough?. 235-244
- 220 Are biologicals safe enough?. 245-256
- 219 Can immunomodulatory therapy be improved by metabolite measurement and combination therapy?. 99-106
- 218 Top-down therapy for inflammatory bowel disease. 109-111
- 217 Step-up versus Top-down strategies in inflammatory bowel disease - what do we know in 2006?. 112-121
- 216 Importance of mucosal healing in Crohn's disease and ulcerative colitis. 122-127
- 215 State-of-the-art therapy in accordance with guidelines. 73-84
- 214 Indications for use of infliximab in inflammatory bowel disease. 165-182
- 213 State-of-the-Art Lecture: Emerging biologic therapies. 192-202
- 212 Inflammation driven carcinogenesis: the players. 165-169
- 211 Standard therapy for ulcerative colitis and Crohn's disease: the ECCO guidelines. **2008**, 76-89

210	Biologics, novel therapeutic alternatives in inflammatory bowel disease. 2008 , 90-94	
209	Biologics in Crohn's Disease and Ulcerative Colitis: Focus on Tumor Necrosis Factor Antagonists. 2007 , 124-140	
208	CRITICAL ANALYSIS OF ANTI-TNF USE IN THE ERA OF NEW BIOLOGICAL AGENTS IN INFLAMMATORY BOWEL DISEASE. 2020 , 57, 323-332	1
207	Ileo-colonic lymphoma: presentation, diagnosis, and management. 2021 , 37, 52-58	0
206	Infliximab-induced remission improves physical activity in patients with active Crohn's disease. 2020 , 66, 1566-1572	1
205	Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn's disease in China. 2020 , 26, 6455-6474	1
204	Early Inflammatory Markers are Associated With Inadequate Post-Induction Infliximab Trough in Pediatric Crohn's Disease. 2021 , 72, 410-416	1
203	Adalimumab therapy for recalcitrant pyoderma gangrenosum. 2006 , 5, e8	38
202	Biologics in inflammatory disease: infliximab associated risk of lymphoma development. 2005 , 54, 732-3	8
201	Smoking status in therapeutic trials in Crohn's disease. 2005 , 54, 1047-8	0
200	Adalimumab in Crohn's disease. 2007 , 1, 355-65	4
199	Maintenance treatment with infliximab for the management of Crohn's disease in adults. 2009 , 3, 39-49	6
198	Biologic targeting in the treatment of inflammatory bowel diseases. 2009 , 3, 77-97	84
197	The impact of the patient-centered medical home on the biologics industry, employers, and third-party payers. 2009 , 6, 33-43	1
196	Crohn's disease. 2007 , 2007,	
195	Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease. 2008 , 2, 209-29	5
194	Infliximab: the evidence for its place in therapy in ulcerative colitis. 2008 , 2, 151-61	1
193	Current Research in Crohn's Disease and Ulcerative Colitis: Highlights from the 2010 ACG Meeting. 2010 , 6, 3-14	2

192	Progress in the diagnosis and treatment of inflammatory bowel disease. 2011 , 7, 3-16	7
191	Infliximab for ulcerative colitis induction of remission and maintenance therapy. 2007 , 3, 55-6	2
190	A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency. 2007 , 3, 381-90	11
189	Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGE Group. 2008 , 4, 713-20	
188	New biologics in the management of Crohn's disease: focus on certolizumab pegol. 2009 , 2, 61-8	2
187	Infliximab therapy in pediatric Crohn's disease: a review. 2010 , 3, 57-63	10
186	Targeting mucosal healing in Crohn's disease. 2011 , 7, 374-80	7
185	Crohn's disease. 2011 , 2011,	1
184	Mucosal healing in inflammatory bowel disease-a true paradigm of success?. 2012 , 8, 29-38	44
183	Measurement of infliximab and anti-infliximab antibody levels can help distinguish maintenance versus loss of response. 2012 , 8, 131-4	3
182	Optimizing infliximab therapy for inflammatory bowel disease- the tools are getting sharper. 2012 , 8, 134-6	1
181	Natalizumab in Crohn's disease: past and future areas of applicability. 2013 , 26, 189-190	5
180	A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013 May 18-21, 2013 [Orlando, Florida] Special Reporting on: Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms [Prevalence of	19
179	Infliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart review. 2014 , 7, 87-93 Symptoms in a Prospective Sampl. 2013 , 9, 1-16	4
178	Addressing Costs and Continuity of Care through Innovative Solutions for Infused Therapies: A Collaborative Experience with Infliximab. 2011 , 4, 39-46	3
177	Need for infliximab dose intensification in Crohn's disease and ulcerative colitis. 2014 , 20, 9170-7	19
176	Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study. 2012 , 7, 862-6	1
175	What is the impact of age on adult patients with inflammatory bowel disease?. 2013 , 86, 3-9	9

174	Effectiveness and risk associated with infliximab alone and in combination with immunosuppressors for Crohn's disease: a systematic review and meta-analysis. 2015 , 8, 4846-54	2
173	Therapeutic Drug Monitoring in Children and Young Adults With Inflammatory Bowel Disease: A Practical Approach. 2015 , 11, 48-55	3
172	The Role of Biosimilars in Inflammatory Bowel Disease. 2016 , 12, 741-751	6
171	Therapeutic effects of human amnion-derived mesenchymal stem cell transplantation and conditioned medium enema in rats with trinitrobenzene sulfonic acid-induced colitis. 2017 , 9, 940-952	21
170	Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. 2014 , 10, 478-489	1
169	Improving IBD Care: A Personalized Approach to Management. 2018 , 14, 1-20	
168	Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn's Disease. 2018 , 11, 253-262	4
167	Adalimumab and Infliximab in Crohn's disease - real life data from a national retrospective cohort study. 2016 , 42, 115-124	2
166	[Mucosal healing in different intestinal segments in patients receiving infliximab treatment for small bowel Crohn's disease]. 2017 , 37, 44-48	
165	Targeting Mucosal Healing in Crohn's Disease. 2019 , 15, 529-538	4
164	Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. 2019 , 15, 656-665	13
163	The Psoriasis Decision Tree. 2021 , 14, 14-22	
162	Rare Complication During Anti-TNF- α Treatment in a Patient with Crohn's Disease: A Case Report and Review of the Literature. 2021 , 47, 132-138	
161	Biosimilar infliximab versus originator in Crohn's disease anti-TNF- α naïve and non-naïve patients. 2021 , 16, 207-212	
160	T cell-derived tumor necrosis factor induces cytotoxicity by activating RIPK1-dependent target cell death. 2021 ,	1
159	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. 2021 , 9,	6
158	Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases. 2021 , 27, S1-S16	1
157	Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. 2021 , 35, 715-733	4

- 156 Management of the Hospitalized Patient with Inflammatory and Strictureing Crohn's Disease. **2022**, 91-108
- 155 From single-target to cellular niche targeting in Crohn's disease: intercepting bad communications. **2021**, 74, 103690 0
- 154 Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn's disease: a retrospective cohort study.. **2022**, 22, 15 1
- 153 Infliximab as Rescue Therapy for Hospitalized Patients With Crohn's Disease Failing Intravenous Corticosteroids. **2020**,
- 152 Perioperative management of biologic agents in ulcerative colitis. **2022**, 100866
- 151 Perioperative management of biologic agents in Crohn's disease. **2022**, 33, 100865
- 150 Biologic therapy for Crohn's disease over the last 3 decades.. **2022**, 10, 594-606 0
- 149 Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.. **2021**, 12, 838082 1
- 148 Biologic agents and small molecules [mechanism of action. **2022**, 100861
- 147 Therapeutic Targeting of Intestinal Fibrosis in Crohn's Disease.. **2022**, 11, 0
- 146 Point-of-care testing and home testing: pragmatic considerations for widespread incorporation: stool tests, serum tests, intestinal ultrasound.. **2021**, 0
- 145 OUP accepted manuscript. 1
- 144 [Biologics in inflammatory bowel diseases].. **2022**, 63, 155 0
- 143 Postoperative Safety Profile of Minimally Invasive Ileocolonic Resections for Crohn's Disease in the Era of Biologic Therapy.. **2022**, 1
- 142 Influence of Corticosteroid Use on Short- and Long-Term Outcomes of Biologic Therapy for Inflammatory Bowel Diseases.. **2022**, 1
- 141 Medical treatment of intestinal Crohn's disease. **2022**, 100862
- 140 Disease Monitoring in IBD: evolving principles and possibilities.. **2022**, 2
- 139 Does Disease Activity After Induction Treatment With Biologics Predict Short-Term Outcome in Crohn's Disease and Ulcerative Colitis?. **2022**,

138	The future of precision medicine to predict outcomes and control tissue remodeling in inflammatory bowel disease.. 2021 ,	3
137	Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity.. 2022 ,	4
136	IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality.. 2022 , 16, ii54-ii63	0
135	Current Therapy in Inflammatory Bowel Disease: Why and How We Need to Change?. 40-49	0
134	Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.. 2022 ,	1
133	New therapeutic strategies have changed the natural history of paediatric Crohn's disease: a two-decade population-based study.. 2022 ,	0
132	Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial. 2021 ,	4
131	Biologic therapy for inflammatory bowel disease comes of age. 2007 , 9, 485-7	
130	Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention.. 2022 , 16, ii3-ii19	2
129	Management of Inflammatory Bowel Disease. 2022 , 23-40	
128	A review of the therapeutic management of Crohn's disease.. 2022 , 15, 17562848221078456	0
127	Ileal and colonic Crohn's disease: Does location makes a difference in therapy efficacy?. 2022 , 3, 100097	1
126	Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease.. 2022 ,	0
125	Novel Therapies for Inflammatory Bowel Disease. 2022 , 20, 81-100	
124	COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience.. 2022 , 10,	
123	Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).. 2022 , 39, 2109	1
122	Efficacy and predictor of anti-TNF agents in patients with intestinal Behçet's disease.. 2022 , 22, 149	1
121	Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease.. 2022 ,	

- 120 Infliximab Treatment Persistence among Japanese Patients with Chronic Inflammatory Diseases: A Retrospective Japanese Claims Data Study.. **2022**, 45, 323-332
- 119 Aktualisierte S3-Leitlinie Diagnostik und Therapie des Morbus Crohn der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) [August 2021] AWMF-Registernummer: 021-004. **2022**, 60, 332-418 5
- 118 Long-term clinical and real-world experience with Crohn's disease treated with anti-tumor necrosis factor- α antibodies.. **2022**,
- 117 Paediatric Crohn's Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment. **2022**, 2022, 1-11
- 116 Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis.. **2022**, 4, CD007216 0
- 115 Association between preoperative biologic use and surgical morbidity in patients with Crohn's disease.. **2022**, 1 0
- 114 Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents.. **2021**, 1
- 113 The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study.. **2021**, 0
- 112 Low adherence to treatment is a weak link in the problems of ulcerative colitis. **2021**, 93, 1419-1427 0
- 111 Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry. **2021**, 1
- 110 Revisiting fibrosis in inflammatory bowel disease: the gut thickens. **2021**, 3
- 109 Osteoporosis Complications in Crohn's Disease Patients: Factors, Pathogenesis, and Treatment Outlines.. **2021**, 13, e20564
- 108 Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications.. **2022**, 15, 17562848221085889 0
- 107 Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?. **2022**, 10,
- 106 Risk factors for anti-drug antibody formation to infliximab: secondary analyses of a randomised controlled trial.. **2022**, 1
- 105 An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis.. **2022**, 11, 0
- 104 Data_Sheet_1.PDF. **2020**,
- 103 Image_1.JPEG. **2020**,

102 Image_2.JPEG. **2020**,

101 Inflammatory Bowel Disease Patients' Treatment Preferences Using a Discrete Choice Experiment Technique: The InPuT Study.. **2022**, 1

100 Comparison of the Pharmacokinetics of CT-P13 Between Crohn's Disease and Ulcerative Colitis.. **2022**,

99 Biosimilar infliximab versus originator in Crohn's disease anti-TNF-naïve and non-naïve patients. **2021**, 16, 207-212

98 OUP accepted manuscript.

97 Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

96 Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study. **2022**, 45, 165-176

95 Medical, Endoscopic and Surgical Management of Strictureing Crohn's Disease: Current Clinical Practice.. **2022**, 11,

94 Case series: Re-induction of Intravenous, Weight-based Ustekinumab is Well Tolerated in Patients with Moderate-Severe Crohn's Disease.

93 Is it time to include older adults in inflammatory bowel disease trials? A call for action. **2022**, 3, e356-e366

92 Position statement. Recommendations of the Spanish group on Crohn's disease and ulcerative colitis (GETECCU) on the treatment of strictures in Crohn's disease. **2022**,

91 Tumour necrosis factor-alpha antagonists for treatment of paediatric Crohn's disease. **2022**, 2022,

90 Cyclin-dependent kinase 9 as a potential target for anti-TNF resistant inflammatory bowel disease. **2022**,

89 Combining pentoxifylline with vedolizumab for Crohn's disease: results of a randomized, placebo-controlled pilot study.

88 EFFICACY AND SAFETY OF INFLIXIMAB RETREATMENT. **2022**, Publish Ahead of Print,

87 The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment). gutjnl-2022-327025

86 How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients. 1-9

85 Stellungnahme der DGVS zur Nutzenbewertung des GBA zum Wirkstoff Filgotinib (Anwendungsgebiet: Colitis Ulcerosa, vorbehandelte Patient*innen). **2022**, 60, 1047-1050

84	Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician. Volume 16, 67-83	
83	Anti-TNF induced rashes in inflammatory bowel disease ▯ systematic review and evidence-based algorithm for management.	
82	Global research trends of immunotherapy and biotherapy for inflammatory bowel disease: a bibliometric analysis from 2002 to 2021. 2022 , 21,	0
81	Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis.	0
80	Treat to transmural healing: how to incorporate intestinal ultrasound into the treatment of inflammatory bowel disease.	
79	Inflammatory bowel disease: focus on enteropathic arthritis and therapy. 2022 , 3, 69-76	1
78	Characterization of the Expression of Angiogenic Factors in Cutaneous Squamous Cell Carcinoma of Domestic Cats. 2022 , 9, 375	1
77	Achieving Deep Remission in Crohn's Disease: Treating Beyond Symptoms. 2014 , 43, 200-202	2
76	Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis. 2022 , 12, 1265	1
75	Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis. gutjnl-2022-328052	1
74	Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets. 2022 , 82, 1151-1163	
73	Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars. 2022 , 14, 1766	2
72	Mesenchymal stem/stromal cells in the pathogenesis and regenerative therapy of inflammatory bowel diseases. 13,	0
71	Dysbiosis in imiquimod-induced psoriasis alters gut immunity and exacerbates colitis development. 2022 , 40, 111191	2
70	Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activity. gutjnl-2022-327321	1
69	Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.	
68	Definition of a therapeutic range for predicting long-term infliximab response in patients with inflammatory bowel disease. 2022 ,	
67	In-depth bibliometric analysis and current scientific mapping research in the context of rheumatoid arthritis pharmacotherapy. 2022 , 154, 113614	7

66	Biologics: how far can they go in Crohn's disease?. 2022 , 10,	3
65	The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn's Disease Patients. 2022 ,	0
64	Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment.	0
63	Role of interleukin-6-mediated inflammation in the pathogenesis of inflammatory bowel disease: focus on the available therapeutic approaches and gut microbiome.	0
62	Comparative safety of infliximab and adalimumab on pregnancy outcomes of Women with Inflammatory Bowel Diseases: A Systematic Review & Meta-Analysis.	0
61	Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations. 2022 , 11, 5669	1
60	Considerations when starting patients on multiple biologics and small molecules. Publish Ahead of Print,	0
59	Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease. 2022 , 14,	0
58	Identification of Novel Loci Involved in Adalimumab Response in Crohn's Disease Patients Using Integration of Genome Profiling and Isoform-Level Immune-Cell Deconvoluted Transcriptome Profiling of Colon Tissue. 2022 , 14, 1893	0
57	Landscape of new drugs and targets in inflammatory bowel disease.	1
56	Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.	0
55	Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients. ASN.2022040454	0
54	Standardised survival and excess Life Years Lost in patients with type 3 intestinal failure. 2022 , 41, 2446-2454	0
53	The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A systematic review and meta-analysis. 2022 , 112, 109269	1
52	Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.	0
51	Crohn's Disease Activity Index. 2022 , 1-4	0
50	Quality of life and dietary habits: a perspective of a physician. 2022 , 33, 61-67	0
49	COMBINATION THERAPY WITH IMMUNOMODULATORS IMPROVES THE PHARMACOKINETICS OF INFLIXIMAB BUT NOT VEDOLIZUMAB OR USTEKINUMAB. 2022 ,	0

- 48 ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. *ard-2022-223296* 5
- 47 Risankizumab-rzaa: A New Therapeutic Option for the Treatment of Crohn's Disease. 106002802211304 0
- 46 Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics. **2022**, 11, 6173 1
- 45 Medical Cannabis Use Patterns and Adverse Effects in Inflammatory Bowel Disease. Publish Ahead of Print, 0
- 44 Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease. 0
- 43 Changing the Game in Ulcerative Colitis: The Impact of Gut-Selective Therapy. 2-10 0
- 42 Targeting Disease Progression in Crohn's Disease: Fighting an Unrelenting Enemy. 11-18 0
- 41 Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn's Disease patients: A retrospective analysis using German claims data. **2022**, 15, 175628482211305 0
- 40 Crohn's Disease: Supporting Patients in Their Pursuit of Disease Control. 49-56 0
- 39 Infliximab and Tumour Necrosis Factor Alpha Measurement on Intestinal Mucosa: A New Tool for the Clinic?. 107-115 0
- 38 The IBD Management Puzzle: Do We Have All the Pieces?. 18-26 0
- 37 Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease. **2022**, 0
- 36 Inhibition of proline tyrosine kinase 2 (Pyk2) phosphorylation during adherent-invasive *Escherichia coli* infection inhibits intra-macrophage replication and inflammatory cytokine release. 0
- 35 Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis. **2022**, 22, 0
- 34 Anti-tumor Necrosis Factor-Alpha Agents. **2022**, 69-87 0
- 33 A review of the therapeutic management of ulcerative colitis. **2022**, 15, 175628482211381 0
- 32 Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach. **2022**, 0
- 31 Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn's disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy. **2023**, 35, 45-51 0

- 30 Design of Nanobody-based Bispecific Constructs by in silico Affinity Maturation and Umbrella Sampling Simulations. **2022**, ○
- 29 Treatment of Crohn's disease. **2022**, 181, ○
- 28 An update on efficacy and safety comparison of biologics in treatment of inflammatory bowel disease targeting TNF- α , interleukins, leukocyte trafficking, Janus-kinase, and sphingosine-1-phosphate receptor. 1-25 ○
- 27 Therapie des Morbus Crohn und der Colitis ulcerosa. **2023**, 131-151 ○
- 26 ECCO Topical Review on Biological Treatment Cycles in Crohn's Disease. ○
- 25 Therapeutic Potential of Bioactive Components from *Scutellaria baicalensis* Georgi in Inflammatory Bowel Disease and Colorectal Cancer: A Review. **2023**, 24, 1954 ○
- 24 Factors associated with chronic intestinal inflammation resembling inflammatory bowel disease in pediatric intestinal failure: A matched case-control study. Publish Ahead of Print, ○
- 23 In It for the Long Haul: Managing the Complexity of Crohn's Disease. 2-11 ○
- 22 The Efficacy of Anti-TNFs in Immune-Mediated Disease. 2-9 ○
- 21 Polyspecificity - An emerging trend in the development of clinical antibodies. **2023**, 155, 175-183 ○
- 20 Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?. 1-11 ○
- 19 The Impact of Intermediate Antidrug Antibodies to Infliximab and Adalimumab on Clinical Outcomes in Patients with Crohn's Disease or Ulcerative Colitis. 84-93 ○
- 18 Definition of a therapeutic range for predicting long-term infliximab response in patients with inflammatory bowel disease. **2023**, 160, 107-112 ○
- 17 Treatment escalation and de-escalation decisions in Crohn's disease: Delphi consensus recommendations from Japan, 2021. **2023**, 58, 313-345 ○
- 16 Pretreatment serum monocyte chemoattractant protein-1 as a predictor of long-term outcome by ustekinumab in patients with Crohn's disease. ○
- 15 Black Inflammatory Bowel Disease Patients Have Lower Response to Antitumor Necrosis Factor Agents Compared With White Patients. ○
- 14 Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13). **2023**, 10, e001105 ○
- 13 Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. **2023**, 407-422 ○

- 12 Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. **2023**, 445-456 ○
- 11 Cytokines and Inflammatory Bowel Disease. **2023**, 33-48 ○
- 10 Network Approaches to Uncover Pathogenesis and Therapeutic Targets of Inflammatory Bowel Diseases. **2023**, ○
- 9 Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases. **2023**, 15, 969 ○
- 8 Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease. ○
- 7 Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn's Disease: A Study Based on the Korean National Database. **2023**, 12, 2397 ○
- 6 Use of biologics for the management of Crohn's disease: IG-IBD technical review based on the GRADE methodology. **2023**, ○
- 5 Inflammatory Bowel Disease. **2013**, 339-353 ○
- 4 Comparative efficacy and safety of combination therapy with infliximab for Crohn's disease: a systematic review and network meta-analysis. **2023**, 38, ○
- 3 Infliximab Inhibits Colitis Associated Cancer in Model Mice by Downregulating Genes Associated with Mast Cells and Decreasing Their Accumulation. **2023**, 45, 2895-2907 ○
- 2 Is there an optimal sequence of biologic therapies for inflammatory bowel disease?. **2023**, 16, 175628482311594 ○
- 1 Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD). 1-10 ○